Amantadine compositions, preparation thereof, and methods of use
Sustained release oral compositions of amantadine address the limitations of current formulations by reducing side effects and enhancing therapeutic efficacy for levodopa-induced dyskinesia and Parkinson's disease symptoms.
Patent Information
- Application Number
- JP2024139596
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-08-24
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current amantadine formulations for treating levodopa-induced dyskinesia in Parkinson's disease are limited by dose-related CNS side effects and gastrointestinal issues, particularly when administered multiple times a day, and there is a need for improved compositions that minimize these side effects while maintaining therapeutic efficacy.
Development of sustained release oral compositions of amantadine or its pharmaceutically acceptable salts, administered once daily, preferably at bedtime, to reduce gastrointestinal adverse events and improve tolerability, with formulations containing less than 6000 ppm of organic solvent and optimized drug coatings to minimize side effects.
The sustained release compositions provide significant reductions in levodopa-induced dyskinesia and Parkinson's disease symptoms, with lower incidence of gastrointestinal and sleep-related side effects, improving clinical outcomes and patient tolerability.
Smart Images

Figure 2024159885000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 549,921, filed Aug. 24, 2017, the disclosure of which is incorporated herein by reference in its entirety.
[0002] The present disclosure relates generally to oral pharmaceutical compositions comprising amantadine or a pharma- ceutically acceptable salt thereof, and more particularly to sustained release oral pharmaceutical compositions comprising amantadine or a pharma- ceutically acceptable salt thereof, the preparation of such compositions, and methods of using such compositions. [Background technology]
[0003] Amantadine is indicated for various conditions that can be treated by NMDA receptor antagonists, including the treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism that may occur after nervous system damage caused by carbon monoxide poisoning.Amantadine also has activity as a viral M2 channel inhibitor and is used to prevent and treat viral diseases, especially influenza A virus infection.
[0004] Levodopa, the most commonly prescribed and effective drug treatment for symptom relief in Parkinson's disease (PD), is associated with dose-limiting motor side effects, including abnormal involuntary movements known as levodopa-induced dyskinesias (LID). As PD progresses to moderate and severe stages with continued levodopa treatment, dyskinesias can become significantly disabling and are associated with reduced quality of life. Encarnacion, EV and Hauser, RA, Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol, 2008. 60(2): p. 57-66. There are currently no approved drugs for the treatment of LID, and therefore a significant unmet medical need exists (as of August 2017).
[0005] LID may require a reduction in levodopa dose, resulting in patients receiving suboptimal PD therapy. Treatment of LID, which is significantly disabling and results in reduced quality of life, is an unmet medical need. Encarnacion et al. (supra).
[0006] As of August 2018, GOCOVRI™, an extended-release formulation of amantadine hydrochloride, was the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesias in people with Parkinson's disease receiving levodopa-based therapy with or without a dopamine agonist. GOCOVRI™ is the first Parkinson's disease medication proven in controlled trials to reduce both dyskinesias and off-time in Parkinson's disease patients receiving levodopa.
[0007] Amantadine is a weak, noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist that promotes dopamine release. Guttman, M., Kish, SJ, Furukawa, Y., Current concepts in the diagnosis and management of Parkinson's disease. Cmaj, 2003. 168(3): p. 293-301. Amantadine has shown efficacy in animal models of LID and is used off-label by neurologists and movement disorder specialists to treat LID in PD patients. Blanchet, PJ, Konitsiotis, S., Chase, TN, Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.Mov Disord,1998.13(5):p.798-802. Fox, SH, Lang, AE, Brotchie, JM, Translation of non-dopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord, 2006.21(10):p.1578-94.
[0008] Several small studies with different designs and endpoints in PD patients have shown that amantadine (IR formulation) is effective in treating LID. At a dose of 200 mg / day of amantadine, a reduction of approximately 25% in LID was reported (da Silva-Junior, FP, Braga-Neto, P., Monte, FS, et al., Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord, 2005.11(7):p.449-52, Snow, BJ, Macdonald, L., Mcauley, D., et al., The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.Clin Neuropharmacol,2000.23(2):p.82-85), and it was reported that at a dose of 300mg / day, the reduction in LID was about 40% (Luginger,E.,Wenning,GK,Bosch,S.,et al.,Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.Mov Disord,2000.15(5):p.873-8,Paci,C.,Thomas,A.,Onofrj,M.,Amantadine for dyskinesia in patients affected by severe Parkinson's disease.Neurol Sci,2001.22(1):p.75-6,Thomas,A.,Iacono,D.,Luciano,AL,et al.,Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry, 2004.75(1):p.141-3). In one study conducted at 300-400 mg / day, a reduction of approximately 60% was reported (Metman, LV, Del Dotto, P., Lepoole, K., et al., Amantadine for Levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol, 1999. 56(11):p.1383-6). In general, the reduction in LID appears to increase with increasing amantadine dose.
[0009] Many commercially available forms of amantadine are generally immediate release formulations that are typically administered two or more times daily. The use of amantadine is limited by dose-related CNS side effects, including dizziness, confusion, hallucinations, insomnia, and nightmares (Gracies JM, Olanow CW; Current and Experimental Therapeutics of Parkinson's Disease; Neuropsychopharmacology: the Fifth Generation of Progress pp1802; American College of Neuropsychopharmacology 2002), which can be particularly exacerbated when amantadine is administered at night (Jackson et al., Bull Pan Am Health Org, 147, 595-603 (1967)); Jackson, JAMA, 235 (25), (1976), 2739-2742; Hayden, AAC, 19 (2) 1981, pp. 226-233, and Hayden, AAC, 23 (3) 1983, pp. 458-464).
[0010] A dose of 200 mg / day of amantadine (IR formulation) was generally tolerated by the majority of PD patients. However, at this dose level, the efficacy of amantadine in LID is suboptimal for many patients. Amantadine IR at doses of 300 mg / day or higher results in a greater reduction in LID symptoms, but is associated with central nervous system (CNS) side effects including hallucinations, insomnia, nausea, and dizziness (lightheadedness) and gastrointestinal (GI) side effects including anorexia, nausea, vomiting, and diarrhea (Jackson et al., supra; Hayden, supra). In one study of immediate-release amantadine, increased plasma concentrations were associated with a higher incidence of CNS and sleep-related side effects but not GI side effects (Hayden 1983, supra).
[0011] It is known that immediate release amantadine can act as a stimulant, causing insomnia and sleep disorders.Therefore, to minimize these side effects, the last dose is typically administered by 4 p.m. (Fachinformation-Amantadin CT 100 mg Filmtabletten, March, 2008; Fung et al, Aust.Prescriber, 24(4)2001, pp 92-95).This administration of amantadine results in peak amantadine plasma concentration in the evening or at night, and very low plasma concentration in the morning.
[0012] Amantadine sustained release forms have been described in the art. U.S. Patent No. 5,358,721 to Guittard et al. and U.S. Patent No. 6,217,905 to Edgren et al. each disclose oral osmotic dosage forms containing antiviral drugs or antiparkinsonian drugs, respectively, and in each case amantadine is listed as an available drug for use in the dosage forms.U.S. Patent No. 6,194,000 to Smith et al. discloses analgesic immediate and controlled release pharmaceutical compositions using NMDA receptor antagonists such as amantadine as active agents. U.S. Patent Application Publication Nos. US2006 / 0252788, US2006 / 0189694 (U.S. Pat. No. 8,389,578), US2006 / 0142398, US2008 / 0227743, and US2011 / 0189273 (U.S. Pat. No. 8,741,343), all to Went et al., each disclose the administration of an NMDA receptor antagonist, such as amantadine, optionally in a controlled release form. Recently, extended release formulations of amantadine have been shown to reduce LID in Parkinson's disease patients taking levodopa (Pahwa et al. Amantadine Extended Release for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASED Study), Mov Disord. 2015.30(6):788-795). These extended release compositions are administered once nightly at 260-420 mg without increasing sleep-related adverse effects (US20110189273, US20150087721, Pahwa et al., supra). Immediate release forms of amantadine have been used to treat fatigue in patients with multiple sclerosis. Recently, extended release compositions have been investigated for the treatment of hypokinetic movement disorders in patients with multiple sclerosis (US2016 / 0228388). As mentioned above, GOCOVRI™, a sustained release formulation of amantadine hydrochloride, was recently approved by the FDA as the first and only FDA-approved medication for the treatment of dyskinesias in people with Parkinson's disease receiving levodopa-based therapy with or without a dopamine agonist. GOCOVRI™ is the first Parkinson's disease medication shown in controlled trials to reduce both dyskinesias and off-time in Parkinson's disease patients receiving levodopa. However, gastrointestinal side effects associated with the administration of immediate release and known sustained release amantadine formulations remain a significant problem, and therefore improved compositions and methods are needed. [Prior art documents] [Patent documents]
[0013] [Patent Document 1] U.S. Pat. No. 5,358,721 [Patent Document 2] US Patent Application Publication No. 2006 / 0252788 [Patent Document 3] U.S. Patent Application Publication No. 2006 / 0189694 [Patent Document 4] U.S. Patent Application Publication No. 2006 / 0142398 [Patent Document 5] U.S. Patent Application Publication No. 2008 / 0227743 [Non-Patent Document]
[0014] [Non-Patent Document 1] Encarnacion, E.V. and Hauser, R.A., Levodopa-induced dyskinesias in Parkinson’s disease: etiology, impact on quality of life, and treatments. Eur Neurol, 2008. 60(2): p. 57-66 [Non-Patent Document 2] Guttman, M., Kish, S.J., Furukawa, Y., Current concepts in the diagnosis and management of Parkinson’s disease. Cmaj, 2003. 168(3): p. 293-301 [Non-Patent Document 3] Blanchet, P.J., Konitsiotis, S., Chase, T.N., Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord, 1998. 13(5): p. 798-802 [Non-Patent Document 4] Fox,SH,Lang,AE,Brotchie,JM,Translation of non-dopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies:keys to success and roads to failure.Mov Disord,2006.21(10):p.1578-94
Direct Environment 5
Outdoor Configuration6
Direct Environment 7
Outdoor Tools 8
[0015] Described herein are sustained release oral compositions comprising amantadine or a pharma- ceutically acceptable salt thereof and methods of administering amantadine or a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) that provide improved gastrointestinal adverse event rates compared to known formulations. The compositions of the present disclosure also provide improved gastrointestinal adverse event rates compared to previously described sustained release formulations. When these sustained release oral compositions are administered once nightly to Parkinson's disease subjects at doses of 50 mg to 500 mg of amantadine or an equivalent amount of a pharma- ceutical acceptable salt thereof, the compositions are well tolerated, provide improvement in Parkinson's disease symptoms, motor fluctuations, levodopa-induced dyskinesia (LID), and provide improvement in the Clinician's Global Impression of Change (CGIC). The efficacy measures of once nightly administration of the amantadine oral compositions described herein are superior to currently available amantadine formulations, e.g., immediate release forms administered in divided doses. Additionally, the compositions of the present disclosure provide improved tolerability compared to known formulations, particularly when administered once daily, and especially when administered once daily 0-4 hours prior to bedtime.
[0016] In some aspects, the disclosure provides sustained release oral compositions comprising 50 mg to 500 mg, 60 mg to 400 mg, 60 mg to 300 mg, 137 mg to 500 mg, preferably 260 mg to 420 mg of amantadine or a pharma- ceutically acceptable salt thereof, in the form of a composition described herein, wherein upon administration to a single dose of the subject, fasted human pharmacokinetic studies provide a low incidence of gastrointestinal side effects including one or more of the following gastrointestinal disorders: abdominal bloating, constipation, diarrhea, indigestion, gum pain, dry mouth, lower abdominal pain, nausea, stomach discomfort, toothache, upper abdominal pain, and vomiting. In some variations, the sustained release oral composition comprises less than 6000 ppm of organic solvent, for example, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm. In certain embodiments, the sustained release oral composition comprises a plurality of core seeds, wherein each core seed is surrounded by a drug coating, and the plurality of coated core seeds comprises less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In some embodiments, the sustained release oral composition contains about 68.5 mg, about 137 mg, about 205.5 mg, or about 274 mg of amantadine. In certain embodiments, the sustained release oral composition contains about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine. In some embodiments, the sustained release oral composition contains about 85 mg, about 170 mg, about 255 mg, or about 340 mg of amantadine hydrochloride. In certain embodiments, the sustained release oral composition contains about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride.
[0017] In a second aspect, the disclosure provides a method of administering to a human subject once daily a sustained release oral composition comprising 50 mg to 500 mg, 60 mg to 400 mg, 60 mg to 300 mg, 137 mg to 500 mg, preferably 260 mg to 420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof, wherein the sustained release oral composition is therapeutically effective in treating the subject, and wherein the sustained release oral composition has a low incidence of one or more of the above-mentioned gastrointestinal side effects when administered to fasted single-dose human pharmacokinetic study subjects. In some embodiments, the fasted single-dose human pharmacokinetic study subjects are dosed in the morning after an overnight fast. In some variations, the sustained release oral composition comprises less than 6000 ppm of organic solvent, for example, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm. In certain embodiments, the sustained release oral composition comprises a plurality of core seeds, wherein each core seed is surrounded by a drug coating, and the plurality of coated core seeds comprises less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In some embodiments, the sustained release oral composition contains about 68.5 mg, about 137 mg, about 205.5 mg, or about 274 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, the sustained release oral composition contains about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the sustained release oral composition contains about 85 mg, about 170 mg, about 255 mg, or about 340 mg of amantadine hydrochloride. In certain embodiments, the sustained release oral composition contains about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride.
[0018] In a third aspect, the disclosure provides a method of administering a sustained release oral composition comprising 50 mg to 500 mg, 60 mg to 400 mg, 60 mg to 300 mg, 137 mg to 500 mg, preferably 260 mg to 420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof to a human subject once daily 0 to 4 hours prior to bedtime, wherein the sustained release oral composition is therapeutically effective in treating the subject, and wherein the sustained release oral composition has a low incidence of one or more of the gastrointestinal side effects described above when administered to subjects in a single-dose human pharmacokinetic study under fasted conditions. In some embodiments, the sustained release oral composition comprises about 68.5 mg, about 137 mg, about 205.5 mg, or about 274 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, the sustained release oral composition comprises about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the sustained release oral composition comprises about 85 mg, about 170 mg, about 255 mg, or about 340 mg of amantadine hydrochloride. In certain embodiments, the sustained release oral composition comprises about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride.
[0019] In some embodiments of any of the aspects described herein, the sustained release oral composition has a low incidence of sleep-related adverse effects when administered to subjects in single-dose human pharmacokinetic studies in the fasted state. In some embodiments of any of the aspects described herein, the sustained release oral composition has a low incidence of sleep-related adverse effects when administered in a therapeutically effective amount to subjects in single-dose human pharmacokinetic studies in the fasted state. In some embodiments of any of the aspects described herein, the sustained release oral composition has a low incidence of gastrointestinal adverse events when administered to subjects in single-dose human pharmacokinetic studies in the fasted state. In other embodiments of any of the aspects described herein, the sustained release oral composition has a low incidence of sleep-related adverse events and gastrointestinal adverse events when administered in a therapeutically effective amount to subjects in single-dose human pharmacokinetic studies in the fasted state. In some embodiments, a low incidence of gastrointestinal adverse events includes less than 12%, less than 10%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of subjects in single-dose human pharmacokinetic studies in the fasted state experiencing at least one gastrointestinal adverse event.
[0020] In some embodiments of the present disclosure, amantadine in the form of a composition described herein or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., hydrochloride salt) is administered at 50 mg to 500 mg, 60 mg to 400 mg, 60 mg to 300 mg, 137 mg to 500 mg, preferably 209 mg to 339 mg once nightly, 0 to 4 hours before bedtime, without sleep-related adverse effects in a subject with Parkinson's disease, and one (or more) of the following: A. LID is significantly improved in the subject; B. PD symptoms are improved; C. Clinical Global Impression of Change is significantly improved (compared to placebo); and / or D. Clinical Global Impression of Change is significantly, but not significantly different from placebo at higher and lower doses. In some embodiments of the present disclosure, the dyskinesia rating scale in A can be part of the UDysRS or other types of rating scales described below. In some embodiments, the sustained release oral composition contains about 68.5 mg, about 137 mg, about 205.5 mg, or about 274 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, the sustained release oral composition contains about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the sustained release oral composition contains about 85 mg, about 170 mg, about 255 mg, or about 340 mg of amantadine hydrochloride. In certain embodiments, the sustained release oral composition contains about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride. In some embodiments, amantadine is administered as between 260 mg and 420 mg of amantadine hydrochloride, hi certain embodiments, 340 mg of amantadine hydrochloride is administered (i.e., equivalent to 274 mg of amantadine).
[0021] In some aspects of the disclosure, amantadine in the form of a composition described herein or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., hydrochloride salt) is administered to a subject with Parkinson's disease at 50 mg to 500 mg, 60 mg to 400 mg, 60 mg to 300 mg, 137 mg to 500 mg, preferably 260 mg to 420 mg (more preferably 340 mg) once nightly, 0 to 4 hours before bedtime, to result in one or more of the following: A. an increase in daily on-time without bothersome dyskinesias compared to placebo; B. an increase in daily on-time without dyskinesias compared to placebo; C. a decrease in daily on-time with dyskinesias compared to placebo (or in a dose-responsive manner); D. a decrease in daily on-time with bothersome dyskinesias compared to placebo (or in a dose-responsive manner); and / or E. The daily off-time is reduced compared to placebo and / or higher amantadine dose potency. Thus, in some embodiments, administration of the drug once nightly before bedtime provides significant improvements in next-day measures of efficacy (e.g., increased on-time without dyskinesia, reduced off-time, improved dyskinesia) and / or tolerability. There is a need in the art for improved formulations of amantadine (or pharma- ceutically acceptable salts thereof) and methods of treatment with such formulations that have a low incidence of gastrointestinal side effects, preferably without adversely affecting sleep, and result in subjects having a higher plasma concentration of amantadine upon awakening in the morning compared to conventional amantadine therapy. In particular, there is a need in the art for methods of administering amantadine or a pharma-ceutically acceptable salt thereof in the late afternoon or early evening (e.g., after 4 p.m.) that reduce the side effects of insomnia and sleep disturbance, provide a low incidence of gastrointestinal side effects, and provide an effective plasma concentration of amantadine upon awakening. In some embodiments, the sustained release oral composition contains about 68.5 mg, about 137 mg, about 205.5 mg, or about 274 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, the sustained release oral composition contains about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the sustained release oral composition contains about 85 mg, about 170 mg, about 255 mg, or about 340 mg of amantadine hydrochloride. In certain embodiments, the sustained release oral composition contains about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride.
[0022] Thus, it is well known in the art that a method of administering a medicament to a subject that can be administered to the subject just before the subject desires to sleep (e.g., bedtime) without causing insomnia or sleep disorders, and with a low incidence of gastrointestinal side effects. There is a need for improved methods of amantadine therapy for the treatment of Parkinson's disease, LID in Parkinson's disease, and general symptoms of Parkinson's disease, including motor fluctuations, that provide a high plasma concentration of amantadine in a subject with multiple sclerosis, including, for example, improved walking speed, improved overall mobility, and / or improved ability to stand up. Additionally, there is a need for amantadine therapy that can be administered to a subject before the subject goes to sleep, and then provides an adequate amantadine plasma concentration when the subject wakes up after a night's sleep, for example, in the morning. Furthermore, there is a need in the art for improved methods of treating gait disorders in subjects with multiple sclerosis, including, for example, methods of improving walking speed, methods of improving overall mobility, and / or methods of improving ability to stand up.
[0023] In some embodiments of the present disclosure, a method of administering amantadine to a subject in need thereof is provided, comprising orally administering an extended release (ER) oral composition comprising amantadine or a pharma- ceutically acceptable salt thereof less than 3 hours before bedtime (e.g., the time the subject desires to sleep). This embodiment also includes the use of such compositions and the use of amantadine or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament as described herein. Alternatively, the composition is administered less than about 4 hours before bedtime. In some variations, the composition comprises less than 6000 ppm of organic solvent. In certain variations, the composition comprises less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In certain variations, the composition comprises a plurality of core seeds, each core seed being surrounded by a drug coating, and the plurality of coated core seeds comprises less than 6000 ppm of organic solvent, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm. In some variations, the organic solvent is an alcohol, such as isopropyl alcohol. In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.). In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl) ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphorus amide (e.g., hexamethylphosphoric triamide (HPMA), etc.).In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol)). In some embodiments, a mixture of two or more solvents may be used. In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents.
[0024] In some embodiments, administration occurs less than 2 hours 30 minutes, less than 2 hours, less than 1 hour 30 minutes, less than 1 hour, or less than 30 minutes before bedtime.
[0025] In some embodiments, the present disclosure provides a method for reducing sleep disturbance in a human subject undergoing treatment with amantadine, comprising administering an extended release (ER) oral composition comprising amantadine or a pharmaceutically acceptable salt thereof less than 3 hours before bedtime (e.g., the time the subject desires to sleep). This embodiment also includes the use of such compositions and the use of amantadine or a pharmaceutically acceptable salt thereof for the manufacture of medicaments as described herein. Alternatively, the composition is administered less than about 4 hours before bedtime.
[0026] In some embodiments of the present disclosure, amantadine or a pharma- ceutically acceptable salt thereof (e.g., hydrochloride salt) in the form of a composition described herein is administered in a reduced amount, e.g., 68.5-260 mg / day or an equivalent amount of a pharma- ceutically acceptable salt thereof, for at least one week prior to administration of a maintenance dose once daily. This titration period may improve tolerability of the maintenance dose. In some embodiments of the present disclosure, the subject is administered 68.5 or 137 mg / day of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof in the form of a composition described herein for at least one week prior to increasing the dose to 137 or 274 mg / day or an equivalent amount of a pharma- ceutically acceptable salt thereof, in this embodiment, the amantadine may be in the form of a pharma- cetically acceptable salt, such as amantadine hydrochloride, and the amount of amantadine hydrochloride may be 85 or 170 mg / day for at least one week prior to increasing the dose to 170 or 340 mg / day. In some embodiments of the methods including the titration period and oral pharmaceutical composition for use in the methods described herein, the subject has Parkinson's disease. In certain embodiments, the methods include treating levodopa-induced dyskinesia, or fatigue, or dementia, or any other symptoms of Parkinson's disease. In certain embodiments, the methods include decreasing off-time, or increasing on-time without bothersome dyskinesia, or a combination thereof, in a subject with Parkinson's disease, where the subject is being treated with a Parkinson's disease medication. In some embodiments, the Parkinson's disease medication is levodopa. In certain embodiments, the Parkinson's disease medication includes levodopa. In some embodiments, the Parkinson's disease medication includes levodopa in combination with carbidopa. In other embodiments of the methods including the titration period and oral pharmaceutical composition for use in the methods described herein, the subject has multiple sclerosis. In certain embodiments, the methods of the present invention include treating a hypokinesia disorder in a subject with multiple sclerosis. In some embodiments, the hypokinetic disorder is a gait disorder.In some embodiments, treating a hypokinetic disorder comprises improving walking speed, improving walking ability, improving overall mobility, and / or improving the ability to stand up.
[0027] In some embodiments, the present disclosure provides a method for treating levodopa-induced dyskinesia, or fatigue, or dementia, or any other symptoms of Parkinson's disease, comprising administering an extended release (ER) oral composition comprising amantadine or a pharmaceutically acceptable salt thereof less than about 3 hours before bedtime (e.g., the time the subject desires to sleep).In other embodiments, the present disclosure provides a method for treating a hypokinesia disorder in a subject with multiple sclerosis, comprising administering an extended release (ER) oral composition comprising amantadine or a pharmaceutically acceptable salt thereof less than 3 hours before bedtime.Also provided herein are oral pharmaceutical compositions for use in one or more of these methods. For example, in some embodiments, the present invention provides an oral pharmaceutical composition for use in treating levodopa-induced dyskinesia in a subject with Parkinson's disease, or reducing off-time in a subject with Parkinson's disease, or reducing on-time with bothersome dyskinesia in a subject with Parkinson's disease, or increasing on-time without bothersome dyskinesia in a subject with Parkinson's disease, or treating a movement-decreasing disorder in a subject with multiple sclerosis.These embodiments also include the use of such compositions for the manufacture of the medicament described herein and the use of amantadine or a pharma- ceutical acceptable salt thereof.In some embodiments, the medicament contains less than 6000 ppm of organic solvent. In certain variations, the composition comprises less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In some variations, the medicament comprises a plurality of core seeds, where each core seed is surrounded by a drug coating, and the plurality of coated core seeds comprises less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent.In some variations, the organic solvent is an alcohol, such as isopropyl alcohol. In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.). In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl)ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphorus amide (e.g., hexamethylphosphoric triamide (HPMA), etc.). In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol)). In some embodiments, a mixture of two or more solvents may be used. In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents.
[0028] In some embodiments, the present disclosure provides a method for treating brain injury, head trauma, dementia, Alzheimer's disease, stroke, Huntington's disease, ALS, multiple sclerosis, neurodegenerative disease, dementia, cerebrovascular pathology, movement disorder, cranial nerve disorder, neuropsychiatric disorder, comprising administering to a subject certain extended release (ER) oral compositions comprising amantadine or a pharmaceutically acceptable salt thereof less than about 3 hours before bedtime (e.g., the time the subject desires to sleep). This embodiment also includes a method for treating symptoms associated with the above-mentioned disorders, including reduced movement disorders such as gait disorders in multiple sclerosis. This embodiment also includes the use of such compositions and the use of amantadine or a pharmaceutically acceptable salt thereof for the manufacture of medicaments as described herein.
[0029] In some embodiments of any of the aspects herein, administration occurs less than 2 hours 30 minutes, less than 2 hours, less than 1 hour 30 minutes, less than 1 hour, or less than 30 minutes before bedtime (e.g., the time the subject desires to sleep).
[0030] In some embodiments of any of the aspects herein, the subject has been diagnosed with Parkinson's disease, hi some embodiments, the subject has been diagnosed with multiple sclerosis.
[0031] In some embodiments of any of the aspects herein, the composition is administered once at night.
[0032] In other embodiments, the daily dose of amantadine is 50 mg to 500 mg, 60 mg to 400 mg, 60 mg to 300 mg, 137 mg to 274 mg (preferably 274 mg), or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the daily dose is 60 mg to 340 mg or 170 mg to 340 mg of amantadine hydrochloride, or an equivalent amount of a different pharma- ceutically acceptable salt thereof, administered in one, two, or three capsules of size 0, 1, or 2 in regular and / or EL form (e.g., depending on capsule sizing).
[0033] In certain embodiments, the daily dose of amantadine is about 68.5 mg, about 137 mg, about 205.5 mg, or about 274 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, the daily dose of amantadine is about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In still other embodiments, the daily dose is about 85 mg, about 170 mg, about 255 mg, or about 340 mg of amantadine hydrochloride. In certain embodiments, the daily dose is about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride. In any of these embodiments, in some embodiments, the dose may be administered in one, two, or three capsules of size 0, 1, or 2 in regular and / or EL form (e.g., capsule sizing).
[0034] In some embodiments of any of the aspects herein, administration of the compositions of the present invention to a subject with Parkinson's disease results in a significant reduction in levodopa-induced dyskinesia (LID). In certain embodiments, administration of the compositions of the present invention results in about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% reduction in levodopa-induced dyskinesia. In further embodiments, the reduction in levodopa-induced dyskinesia is measured on a numerical scale used by the FDA to evaluate the effectiveness of drugs shown to reduce LID. In further specific embodiments, the scale used to measure the reduction in LID can be the UDysRS, UPDRS part IV (subscores 32, 33), MDS-UPDRS part IV and subscores 4.1 and 4.2, the Dyskinesia Rating Scale (DRS), the Abnormal Involuntary Movement Scale (AIMS), or other scales developed for this purpose.
[0035] In some embodiments of any of the aspects herein, administration of the oral composition to a subject with Parkinson's disease results in a significant reduction in Parkinson's disease symptoms, including motor fluctuations. In certain embodiments, administration of the composition of the present invention results in about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% reduction in Parkinson's disease symptoms, including motor fluctuations. In further specific embodiments, the reduction in Parkinson's disease symptoms is measured by a numerical scale used by the FDA to evaluate the effectiveness of drugs that have been shown to reduce Parkinson's disease symptoms, including motor fluctuations. In further specific embodiments, the scale used to measure the reduction in Parkinson's disease symptoms, including motor fluctuations, can be the Unified Parkinson's Disease Rating Scale (UPDRS), MDS-UPDRS, or analysis of PD Diary data (for motor fluctuations).
[0036] In some embodiments of any of the aspects herein, administration of the oral composition to a subject results in a significant improvement in the Clinician Global Impression (CGI) or any other physician measurement of the subject's overall condition. In certain embodiments, administration of the composition of the invention results in about a 5%, 10%, 15%, 20%, 25%, 30%, 35% or 40% improvement in the CGI. In further specific embodiments, the improvement in the CGI is measured on a numerical scale used by the FDA to evaluate the effectiveness of drugs shown to treat CNS disorders.
[0037] In yet another embodiment, provided herein is a method for reducing off-time in a subject with Parkinson's disease and an oral pharmaceutical composition for use in reducing off-time, wherein the subject is treated with a Parkinson's disease medication comprising administering to the subject an oral pharmaceutical composition as described herein. In some embodiments, the total daily time of off-time is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%. In some embodiments, the off-time is reduced compared to placebo as assessed in a placebo-controlled double-blind clinical trial. In other embodiments, the off-time is reduced compared to the subject's off-time before starting administration of the oral pharmaceutical composition.
[0038] In yet another embodiment, provided herein is a method for increasing on-time without bothersome dyskinesias in a subject with Parkinson's disease and an oral pharmaceutical composition for use in increasing on-time without bothersome dyskinesias, wherein the subject is being treated with a Parkinson's disease medication comprising administering to the subject a pharmaceutical composition as described herein. In some embodiments, the total daily time of on-time without bothersome dyskinesias is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or less or at least 70%. In some embodiments, the on-time without bothersome dyskinesias is increased compared to placebo as assessed in a placebo-controlled double-blind clinical trial. In other embodiments, the on-time without bothersome dyskinesias is increased compared to the on-time without bothersome dyskinesias of the subject before starting administration of the oral pharmaceutical composition.
[0039] In some embodiments of the method for treating hypokinesia in a subject with multiple sclerosis and the oral pharmaceutical composition for treating hypokinesia in a subject with multiple sclerosis provided herein, walking speed is improved, walking ability is improved, overall mobility is improved, or the ability to stand up is improved, or any combination thereof.In some embodiments, administering a composition as described herein to a subject with multiple sclerosis results in 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% improvement in one or more of walking speed, walking ability, overall mobility, or the ability to stand up.Overall mobility can include, for example, the total amount of walking throughout the day, or the ability to stand up one or more times throughout the day, or a combination thereof. In some embodiments, walking speed, walking ability, overall mobility, or ability to stand is assessed by at least one or a combination of the following: Timed 25-foot walk test (T25FW), Timed Up and Go (TUG), 2-minute walk test, 6-minute walk test (6MTW), and / or 12-item Multiple Sclerosis Walking Scale (MSWS-12). In some embodiments, T25FW, TUG, 2-minute walk, 6MTW, and / or MSWS-12 are significantly improved compared to placebo as assessed in a placebo-controlled double-blind clinical trial. In other embodiments, T25FW, TUG, 2-minute walk, 6MTW, and / or MSWS-12 are significantly improved compared to before the subject began administering the composition as described herein. In some embodiments, reduced gait disturbance is measured by a numerical scale used or accepted by the FDA or other regulatory agencies to evaluate the effectiveness of and approve approved drugs for the treatment of gait disturbance. In some embodiments, administration of the composition results in about a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% improvement in one or more of the assessment scores described herein.
[0040] In some embodiments of any of the aspects herein, the amantadine plasma concentration does not increase for at least 1 hour after administration at a steady state plasma concentration.
[0041] In some embodiments of any of the aspects herein, the amantadine plasma concentration does not increase for at least 2 hours after administration at a steady state plasma concentration.
[0042] In some embodiments of any of the aspects herein, administration of the oral composition to a human subject at a steady state amantadine plasma concentration increases the amantadine plasma concentration by less than 5%, 10%, 15%, 20% or 25% 1, 2, 2.5 or 3 hours after such administration. For example, administration of the composition to a human subject at a steady state amantadine plasma concentration increases the amantadine plasma concentration by less than 5% 1, 2, 2.5 or 3 hours after such administration; or less than 10% 1, 2, 2.5 or 3 hours after such administration; or less than 15% 1, 2, 2.5 or 3 hours after such administration; or less than 20% 1, 2, 2.5 or 3 hours after such administration; or less than 25% 1, 2, 2.5 or 3 hours after such administration.
[0043] In some embodiments of any of the aspects herein, amantadine has a single dose Tmax of 11 to 19 hours. In more specific embodiments, amantadine has a single dose Tmax of 11 to 18 hours after administration. In some embodiments, the Tmax of amantadine is 11, 12, 13, 14 hours to 15, 16, 17, 18, 19 hours after administration to healthy subjects in a single dose fasted human pharmacokinetic study.
[0044] In some embodiments of any of the aspects herein, the amantadine has a steady state Tmax of 7-16 hours. In certain embodiments, the amantadine has a steady state Tmax of 7-14 hours after administration. In other embodiments, the amantadine has a steady state Tmax of 8-12 hours after administration. In some embodiments, the steady state Tmax is the median value obtained from a multiple-dose, fasting human pharmacokinetic study in healthy subjects.
[0045] In some embodiments of any of the aspects described herein, at least 80%, preferably at least 90%, of the amantadine or a pharmacokinetically acceptable salt thereof is released from the compositions of the invention when administered to fasting human pharmacokinetic study subjects at a single dose, as determined by bioavailability, compared to an immediate release oral formulation of the same drug substance at a comparable dose.
[0046] In some embodiments of any of the aspects described herein, the AUC of amantadine for the compositions of the disclosure inf is 40, 41, 42, 43, 44, or 45 to 64, 66, 68, 70, or 72 ng*hr / ml per mg of drug of the composition, as determined by administering the composition to subjects in a fasted human pharmacokinetic study at a single dose. In some embodiments, the composition has an AUC of 42 to 72 ng*hr / ml per mg of drug of the composition, as determined by administering the composition to subjects in a fasted human pharmacokinetic study at a single dose. inf In certain embodiments, the composition has an AUC of 44 to 72 ng*hr / ml per mg of drug of the composition as determined by administration of the composition to subjects in a single dose fasted human pharmacokinetic study. inf has.
[0047] In some embodiments described herein, the pAUC of amantadine for the compositions of the present disclosure 0-6 is less than or equal to 1.0 ng*hr / ml per mg of drug of the composition as determined by administration of the composition to subjects in a fasted human pharmacokinetic study at a single dose. 0-6 is 0.1, 0.2, 0.3, 0.4 or 0.5-0.6, 0.7, 0.8, 0.9 or 1.0 ng*hr / ml per mg of drug of the composition as determined by administration of the composition to fasting human pharmacokinetic study subjects at a single dose. More preferably, the pAUC of amantadine for the compositions of the invention is 0-6is 0.3-0.9 ng*hr / ml per mg of drug of the composition as determined by administration of the composition to fasting human pharmacokinetic study subjects in a single dose.
[0048] In some embodiments described herein, the pAUC of amantadine for compositions of the present disclosure is determined by administering the compositions to subjects in a single-dose fasted human pharmacokinetic study. 0-8 is less than or equal to 2.0 ng*hr / ml per mg of drug in the composition. Preferably, the pAUC of amantadine for the compositions of the present invention is 0-8 is 1.0, 1.1, 1.2, 1.3 or 1.4 to 1.8, 1.9, 2.0, 2.1, 2.2, 2.3 or 2.4 ng*hr / ml per mg of drug of the composition as determined by administration of the composition to fasting human pharmacokinetic study subjects at a single dose. More preferably, the pAUC of amantadine for the compositions of the invention is 0-8 is 1.0-2.0 ng*hr / ml per mg of drug of the composition as determined by administration of the composition to fasted human pharmacokinetic study subjects in a single dose.
[0049] In some embodiments of any of the aspects herein, a single nighttime oral administration of a composition of the invention to a human subject provides a steady-state plasma concentration profile characterized by an increase in amantadine concentration of less than 25% at 3 hours after administration. In more specific embodiments, the steady-state plasma concentration profile is characterized by an increase in amantadine concentration of less than 25% at 4 hours after administration.
[0050] In some embodiments of any of the aspects herein, the compositions of the invention are administered once daily and the ratio of Cmax to Cmin at steady state is 1.3 to 1.8, or more specifically 1.4 to 1.7, or more specifically about 1.6.
[0051] In embodiments of any of the aspects herein, the steady state plasma concentration profile following multiple administration of a composition of the invention to a human subject at bedtime is characterized by an average daytime plasma concentration ("C-ave-day", defined as the average daytime amantadine plasma concentration as measured in a human PK study) that is 1.2 to 1.7 times the average nighttime plasma concentration ("C-ave-night", defined as the average nighttime amantadine plasma concentration as measured in a human PK study). In more specific embodiments, C-ave-day is the average amantadine plasma concentration measured between 5:00 AM, 6:00 AM, 7:00 AM, 8:00 AM, or 9:00 AM to 4:00 PM, 5:00 PM, 6:00 PM, 7:00 PM, or 8:00 PM, e.g., between 6:00 AM to 4:00 PM, 6:00 AM to 4:00 PM, 7:00 AM to 6:00 PM, or 7:00 AM to 5:00 PM. C-ave-night is the mean amantadine plasma concentration measured between 4 PM, 5 PM, 6 PM, 7 PM, 8 PM, 9 PM, 10 PM or 11 PM-5 AM, 6 AM, 7 AM, 8 AM or 9 AM, e.g., 8 PM-5 AM, 10 PM-6 AM, 7 PM-6 AM, or 8 PM-6 AM.
[0052] In some embodiments of any of the aspects herein, amantadine is administered as a pharma- ceutically acceptable salt, preferably amantadine hydrochloride.
[0053] In some embodiments of any of the aspects herein, administration of a single dose of a composition of the invention to a human subject provides a plasma concentration profile characterized by: AUC 0-inf a partial AUC from 0 to 4 hours that is less than 1%, preferably less than 0.5%, more preferably less than 0.3%, and most preferably less than 0.2% of the AUC 0-inf partial AUC from 0 to 8 hours, which is 4.5% or less, preferably 1.0% to 4.0%, more preferably 1.5% to 3.75%, and most preferably 1.75% to 3.5% of the total; AUC 0-inf A partial AUC from 0 to 12 hours, which is about 5% to 15%, preferably about 7.0% to 12.0% of the AUC 0-infa partial AUC from 0 to 18 hours that is about 20% to 35%, preferably about 22.5% to 27.5%, of the AUC 0-inf A partial AUC from 0 to 24 hours that is about 34% to 48%, preferably about 36% to 44% of. In some embodiments, the subject is a subject in a single-dose fasted human pharmacokinetic study. In some embodiments, the single-dose fasted human pharmacokinetic study is dosed in the morning after an overnight fast.
[0054] In some embodiments of any of the aspects described herein, the once-nightly dose of amantadine in the composition form described herein may range from 68.5 mg to 500 mg, or a corresponding range of a pharma- ceutically acceptable salt thereof. Preferably, the dose of amantadine is 50 mg to 500 mg, 60 mg to 400 mg, 60 mg to 300 mg, 137 mg to 403 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof. More preferably, the dose of amantadine is 68.5 mg to 274 mg, or 137 mg to 274 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof. Alternatively, the dose of amantadine hydrochloride is 60 mg to 340 mg, or 170 mg to 340 mg. In other embodiments, the nightly dose of amantadine is greater than 340 mg / day or an equivalent pharmaceutically acceptable salt thereof, e.g., the dose of amantadine is 340-500 mg / day, more specifically, 410-480 mg / day, or an equivalent pharmaceutically acceptable salt thereof. In other embodiments, the nightly dose of a pharmaceutically acceptable salt of amantadine (e.g., amantadine hydrochloride) is greater than 340 mg / day, e.g., the dose of a pharmaceutically acceptable salt is 340-500 mg / day, more specifically, 410-480 mg / day. In various specific embodiments, the daily dose of amantadine is 50-75 mg, 70-95 mg, 90-115 mg, 110-135 mg, 130-155 mg, 150-175 mg, 170-195 mg, 190-215 mg, 210-235 mg, 230-255 mg, 250-275 mg, 270-295 mg, 290-305 mg, 300-315 mg, 310 In yet other embodiments, the daily dose of amantadine is about 68.5 mg, about 137 mg, about 205.5 mg, or about 274 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof.In certain embodiments, the daily dose is about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the daily dose is about 85 mg, about 170 mg, about 255 mg, or about 340 mg of amantadine hydrochloride. In certain embodiments, the daily dose is about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride.
[0055] In some embodiments of any of the aspects herein, the compositions of the invention contain 50 mg to 500 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. More specifically, the compositions of the invention may contain 100 mg to 450 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. Even more specifically, the compositions of the invention may contain 130 mg to 210 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In various specific embodiments, the dosage forms containing the compositions of the invention contain 50-75 mg, 70-95 mg, 90-115 mg, 110-135 mg, 130-155 mg, 150-175 mg, 170-195 mg, 190-215 mg, 210-235 mg, 230-255 mg, 250-275 mg, 270-295 mg, 290-305 mg, 300-315 mg, 310-325 mg, 320-335 mg, 330-345 mg, 340-355 mg, or 350-365 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, a single nightly dose of a pharma- ceutically acceptable salt of amantadine is 340 mg of the composition forms described herein. In yet other embodiments, the dosage form of the composition of the invention contains about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, about 245 mg to about 305 mg, about 68.5 mg, about 137 mg, about 205.5 mg, or about 274 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, the dosage form of the composition of the invention contains about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, about 305 mg to about 375 mg, about 85 mg, about 170 mg, about 255 mg, or about 340 mg of amantadine hydrochloride.
[0056] In some embodiments of any of the aspects described herein, the once nightly oral composition is administered as 1, 2, 3, or 4 unit dosage forms, either unequally or preferably equally divided units. In some more specific embodiments, the compositions of the invention are administered as 2 or 3 unit dosage forms, each containing 68.5 to 175 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, the compositions of the invention are administered as 2 or 3 unit dosage forms, each containing about 60 mg to about 175 mg, or about 60 mg to about 155 mg, or about 60 mg to about 80 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0057] In some embodiments of any of the aspects herein, the compositions of the invention are administered as two or three unit dosage forms of unequal or preferably equal doses, each containing 68.5-250 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some more specific embodiments, the compositions of the invention are administered as two unit dosage forms, each containing 150-180 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In yet other embodiments, the compositions of the invention are administered as two unit dosage forms, each containing 150-180 mg of a pharma- ceutically acceptable salt of amantadine.
[0058] In some embodiments of any of the aspects herein, oral administration of a single dose of a composition of the invention to a cohort of healthy human volunteer subjects in a fasted state provides a mean maximum plasma concentration (Cmax) of amantadine of 1.1-2.3 ng / ml per mg amantadine or a pharmacologic salt thereof. In more specific embodiments, oral administration of a single dose of a composition of the invention to a cohort of human subjects in a fasted state provides a mean maximum plasma concentration (Cmax) of amantadine of 1.2-2.0 ng / ml per mg amantadine or a pharmacologic salt thereof and an AUC of amantadine of 42-72 ng*h / mL per mg amantadine or a pharmacologic salt thereof. 0-inf (area under the concentration curve from t=0 to t=infinity).
[0059] In some embodiments of any of the aspects herein, daily oral administration of a single dose of a composition of the invention to a cohort of human subjects provides a steady state plasma concentration profile characterized by at least one of the following: (i) a mean Cmax of amantadine of 2.2-3.6 ng / ml per mg of amantadine or a pharmaceutically acceptable salt thereof, (ii) a mean Cmin of amantadine of 1.4-2.0 ng / ml per mg of amantadine or a pharmaceutically acceptable salt thereof, and (iii) a mean AUC of 46-72 ng*h / mL per mg of amantadine or a pharmaceutically acceptable salt thereof. 0-24 In a more specific example, all three criteria (i), (ii) and (iii) are met.
[0060] In more specific embodiments, the steady state plasma concentration profile is further characterized by: (iv) no increase in the concentration of amantadine for at least 1 hour after administration; and (v) a Cmax / Cmin ratio of 1.4 to 2.0. In more specific embodiments, both criteria (iv) and (v) are met.
[0061] In some embodiments of any of the aspects herein, the compositions of the invention have an in vitro dissolution profile of amantadine or a pharma- ceutically acceptable salt thereof that exhibits at least one of the following: (i) no more than 10% dissolution in 2 hours, (ii) 5% to 13% dissolution in 4 hours, (iii) 20% to 43% dissolution in 6 hours, (iv) 50% to 70% dissolution in 8 hours, and (v) at least 80% dissolution in 12 hours using USP Apparatus II (paddle) at 50 rpm with 500 ml of water at 37.0±0.5°C as the dissolution medium. In more specific embodiments, two of criteria (i), (ii), (iii), (iv) and (v) are met. In more specific embodiments, three of criteria (i), (ii), (iii), (iv) and (v) are met. In more specific embodiments, four of criteria (i), (ii), (iii), (iv) and (v) are met. In even more specific embodiments, all five of criteria (i), (ii), (iii), and (iv) are met. In some embodiments, criteria (i), (iii), (iv), and (v) are met.
[0062] In some embodiments of any of the aspects herein, the compositions of the invention have an in vitro dissolution profile of amantadine or a pharma- ceutically acceptable salt thereof that exhibits at least one of the following: (i) 9% or less dissolution in 2 hours, (ii) 3% to 14% dissolution in 4 hours, (iii) 20% to 43% dissolution in 6 hours, (iv) 45% to 70% dissolution in 8 hours, and (v) at least 82% dissolution in 12 hours using USP Apparatus II (paddle) at 50 rpm with 500 ml of water at 37.0±0.5°C as the dissolution medium. In more specific embodiments, two of criteria (i), (ii), (iii), (iv), and (v) are met. In more specific embodiments, three of criteria (i), (ii), (iii), (iv), and (v) are met. In certain embodiments, four of criteria (i), (ii), (iii), (iv), and (v) are met. In still more specific embodiments, all five of criteria (i), (ii), (iii), and (iv) are met. In some embodiments, criteria (i), (iii), (iv), and (v) are met. In another aspect, the disclosure provides an oral pharmaceutical composition comprising a plurality of coated core seeds and a capsule shell, wherein the coated core seeds are encapsulated within a capsule shell, the coated core seeds comprising a core seed comprising an inert material; a drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof and a binder; and a sustained release coating surrounding the drug coating, the drug coating comprising ethylcellulose, a pore-forming agent, e.g., hydroxypropylmethylcellulose or povidone, and a plasticizer. In some embodiments of this aspect, the drug coating of amantadine and a binder is prepared and applied to the core seeds without the use of organic solvents.
[0063] In another aspect, the disclosure provides an oral pharmaceutical composition for use in the methods of the aspects described herein, wherein the composition is for oral administration and comprises a capsule for oral administration, the capsule comprising a plurality of coated core seeds comprising: (a) core seeds, (b) a drug coating surrounding the core seeds, the drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof, and (c) a sustained release coating surrounding the drug coating. In some embodiments of this aspect, the drug coating comprises amantadine or a pharma- ceutically acceptable salt thereof and one or more binders, and the drug coating is prepared and applied to the core seeds without the use of organic solvents.
[0064] In some embodiments, the sustained release coating comprises ethylcellulose and at least one of povidone and hydroxypropyl methylcellulose, and a plasticizer. In more specific embodiments, the sustained release coating comprises ethylcellulose, povidone, and a plasticizer.
[0065] In some embodiments, the drug coating comprises amantadine and a binder and surrounds the core seed. In some embodiments, the core seed is a granulated sugar (nonpareil) or a microcrystalline cellulose seed (e.g., Celphere®). In more specific embodiments, the core seed is a microcrystalline cellulose core. In another specific embodiment, the core seed has a diameter ranging from 100 microns to 1,000 microns. In further specific embodiments, the core seed has a diameter of 100, 200, 300, 400, 500, 600, or 700 microns. In further specific embodiments, 90% or more of the core seeds of the compositions of the present invention have a diameter of 100-200 microns, 150-250 microns, 200-300 microns, 250-350 microns, 300-400 microns, 350-450 microns, 400-500 microns, 500-600 microns, 550-650 microns, 600-700 microns, In some embodiments, the core seeds have a diameter of less than 500 microns.
[0066] In some embodiments, amantadine or a pharma- ceutically acceptable salt thereof is present in an amount of 20-80% by weight, based on the combined weight of the core seed, drug coating, and sustained release coating, and is present in an amount of 0.3-1.2 g / cm. 3 It has a bulk density of.
[0067] In some embodiments, amantadine or a pharma- ceutically acceptable salt thereof is present in an amount of 40-60% by weight, based on the combined weight of the core seed, drug coating, and sustained release coating, and is present in an amount of 0.5-1.2 g / cm 3 It has a bulk density of.
[0068] In some embodiments, amantadine or a pharma- ceutically acceptable salt thereof is present in an amount of 60-80% by weight, based on the combined weight of the core seed, drug coating, and sustained release coating, and is present in an amount of 0.5-1.2 g / cm. 3 It has a bulk density of.
[0069] In some embodiments, the binder is present in an amount of 8-25% by weight, based on the combined weight of the core seed, drug coating, and sustained release coating.
[0070] In some embodiments, the core seeds are present in an amount of 8-25% by weight, based on the combined weight of the core seeds, the drug coating, and the sustained release coating.
[0071] In some embodiments, the ethylcellulose is present in an amount of 10-24% by weight, based on the combined weight of the core seed, drug coating, and sustained release coating.
[0072] In some embodiments, povidone is present in an amount of 1-4% by weight, based on the combined weight of the core seed, drug coating, and sustained release coating.
[0073] In some embodiments, the plasticizer is present in an amount of 1-4% by weight, based on the combined weight of the core seed, drug coating, and sustained release coating.
[0074] In some embodiments, the coated core seeds have an average diameter ranging from 200 microns to 1700 microns. In further specific embodiments, the coated core seeds have an average diameter ranging from 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, or 1,500 microns. In further embodiments, the coated core seeds have an average diameter ranging from 200, 300, 400, 500, 600, 700, 800, 900 microns to 400, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, or 1,500 microns. In certain specific embodiments, the coated core seeds have an average diameter of less than 1000 microns (e.g., 500 to 1000 microns).
[0075] In some embodiments, the coated core seeds further comprise a sealing coating surrounding the drug coating, where the sustained release coating surrounds the sealing coating. In some embodiments, an inert coating may be applied to the inert core seeds prior to the drug coating, or to the drug coated core seeds, or to the sustained release coated core seeds. In another embodiment, an enteric coating may be applied to the drug coated core seeds or the sustained release coated core seeds.
[0076] In some embodiments, the drug coating comprises a binder selected from the group consisting of hydroxypropyl methylcellulose, copovidone, and mixtures thereof.
[0077] In some embodiments, the compositions described herein are provided in size 3, size 2, size 1, size 0 or 00 capsules in regular and / or EL format.
[0078] In some embodiments, a therapeutically effective daily dose of a composition described herein is administered in no more than two capsules. In another embodiment, a therapeutically effective daily dose of a composition of the invention is administered in no more than three size 1 capsules. In another embodiment, a therapeutically effective daily dose of a composition of the invention is administered in no more than two size 0 capsules. In yet other embodiments, a therapeutically effective daily dose of a composition of the invention is administered in no more than two size 1 capsules. In another embodiment, a therapeutically effective bi-daily dose of a composition of the invention is administered in no more than three size 1 capsules.
[0079] In some embodiments, the compositions described herein are provided in an amount of 50-110 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof in a size 2 capsule, or in an amount of 110 mg-210 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof in a size 1 capsule. In further embodiments, the compositions described herein contain 40-80% by weight of amantadine or a pharma- ceutically acceptable salt thereof, and are provided in a concentration of 0.5-1.2 g / cm. 3In certain embodiments, the compositions described herein have an in vitro dissolution profile of amantadine that exhibits at least one of the following: (i) no more than 10% dissolution in 2 hours, (ii) 5% to 13% dissolution in 4 hours, (iii) 20% to 43% dissolution in 6 hours, (iv) 45% to 70% dissolution in 8 hours, and (v) at least 82% dissolution in 12 hours using USP Apparatus II (paddle) at 50 rpm with 500 ml of water at 37.0±0.5° C. as the dissolution medium. In more specific embodiments, two of criteria (i), (ii), (iii), (iv) and (v) are met. In some embodiments, three of criteria (i), (ii), (iii), (iv) and (v) are met. In more specific embodiments, four of criteria (i), (ii), (iii), (iv) and (v) are met. In even more specific embodiments, all five of criteria (i), (ii), (iii), (iv) and (v) are met. In certain embodiments, criteria (i), (iii), (iv) and (v) are met.
[0080] In some embodiments, the plasticizer is selected from the group consisting of medium chain triglycerides, diethyl phthalate, citrate esters, polyethylene glycols, glycerol, acetylated glycerides, and castor oil. In certain embodiments, the plasticizer is a medium chain triglyceride (e.g., Miglyol 812N).
[0081] In other embodiments, the disclosure provides methods of treating Parkinson's disease and / or LID in a human subject in need thereof, comprising orally administering a composition of any of the aspects herein. In certain embodiments, the disclosure provides methods of treating a disease in a human subject in need thereof, comprising orally administering a composition of any of the aspects herein once nightly, administering 1, 2 or 3 dosage forms.
[0082] Reference to administering amantadine or a pharmaceutically acceptable salt thereof to a subject in need thereof includes treating a subject with a disease or condition, including iatrogenic conditions (e.g., LID) that can be treated, prevented, or cured by an NMDA antagonist. More specifically, administering amantadine or a pharmaceutically acceptable salt thereof to a subject in need thereof includes treating a subject diagnosed with Parkinson's disease, brain injury, head trauma, dementia, Alzheimer's disease, stroke, Huntington's disease, ALS, multiple sclerosis, neurodegenerative disease, dementia, cerebrovascular conditions, movement disorders, cranial nerve disorders, neuropsychiatric disorders, and other CNS disorders.
[0083] Some embodiments described herein provide a method of improving a CGI in a subject having Parkinson's disease, comprising administering to the subject a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof and at least one modified release excipient once nightly, 0-4 hours before bedtime. In some embodiments, the composition of the invention comprises 260-340 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the composition of the invention comprises 260 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the composition of the invention comprises 340 mg of a pharma- ceutically acceptable salt of amantadine. In some embodiments, the change in CGI is measured in a placebo-controlled double-blind clinical trial. Also provided is an oral pharmaceutical composition as described herein for use in improving a CGI in a subject having Parkinson's disease, comprising administering to the subject a once nightly, 0-4 hours before bedtime.
[0084] Some embodiments described herein provide a method for producing at least one, preferably at least two of the outcomes selected from the group consisting of: (A) increased on-time without bothersome dyskinesias; and (B) reduced off-time; and (C) improved CGI in a subject with a CNS disorder, comprising administering to the subject a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof and at least one modified release excipient once nightly, 0-4 hours before bedtime. In some embodiments, the composition of the invention comprises 260-340 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the composition of the invention comprises 260 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the composition of the invention comprises 340 mg of a pharma- ceutically acceptable salt of amantadine. In some embodiments, the change in on-time without dyskinesias, off-time, and / or CGI is measured in a placebo-controlled double-blind clinical trial using a PD home diary. In some embodiments, the CGI is measured by questions answered by an investigator.Also provided is an oral pharmaceutical composition as described herein for use in a subject with a CNS disorder, comprising administering to the subject once nightly, 0-4 hours before bedtime, for at least one or at least two of the following outcomes selected from the group consisting of: (A) increasing on-time without bothersome dyskinesias; (B) reducing off-time; and (C) improving CGI.
[0085] Some embodiments described herein provide a method for producing at least one, preferably at least two of the results selected from the group consisting of: (A) increased on-time without bothersome dyskinesias; and (B) reduced off-time; and (C) improved CGI in a subject with a CNS disorder, comprising administering to the subject once daily a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharmacologic acceptable salt thereof and at least one modified release excipient. Also provided herein are oral pharmaceutical compositions for use in such methods. In some embodiments, the compositions of the invention comprise 260-340 mg of amantadine or an equivalent amount of a pharmacologic acceptable salt thereof. In some embodiments, the compositions of the invention comprise 260 mg of amantadine or an equivalent amount of a pharmacologic acceptable salt thereof. In some embodiments, the compositions of the invention comprise 340 mg of a pharmacologic acceptable salt of amantadine. In some embodiments, changes in on-time, off-time, and / or CGI without dyskinesia are measured in a placebo-controlled double-blind clinical trial using a PD home diary. In some embodiments, CGI is measured by questions answered by an investigator. In some such methods, C-ave-day is 1.2-1.7 times the C-ave-night, and in some embodiments of the methods, C-ave-day is measured between 8AM and 8PM and C-ave-night is measured between 8PM and 8AM. In certain embodiments of the methods of the invention, C-ave-day is measured between 5AM and 4PM and C-ave-night is measured between 8PM and 5AM. In some such methods, administration of a single dose of the composition of the invention to a cohort of healthy human volunteer subjects in a fasted state results in a mean maximum plasma concentration (Cmax) of 1.1 to 2.0 ng / ml per mg of amantadine or a pharmacokinetic (AUC) of 44 to 72 ng*h / mL ... 0-infIn some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.4-3.1 ng / ml per mg amantadine or a pharmacologic salt thereof, (ii) a mean Cmin of 1.4-2.1 ng / ml per mg amantadine or a pharmacologic salt thereof, and (iii) a mean AUC of 44-72 ng*h / mL per mg amantadine or a pharmacologic salt thereof. 0-24 and in a more particular method, all three criteria of (i), (ii) and (iii) are met.
[0086] The PD home diary is based on the paper by Hauser, et al., “A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia”, Clin. Neuropharmacol., 23(3), pp.75-81 (2000), which is incorporated herein by reference in its entirety. As used herein, the terms "on-time" and "off-time" have the meanings described by Hauser et al. (Ibid.). In summary, on-time is the period during which Parkinson's disease medication is providing benefits in terms of mobility, slowness, and stiffness, and off-time is the period during which the effects of Parkinson's disease medication are waning and no longer providing benefits in terms of mobility, slowness, and stiffness. (Ibid.). These time measures are different from the measures used to measure reduction in LID, which primarily assess changes in severity or intensity of dyskinesia. Thus, these measures capture the benefits of a given treatment on all four motor states throughout the day and throughout the night. In some embodiments, the product profile includes benefits across this measure.
[0087] Dyskinesias are involuntary twisting, rotating movements. (Ibid.) These movements are an effect of medication (i.e., levodopa) and occur during on-time. (Ibid.) Dyskinesias are different from tremors, which are a back and forth swaying (a symptom of the underlying Parkinson's disease). Bothersome dyskinesias are dyskinesias that cause at least some impairment in function. (Ibid.) [Brief description of the drawings]
[0088] [Figure 1] 1 shows the dissolution profiles of the two formulations described in Examples 1 and 2. [Diagram 2] 1 shows the mean concentrations over time following administration of the two formulations of Examples 1 and 2 in a single-dose fasted human pharmacokinetic study described in Example 4. [Diagram 3] 1 shows the mean concentrations over time following administration of the two formulations of Examples 1 and 2 in a single-dose fasted human pharmacokinetic study described in Example 4. [Figure 4] FIG. 1 is a schematic diagram showing the isopropanol content at various times during drug coating of pellets without intermediate drying (Batch 166). [Diagram 5] FIG. 1 is a schematic diagram showing the isopropanol content at various times during drug coating of pellets using an intermediate drying step (Batch 167). [Figure 6] 1 is a graph showing the effect of intermediate drying on the isopropanol content of drug-coated pellets. [Figure 7] 1 is a graph showing the effect of different drying conditions on the isopropanol content of drug-coated pellets. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0089] Pharmaceutical compositions formulated for oral administration may include, for example, tablets, capsules, or multiple pellets in a capsule. These formulations may include one or more coatings, such as drug coatings in the case of compositions containing pellets. In the preparation of pharmaceutical compositions, it is common to dissolve or disperse one or more components (e.g., active drug) in a solvent (e.g., organic solvent) to create a mixture, use the mixture in one or more steps of the process, and then remove at least a portion of the solvent to produce the desired product. In the preparation of solid formulations, such as pellets in a capsule, all or nearly all of the solvent is removed, for example, by applying heat and / or gas flow. Thus, some pharmaceutical formulations have very low, if any, residual solvent content.
[0090] As described herein, administration of the composition amantadine or a pharma- ceutically acceptable salt thereof, for example, in the treatment of symptoms of Parkinson's disease, may cause gastrointestinal side effects such as dry mouth, anorexia, nausea, vomiting, or diarrhea. The inventors have surprisingly discovered that in the preparation of certain formulations of oral compositions comprising amantadine or a pharma- ceutically acceptable salt thereof, the use of organic solvents in certain steps results in residual organic solvent content in the final pharmaceutical composition, and additional attempts to remove the organic solvent (e.g., increasing drying time) did not consistently result in a reduction in the organic solvent content. However, in certain steps (but not necessarily all steps), a composition with a lower residual organic solvent content may be obtained by replacing the organic solvent with water. Thus, in some embodiments, organic solvents are still used in one or more steps, but the resulting final formulation has a low residual organic solvent content. In some embodiments, the amount of organic solvent is reduced in one or more steps, for example, by replacing a portion of the organic solvent with water, and the resulting final formulation has a low residual organic solvent content. Furthermore, the inventors have surprisingly discovered that a higher incidence of gastrointestinal side effects is associated with the administration of compositions with a higher residual organic solvent content.Therefore, provided herein is an oral pharmaceutical composition with a low organic solvent content, comprising amantadine or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable excipient.Also provided herein is a method for administering an oral pharmaceutical composition comprising amantadine or a pharma- ceutically acceptable salt thereof.
[0091] I. Method of Administration The present disclosure provides a method for orally administering a composition comprising a therapeutically effective amount of amantadine or a pharma- ceutically acceptable salt thereof once daily, the composition having a reduced incidence of gastrointestinal adverse events compared to known amantadine formulations. Some embodiments described herein provide a method for increasing on-time without dyskinesia in a subject with Parkinson's disease, the method comprising orally administering to the subject once daily, 0-4 hours before bedtime, a composition comprising the equivalent of 260-420 mg of amantadine or a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In certain embodiments, a method is provided for increasing on-time without dyskinesia in a subject with Parkinson's disease, comprising orally administering to the subject once daily 0-4 hours before bedtime about 68.5 mg, about 137 mg, about 205.5 mg, about 274 mg, about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the oral composition is administered at night. In some such methods, the change in on-time without dyskinesia is measured in a placebo-controlled, double-blind clinical trial using the PD Home Diary. In some such methods, amantadine is provided as amantadine hydrochloride, with a dose of 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some embodiments, this once-daily dose also provides treatment that reduces or does not increase sleep-related adverse events compared to placebo (as measured by a randomized, placebo-controlled, double-blind study of subjects with Parkinson's disease).
[0092] Some embodiments described herein provide a method of reducing dyskinetic on-time in a subject with Parkinson's disease, comprising orally administering to the subject once daily, 0-4 hours before bedtime, a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In certain embodiments described herein, a method of reducing dyskinetic on-time in a subject with Parkinson's disease is provided, comprising orally administering to the subject once daily 0-4 hours before bedtime a composition comprising about 68.5 mg, about 137 mg, about 205.5 mg, about 274 mg, about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the oral composition is administered once at night. In some such methods, changes in dyskinetic on-time are measured in a placebo-controlled, double-blind clinical trial using a PD Home Diary. In some such methods, the dosage of a pharma- ceutically acceptable salt of amantadine is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day.
[0093] Some embodiments described herein provide a method of reducing bothersome dyskinetic on-time in a subject with Parkinson's disease, comprising orally administering to the subject once daily, 0-4 hours before bedtime, a composition comprising 260-420 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride), and at least one modified release excipient. In certain embodiments described herein, methods are provided for reducing on-time with bothersome dyskinesias in a subject with Parkinson's disease, comprising orally administering to the subject once daily 0-4 hours before bedtime about 68.5 mg, about 137 mg, about 205.5 mg, about 274 mg, about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some such methods, the change in on-time without bothersome dyskinesias is measured in a placebo-controlled, double-blind clinical trial using a PD Home Diary. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride. In some such methods, the dosage comprises amantadine hydrochloride in an amount of 300-360 mg / day, particularly 330-350 mg / day, and 340 mg / day. In some embodiments, the oral composition is administered at night.
[0094] Some embodiments described herein provide a method of reducing off-time in a subject with Parkinson's disease, comprising orally administering to the subject once daily 0-4 hours before bedtime a composition comprising 260-340 mg of amantadine hydrochloride and at least one modified release excipient. In certain embodiments described herein, a method of reducing off-time in a subject with Parkinson's disease is provided, comprising orally administering to the subject once daily 0-4 hours before bedtime a composition comprising about 68.5 mg, about 137 mg, about 205.5 mg, about 274 mg, about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some such methods, the change in off-time is measured in a placebo-controlled double-blind clinical trial using a PD Home Diary. In some such methods, the dose of amantadine hydrochloride is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some embodiments, the composition is administered at night.
[0095] In some embodiments, provided herein is a method of reducing off-time in a subject having Parkinson's disease, the subject being treated with a Parkinson's disease medication, comprising administering to the subject an oral pharmaceutical composition as described herein. Also provided herein is an oral pharmaceutical composition for use in reducing off-time in a subject having Parkinson's disease, the subject being treated with a Parkinson's disease medication. In some embodiments, the Parkinson's disease medication is levodopa. In some embodiments, the Parkinson's disease medication includes levodopa. For example, in some embodiments, the Parkinson's disease medication includes levodopa in combination with carbidopa. In certain embodiments, the Parkinson's disease medication includes levodopa in combination with carbidopa and entacapone. In some embodiments, the oral pharmaceutical composition is administered to the subject once daily, 0-4 hours before bedtime. In some embodiments, the oral pharmaceutical composition is administered to the subject once daily, 0-3 hours before bedtime. In some embodiments of the oral pharmaceutical composition for the methods of the invention and uses as provided herein, the oral pharmaceutical composition comprises 50 mg to 500 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof and at least one modified release excipient. In some embodiments, the oral pharmaceutical composition comprises 100 mg to 450 mg, or 120 to 150 mg, or 260 mg to 305 mg, or 137 mg to 174 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the oral pharmaceutical composition comprises 245 mg to 305 mg of amantadine. In some embodiments, the oral pharmaceutical composition comprises a pharma- ceutically acceptable salt of amantadine in an amount equivalent to 245 mg to 305 mg of amantadine. In other embodiments, the oral pharmaceutical composition comprises 120 mg to 150 mg of amantadine. In some embodiments, the oral pharmaceutical composition comprises a pharma- ceutically acceptable salt of amantadine in an amount equivalent to 120 mg to 150 mg of amantadine. In certain embodiments, the pharma- ceutically acceptable salt is amantadine hydrochloride.In some embodiments, the sustained release oral composition contains about 68.5 mg, about 137 mg, about 205.5 mg, about 274 mg of amantadine, about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the sustained release oral composition contains about 85 mg, about 170 mg, about 255 mg, about 340 mg, about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride.
[0096] In some embodiments, the total daily hours of off-time is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%. In some embodiments, the total daily hours of off-time is reduced by 10%-70%, 10%-60%, 10%-50%, 10%-40%, 10%-30%, 10%-20%, 20%-70%, 20%-60%, 20%-50%, 20%-40%, 20%-30%, 30%-70%, 30%-60%, 30%-50%, or 30%-40%. In some embodiments, the total daily hours of off-time is reduced by at least 0.25 hours, 0.5 hours, at least 0.75 hours, at least 1.0 hours, at least 1.25 hours, or at least 1.5 hours.
[0097] In certain embodiments, after at least 6 weeks of administering the oral pharmaceutical composition once daily to the subject, at least 7 weeks of administering the oral pharmaceutical composition once daily to the subject, at least 8 weeks of administering the oral pharmaceutical composition once daily to the subject, at least 9 weeks of administering the oral pharmaceutical composition once daily to the subject, at least 10 weeks of administering the oral pharmaceutical composition once daily to the subject, at least 11 weeks of administering the oral pharmaceutical composition once daily to the subject, or at least 12 weeks of administering the oral pharmaceutical composition once daily to the subject, the total daily hours of off-time are reduced by an amount described herein. In some embodiments, during the titration period of induction, the subject is first administered the first composition comprising a lower dose of amantadine or an equivalent amount of a pharmaceutically acceptable salt thereof, after at least 6 weeks of administering the second oral pharmaceutical composition once a day to the subject, after at least 7 weeks of administering the second oral pharmaceutical composition once a day to the subject, after at least 8 weeks of administering the second oral pharmaceutical composition once a day to the subject, after at least 9 weeks of administering the second oral pharmaceutical composition once a day to the subject, after at least 10 weeks of administering the second oral pharmaceutical composition once a day to the subject, after at least 11 weeks of administering the second oral pharmaceutical composition once a day to the subject, or after at least 12 weeks of administering the second oral pharmaceutical composition once a day to the subject, the total daily hours of off-time are reduced by the times described herein, where the second oral pharmaceutical composition has a higher dose of amantadine or an equivalent amount of a pharmaceutically acceptable salt thereof.In some embodiments, the off-time is reduced compared to placebo, as assessed in a placebo-controlled clinical trial. In other embodiments, the off-time is reduced compared to the off-time of the subject before starting to administer oral pharmaceutical composition.In some embodiments, the off-time is reduced compared to the off-time of the subject before starting to administer a first oral pharmaceutical composition, where the subject is administered a first oral pharmaceutical composition (containing a lower dose of amantadine or an equivalent amount of its pharmaceutically acceptable salt) during the titration period of induction, and then is administered a second oral pharmaceutical composition (containing a higher dose of amantadine or an equivalent amount of its pharmaceutically acceptable salt).
[0098] In some embodiments, provided herein is a method of increasing on-time without bothersome dyskinesias in a subject with Parkinson's disease, the subject being treated with a Parkinson's disease medication, comprising administering to the subject an oral pharmaceutical composition as described herein. Also provided herein is an oral pharmaceutical composition for use in increasing on-time without bothersome dyskinesias in a subject with Parkinson's disease, the subject being treated with a Parkinson's disease medication. In some embodiments, the Parkinson's disease medication is levodopa. In some embodiments, the Parkinson's disease medication includes levodopa. For example, in some embodiments, the Parkinson's disease medication includes levodopa in combination with carbidopa. In certain embodiments, the Parkinson's disease medication includes levodopa in combination with carbidopa and entacapone. In some embodiments, the oral pharmaceutical composition is administered to the subject once daily, 0-4 hours before bedtime. In some embodiments, the oral pharmaceutical composition is administered to the subject once a day, 0-3 hours before bedtime. In some embodiments of the oral pharmaceutical composition for the methods of the invention and uses as provided herein, the oral pharmaceutical composition comprises 50 mg to 500 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof and at least one modified release excipient. In some embodiments, the oral pharmaceutical composition comprises 100 mg to 450 mg, or 120 to 150 mg, or 260 mg to 305 mg, or 137 mg or 174 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the oral pharmaceutical composition comprises 245 mg to 305 mg of amantadine. In some embodiments, the oral pharmaceutical composition comprises a pharma- ceutically acceptable salt of amantadine in an amount equivalent to 245 mg to 305 mg of amantadine. In other embodiments, the oral pharmaceutical composition comprises 120 mg to 150 mg of amantadine. In some embodiments, the oral pharmaceutical composition comprises a pharma- ceutically acceptable salt of amantadine in an amount equivalent to 120 mg to 150 mg of amantadine, hi certain embodiments, the pharma- ceutically acceptable salt is amantadine hydrochloride.In some embodiments, the sustained release oral composition contains about 68.5 mg, about 137 mg, about 205.5 mg, about 274 mg of amantadine, about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the sustained release oral composition contains about 85 mg, about 170 mg, about 255 mg, about 340 mg, about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride.
[0099] In some embodiments, the total daily time on-time without bothersome dyskinesias is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or by at least 70%. In some embodiments, the total daily time on-time without bothersome dyskinesias is increased by 10%-70%, 10%-60%, 10%-50%, 10%-40%, 10%-30%, 10%-20%, 20%-70%, 20%-60%, 20%-50%, 20%-40%, 20%-30%, 30%-70%, 30%-60%, 30%-50%, or 30%-40%. In some embodiments, the total daily time on-time without bothersome dyskinesias is increased by at least 0.25 hours, 0.5 hours, at least 0.75 hours, at least 1.0 hour, at least 1.25 hours, or at least 1.5 hours.
[0100] In certain embodiments, after administering the oral pharmaceutical composition once daily to a subject for at least 6 weeks, after administering the oral pharmaceutical composition once daily to a subject for at least 7 weeks, after administering the oral pharmaceutical composition once daily to a subject for at least 8 weeks, after administering the oral pharmaceutical composition once daily to a subject for at least 9 weeks, after administering the oral pharmaceutical composition once daily to a subject for at least 10 weeks, after administering the oral pharmaceutical composition once daily to a subject for at least 11 weeks, or after administering the oral pharmaceutical composition once daily to a subject for at least 12 weeks, the total daily time on-time without bothersome dyskinesias is increased by an amount described herein. In certain embodiments, during the induction titration phase, where the subject is initially administered a first composition comprising a lower dose of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof, after administering the second oral pharmaceutical composition once daily to the subject for at least 6 weeks, after administering the second oral pharmaceutical composition once daily to the subject for at least 7 weeks, after administering the second oral pharmaceutical composition once daily to the subject for at least 8 weeks, after administering the second oral pharmaceutical composition once daily to the subject for at least 9 weeks, after administering the second oral pharmaceutical composition once daily to the subject for at least 10 weeks, after administering the second oral pharmaceutical composition once daily to the subject for at least 11 weeks, or after administering the second oral pharmaceutical composition once daily to the subject for at least 12 weeks, the total daily time on-time without bothersome dyskinesias increases by the times described herein, where the second oral pharmaceutical composition has a higher dose of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, on-time free of bothersome dyskinesias is increased relative to placebo as assessed in a placebo-controlled clinical trial. In other embodiments, on-time free of bothersome dyskinesias is increased relative to the subject's on-time free of bothersome dyskinesias prior to initiating administration of the oral pharmaceutical composition.In certain embodiments, the on-time free of bothersome dyskinesias is increased compared to the subject's on-time free of bothersome dyskinesias before starting administration of a first oral pharmaceutical composition, where the subject is administered a first oral pharmaceutical composition (containing a lower dose of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof) during an induction titration phase and then is administered a second oral pharmaceutical composition (containing a higher dose of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof).
[0101] In yet another embodiment, provided herein is a method of treating a hypokinetic disorder in a subject with multiple sclerosis, comprising administering to the subject an oral pharmaceutical composition as described herein. Also provided herein is an oral pharmaceutical composition for use in treating a hypokinetic disorder in a subject with multiple sclerosis. In some embodiments, the oral pharmaceutical composition is administered to the subject once daily, 0-4 hours before bedtime. In some embodiments, the oral pharmaceutical composition is administered to the subject once daily, 0-3 hours before bedtime. In some embodiments of the oral pharmaceutical composition for the methods of the invention and uses as provided herein, the oral pharmaceutical composition comprises 50 mg to 500 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof and at least one modified release excipient. In some embodiments, the oral pharmaceutical composition comprises 100 mg to 450 mg, or 120 to 150 mg, or 260 mg to 305 mg, or 137 mg or 174 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the oral pharmaceutical composition comprises between 245 mg and 305 mg of amantadine. In some embodiments, the oral pharmaceutical composition comprises a pharma- ceutically acceptable salt of amantadine in an amount equivalent to between 245 mg and 305 mg of amantadine. In other embodiments, the oral pharmaceutical composition comprises between 120 mg and 150 mg of amantadine. In some embodiments, the oral pharmaceutical composition comprises a pharma- ceutically acceptable salt of amantadine in an amount equivalent to between 120 mg and 150 mg of amantadine. In certain embodiments, the pharma- ceutically acceptable salt is amantadine hydrochloride. In some embodiments, the sustained release oral composition contains about 68.5 mg, about 137 mg, about 205.5 mg, about 274 mg of amantadine, about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the sustained release oral composition contains about 85 mg, about 170 mg, about 255 mg, about 340 mg, about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride.
[0102] In certain embodiments of the method for treating hypokinesia in a subject with multiple sclerosis and the oral pharmaceutical composition for use in treating hypokinesia in a subject with multiple sclerosis, after starting administration of the oral pharmaceutical composition, walking speed is improved, walking ability is improved, overall mobility is improved, or the ability to stand up is improved.In certain embodiments, after starting administration of the oral pharmaceutical composition, two or more or three or more or each of walking speed is improved, walking ability is improved, overall mobility is improved, or the ability to stand up is improved.In some embodiments, administration of a composition as described herein to a subject with multiple sclerosis results in a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% improvement in one or more of walking speed, walking ability, overall mobility, or the ability to stand up. In certain embodiments, administration of a composition as described herein to a subject with multiple sclerosis results in a 10%-60%, 10%-50%, 10%-40%, 10%-30%, 10%-20%, 20%-60%, 20%-50%, 20%-40%, 20%-30%, 30%-60%, 30%-50%, or 30%-40% improvement in one or more of walking speed, walking ability, overall mobility, or ability to stand up. Overall mobility can include, for example, the total amount of walking throughout the day, or the ability to stand up one or more times throughout the day, or a combination thereof. In some embodiments, walking speed, walking ability, overall mobility, or ability to stand is assessed by at least one or a combination of the following: Timed 25-foot walk test (T25FW), Timed Up and Go (TUG), 2-minute walk test, 6-minute walk test (6MTW), and / or 12-item Multiple Sclerosis Walking Scale (MSWS-12). In some embodiments, T25FW, TUG, 2-minute walk, 6MTW, and / or MSWS-12 are significantly improved compared to placebo as assessed in a placebo-controlled clinical trial.In other embodiments, T25FW, TUG, 2-minute walk, 6MTW, and / or MSWS-12 are significantly improved in the subject compared to before starting administration of the composition as described herein.In some embodiments, reduced gait disturbance is measured by a numerical scale used or accepted by the FDA or other regulatory agencies to evaluate and approve the effectiveness of approved drugs for the treatment of gait disturbance.In some embodiments, administration of the composition results in about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% improvement in one or more of the assessment scores described herein (e.g., T25FW, TUG, 2-minute walk, 6MTW, and / or MSWS-12).
[0103] In certain embodiments of the methods of treating a hypokinetic disorder in a subject with multiple sclerosis and the oral pharmaceutical compositions for use in treating a hypokinetic disorder in a subject with multiple sclerosis, the amounts described herein improve walking speed, improve walking ability, improve overall mobility, or improve ability to stand up after at least 6 weeks of administering the oral pharmaceutical composition once daily to the subject, after at least 7 weeks of administering the oral pharmaceutical composition once daily to the subject, after at least 8 weeks of administering the oral pharmaceutical composition once daily to the subject, after at least 9 weeks of administering the oral pharmaceutical composition once daily to the subject, after at least 10 weeks of administering the oral pharmaceutical composition once daily to the subject, after at least 11 weeks of administering the oral pharmaceutical composition once daily to the subject, or after at least 12 weeks of administering the oral pharmaceutical composition once daily to the subject. In certain embodiments, during the induction titration phase, the subject is initially administered a first composition comprising a lower dose of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof, the improved walking speed, improved walking ability, improved overall mobility, or improved ability to stand is achieved in the amounts described herein after at least 6 weeks of administering the second oral pharmaceutical composition once daily to the subject, after at least 7 weeks of administering the second oral pharmaceutical composition once daily to the subject, after at least 8 weeks of administering the second oral pharmaceutical composition once daily to the subject, after at least 9 weeks of administering the second oral pharmaceutical composition once daily to the subject, after at least 10 weeks of administering the second oral pharmaceutical composition once daily to the subject, after at least 11 weeks of administering the second oral pharmaceutical composition once daily to the subject, or after at least 12 weeks of administering the second oral pharmaceutical composition once daily to the subject, wherein the second oral pharmaceutical composition has a higher dose of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the walking speed is improved, the walking ability is improved, the overall mobility is improved, or the ability to stand is improved compared to placebo, as assessed in a placebo-controlled clinical trial. In other embodiments, the walking speed is improved, the walking ability is improved, the overall mobility is improved, or the ability to stand is improved compared to the same measures in the subject before starting administration of the oral pharmaceutical composition.In certain embodiments, walking speed is improved, walking ability is improved, overall mobility is improved, or ability to stand is improved compared to the same indices in a subject prior to initiating administration of a first oral pharmaceutical composition, where the subject is administered a first oral pharmaceutical composition (containing a lower dose of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof) during an induction titration phase and then is administered a second oral pharmaceutical composition (containing a higher dose of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof).
[0104] Some embodiments described herein provide a method of increasing on-time without bothersome dyskinesias and without increasing sleep disturbance in a subject with Parkinson's disease, comprising orally administering to the subject once daily, 0-4 hours before bedtime, a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride. In some such methods, the dose of amantadine hydrochloride is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some embodiments, the composition is administered at night.
[0105] Some embodiments described herein provide a method of improving Clinician Global Impression without increasing sleep disturbance in a subject with Parkinson's disease, comprising orally administering to the subject once daily, 0-4 hours before bedtime, a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride. In some such methods, the dose of amantadine hydrochloride is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some embodiments, the composition is administered at night.
[0106] Some embodiments described herein provide a method of increasing on-time without dyskinesia in a subject with Parkinson's disease, comprising orally administering to the subject once a day a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride. In some such methods, the change in on-time without dyskinesia is measured in a placebo-controlled double-blind clinical trial using a PD Home Diary. In some such methods, the dose of amantadine hydrochloride is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some embodiments, the composition is administered at night. In some such methods, C-ave-day is 1.2-1.7 times that of C-ave-night, and in some embodiments of the methods, C-ave-day is measured between 6 AM and 4 PM and C-ave-night is measured between 8 PM and 5 AM. In some such methods, administration of a single dose of the composition to a cohort of fasted healthy human volunteer subjects results in a mean maximum plasma concentration (Cmax) of 1.1-2.0 ng / ml per mg of amantadine or an AUC of 42-56 ng*h / mL per mg of amantadine. 0-inf In some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.2-3.1 ng / ml per mg of amantadine, (ii) a mean Cmin of 1.4-1.7 ng / ml per mg of amantadine, and (iii) a mean AUC of 43-72 ng*h / mL per mg of amantadine. 0-24 and in a more particular method, all three criteria of (i), (ii) and (iii) are met.
[0107] Some embodiments described herein provide a method of reducing dyskinetic on-time in a subject with Parkinson's disease, comprising orally administering to the subject once a day a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride. In some such methods, the change in dyskinetic on-time is measured in a placebo-controlled double-blind clinical trial using a PD Home Diary. In some such methods, the dose of amantadine or a pharma- ceutically acceptable salt thereof is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some embodiments, the composition is orally administered at night. In some such methods, C-ave-day is 1.2-1.7 times that of C-ave-night, and in some embodiments of the methods, C-ave-day is measured between 8 AM and 4 PM and C-ave-night is measured between 8 PM and 5 AM. In some such methods, administration of a single dose of the composition to a cohort of healthy human volunteer subjects in a fasted state results in a mean maximum plasma concentration (Cmax) of 1.1-2.0 ng / ml per mg of amantadine or an AUC of 42-70 ng*h / mL per mg of amantadine. 0-inf In some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.2-3.1 ng / ml per mg of amantadine, (ii) a mean Cmin of 1.4-1.7 ng / ml per mg of amantadine, and (iii) a mean AUC of 43-70 ng*h / mL per mg of amantadine. 0-24 and in a more specific method, all three criteria of (i), (ii) and (iii) are met.
[0108] Some embodiments described herein provide a method of reducing on-time with bothersome dyskinesias in a subject with Parkinson's disease, comprising orally administering to the subject once daily a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride. In some embodiments, the composition is orally administered at night. In some such methods, the change in on-time without bothersome dyskinesias is indicative of a reduction in PD. The dose of amantadine is measured in a placebo-controlled double-blind clinical trial using a home diary. In some such methods, the dose of the pharma- ceutically acceptable salt of amantadine is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some such methods, C-ave-day is 1.2-1.7 times the C-ave-night, and in some embodiments of the method, C-ave-day is measured between 8:00 AM and 4:00 PM, and C-ave-night is measured between 8:00 PM and 5:00 AM. In some such methods, administration of a single dose of the composition to a cohort of fasted healthy human volunteer subjects results in a mean maximum plasma concentration (Cmax) of 1.1-2.0 ng / ml per mg of amantadine or an AUC of 42-70 ng*h / mL per mg of amantadine. 0-inf In some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.2-3.0 ng / ml per mg of amantadine, (ii) a mean Cmin of 1.4-1.7 ng / ml per mg of amantadine, and (iii) a mean AUC of 42-69 ng*h / mL per mg of amantadine. 0-24 and in a more particular method, all three criteria of (i), (ii) and (iii) are met.
[0109] Some embodiments described herein provide a method of reducing off-time in a subject with Parkinson's disease, comprising orally administering to the subject once a day a composition comprising 260-340 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride. In some such methods, the change in off-time is measured in a placebo-controlled double-blind clinical trial using a PD Home Diary. In some such methods, the dose of the pharma- ceutically acceptable salt of amantadine is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some such methods, C-ave-day is 1.4-1.7 times that of C-ave-night, and in some embodiments of the methods, C-ave-day is measured between 8 AM and 8 PM and C-ave-night is measured between 8 PM and 8 AM. In some such methods, administration of a single dose of the composition to a cohort of healthy human volunteer subjects in a fasted state results in a mean maximum plasma concentration (Cmax) of 1.1-1.7 ng / ml per mg of amantadine or an AUC of 46-56 ng*h / mL per mg of amantadine. 0-inf (area under the concentration curve from t=0 to t=infinity) or both. In some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.2-2.7 ng / ml per mg of amantadine, (ii) a mean Cmin of 1.4-1.7 ng / ml per mg of amantadine, and (iii) a mean AUC of 46-56 ng*h / mL per mg of amantadine. 0-24 and in a more particular method, all three criteria of (i), (ii) and (iii) are met.
[0110] Some embodiments described herein provide a method of increasing on-time without bothersome dyskinesias and without increasing sleep disturbance in a subject with Parkinson's disease, comprising orally administering to the subject once daily a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride. In some such methods, the dose of a pharma- ceutically acceptable salt of amantadine, such as amantadine hydrochloride, is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some such methods, C-ave-day is 1.2-1.7 times that of C-ave-night, and in some embodiments of the methods, C-ave-day is measured between 8 AM and 4 PM and C-ave-night is measured between 8 PM and 5 AM. In some such methods, administration of a single dose of the composition to a cohort of healthy human volunteer subjects in a fasted state results in a mean maximum plasma concentration (Cmax) of 1.1-2.0 ng / ml per mg of amantadine or an AUC of 42-69 ng*h / mL per mg of amantadine. 0-inf (area under the concentration curve from t=0 to t=infinity) or both. In some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.2-3.1 ng / ml per mg of amantadine, (ii) a mean Cmin of 1.4-1.7 ng / ml per mg of amantadine, and (iii) a mean AUC of 42-69 ng*h / mL per mg of amantadine. 0-24 and in a more particular method, all three criteria of (i), (ii) and (iii) are met.
[0111] Some embodiments described herein provide a method of improving clinician's global impression without increasing sleep disturbance in a subject with Parkinson's disease, comprising orally administering to the subject once daily a composition comprising 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof (e.g., amantadine hydrochloride) and at least one modified release excipient. In some embodiments, the composition comprises 260-340 mg of amantadine hydrochloride or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some such methods, the dose of the pharma- ceutically acceptable salt of amantadine, such as amantadine hydrochloride, is 300-360 mg / day, particularly 330-350 mg / day, and particularly 340 mg / day. In some such methods, C-ave-day is 1.2-1.7 times that of C-ave-night, and in some embodiments of the methods, C-ave-day is measured between 8 AM and 4 PM and C-ave-night is measured between 8 PM and 5 AM. In some such methods, administration of a single dose of the composition to a cohort of healthy human volunteer subjects in a fasted state results in a mean maximum plasma concentration (Cmax) of 1.1-2.0 ng / ml per mg of amantadine or an AUC of 42-69 ng*h / mL per mg of amantadine. 0-inf (area under the concentration curve from t=0 to t=infinity) or both. In some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.2-3.1 ng / ml per mg of amantadine, (ii) a mean Cmin of 1.4-1.7 ng / ml per mg of amantadine, and (iii) a mean AUC of 42-69 ng*h / mL per mg of amantadine. 0-24 and in a more particular method, all three criteria of (i), (ii) and (iii) are met.
[0112] The present disclosure also provides a method of reducing gastrointestinal (GI) adverse events in a subject undergoing treatment with amantadine. The method comprises orally administering to a subject in need thereof a composition comprising amantadine or a pharmaceutically acceptable salt thereof such that the frequency of GI adverse events (as measured in a single-dose fasted human pharmacokinetic study) is less than 19.5%, preferably less than 17.5%, more preferably less than 12.5%. In some embodiments, the low incidence of GI adverse events includes subjects experiencing at least one GI adverse event in less than 12%, less than 10%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of single-dose human pharmacokinetic studies in the fasted state. In some embodiments, the GI effects are selected from the group consisting of abdominal bloating, constipation, diarrhea, indigestion, gum pain, dry lips, lower abdominal pain, nausea, stomach discomfort, toothache, upper abdominal pain, and vomiting. In some embodiments, the composition comprises less than 6000 ppm of organic solvent. In certain embodiments, the composition comprises less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In some embodiments, the composition comprises a plurality of coated core seeds, wherein each coated core seed comprises a core seed surrounded by a drug coating, and the plurality of coated core seeds comprises less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.).In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl)ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphoramide (e.g., hexamethylphosphoric acid triamide (HPMA), etc.). In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol)). In some embodiments, a mixture of two or more solvents may be used. In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents. In some embodiments, the daily dose of amantadine is between 170 mg and 340 mg or an equivalent amount of a pharma- ceutically acceptable salt thereof, preferably the daily dose comprises between 170 mg and 340 mg of amantadine hydrochloride or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some such methods, C-ave-day is between 1.2 and 1.7 times the C-ave-night, and in some embodiments of the method, C-ave-day is measured between 8:00 AM and 4:00 PM and C-ave-night is measured between 8:00 PM and 5:00 AM. In some such methods, administration of a single dose of the composition to a cohort of fasted healthy human volunteer subjects results in a mean maximum plasma concentration (Cmax) of 1.1 to 2.0 ng / ml per mg of amantadine or an AUC of 42 to 69 ng*h / mL per mg of amantadine. 0-infIn some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.2-3.0 ng / ml per mg of amantadine, (ii) a mean Cmin of 1.4-1.7 ng / ml per mg of amantadine, and (iii) a mean AUC of 42-69 ng*h / mL per mg of amantadine. 0-24 and in a more particular method, all three criteria of (i), (ii) and (iii) are met.
[0113] The present disclosure also provides a method for reducing sleep disturbance in a subject undergoing treatment with amantadine or its pharma- ceutically acceptable salt.The method includes orally administering amantadine or its pharma- ceutically acceptable salt to a subject who needs it so that the amantadine or its pharma- ceutically acceptable salt does not interfere with sleep, but provides maximum benefit in the morning.For example, morning includes from 5:00 a.m., 6:00 a.m., 7:00 a.m., 8:00 a.m., or 9:00 a.m. to 11:00 a.m., 11:30 a.m., 12:00 p.m., 12:30 p.m., or 1:00 p.m. In some embodiments, the method provides nighttime coverage of Parkinson's disease symptoms.Nighttime coverage can include providing benefit when the subject wakes up and wants to go back to sleep. In some such methods, C-ave-day is 1.2-1.7 times that of C-ave-night, and in some embodiments of the methods, C-ave-day is measured between 8 AM and 4 PM and C-ave-night is measured between 8 PM and 5 AM. In some such methods, administration of a single dose of the composition to a cohort of healthy human volunteer subjects in a fasted state results in a mean maximum plasma concentration (Cmax) of 1.1-2.0 ng / ml per mg of amantadine or an AUC of 42-69 ng*h / mL per mg of amantadine. 0-infIn some such methods, daily oral administration of a single dose of the composition to a cohort of human subjects provides (i) a mean Cmax of 2.2-3.0 ng / ml per mg of amantadine, (ii) a mean Cmin of 1.4-1.7 ng / ml per mg of amantadine, and (iii) a mean AUC of 42-69 ng*h / mL per mg of amantadine. 0-24 and in a more particular method, all three criteria of (i), (ii) and (iii) are met.
[0114] In some embodiments, the method provided herein comprises orally administering to a subject an extended release (ER) composition formulated for nighttime administration, comprising amantadine or a pharma- ceutically acceptable salt thereof. The composition can be administered less than 3 hours before bedtime, preferably less than 2.5 hours, less than 2 hours, less than 1.5 hours, or less than 1 hour before bedtime. Most preferably, the ER composition is taken less than 30 minutes before bedtime (e.g., the time when the subject wants to sleep). Alternatively, the composition is administered less than about 4 hours before bedtime.
[0115] As used herein, "extended release" includes "controlled release," "modified release," "sustained release," "timed release," "delayed release," and combinations of each of the above with delayed release, immediate release, enteric coated, and the like.
[0116] The methods included herein include orally administering to a subject a pharmaceutical composition comprising amantadine or a pharma- ceutically acceptable salt thereof. The subject may be diagnosed with any disease or disorder for which amantadine or a pharma- ceutically acceptable salt thereof is prescribed, such as Parkinson's disease, multiple sclerosis, drug-induced extrapyramidal reactions, levodopa-induced dyskinesia, and viral diseases (e.g., influenza, HBV, and HCV). In certain embodiments, the subject has Parkinson's disease, where Parkinson's disease, as used herein, also encompasses a diagnosis of parkinsonism. In some embodiments, the subject has early Parkinson's disease, and a pharmaceutical composition as described herein is used as a monotherapy or in combination with a monoamine oxidase type B (MAO-B) inhibitor without levodopa. In another embodiment, the subject has late Parkinson's disease, and the subject takes levodopa in addition to a pharmaceutical composition as described herein. In another embodiment, the subject has multiple sclerosis, and a pharmaceutical composition as described herein is used for fatigue treatment. In other embodiments, the subject has brain injury, brain damage, head trauma, dementia, Alzheimer's disease, stroke, Huntington's disease, ALS, multiple sclerosis, a neurodegenerative disease, dementia, a cerebrovascular condition, a movement disorder, a cranial nerve disorder, a neuropsychiatric disorder.
[0117] The oral pharmaceutical compositions provided herein and for use in the methods described herein can be formulated for nocturnal oral administration to provide a plasma concentration profile that does not interfere with the subject's sleep. The compositions of the present disclosure can provide a gradual initial increase in the plasma concentration of amantadine when administered to a human subject, such that, under steady-state conditions, administration of a single dose of the composition results in an increase in amantadine plasma concentration of less than 25% 3 hours after the dose is administered. For example, if the subject has a steady-state plasma concentration of amantadine of 500ng / ml when a single dose of the composition is administered, the subject's amantadine plasma concentration after 3 hours can be less than 625ng / ml. Preferably, the increase in amantadine plasma concentration after 3 hours of administration of an oral pharmaceutical composition as described herein is less than 15%, most preferably less than 10%. In certain embodiments, the compositions of the present invention have a plasma concentration profile further characterized by no increase or even decrease in amantadine plasma concentration (under steady-state conditions) for at least 1 hour, or in some embodiments, 2 hours after administration. The compositions provided herein and for use in the methods provided herein may be suitable for bedtime administration (e.g., the time a subject desires to sleep) by providing a maximum concentration (Cmax) of amantadine in the morning. The time to reach Cmax (Tmax) measured after single dose administration in the fasted state may be at least 9 hours and up to 15, 16, 17, or 18 hours, or at least 10 hours and up to 14, 15, 16, 17, or 18 hours, or at least 12 hours and up to 14, 15, 16, or 17 hours. In certain embodiments, Tmax may be 9 to 18 hours, most preferably 12 to 18 hours. At steady state, using a single nighttime administration of the compositions of the invention, Tmax may be 7 to 13 hours, most preferably 8 to 12 hours. Suitable ER amantadine compositions have a steady state Cmax / Cmin ratio of 1.3 to 1.8, preferably 1.4 to 1.7, resulting in a composition with a diurnal profile.
[0118] In another embodiment, the plasma concentration profile is an AUC profile following administration of a single dose of a composition of the invention, the partial AUC from 0 to 4 hours being AUC 0-inf and the partial AUC from 0 to 8 hours is less than AUC 0-inf and the partial AUC from 0 to 12 hours is AUC 0-inf and the partial AUC from 0 to 18 hours is AUC 0-inf and the partial AUC from 0 to 24 hours is AUC 0-inf The profile is about 40 to 75%, preferably about 50 to 70% of the above.
[0119] In a further embodiment, the plasma concentration profile of the pharmaceutical composition of the present invention is an AUC profile following a single nocturnal administration of the composition of the present invention under steady state conditions, the partial AUC from 0 to 4 hours being AUC 0-24 and the partial AUC from 0 to 8 hours is AUC 0-24 and the partial AUC from 0 to 12 hours is AUC 0-24 and the partial AUC from 0 to 18 hours is AUC 0-24 The AUC profile is about 60 to 95%, preferably about 75 to 90% of the AUC profile.
[0120] In some embodiments of any aspect herein, the steady state plasma concentration profile following multiple oral administration of a composition of the invention to a human subject at bedtime is characterized by an average daytime plasma concentration ("C-ave-day", defined as the average daytime amantadine plasma concentration as measured in a human PK study) that is 1.1-2.0 times the average nighttime plasma concentration ("C-ave-night", defined as the average nighttime amantadine plasma concentration as measured in a human PK study). In some embodiments, the C-ave-day / C-ave-night ratio at steady state is within one of the following ranges: 1.3-1.9, 1.3-1.8, 1.3-1.7, 1.3-1.6, 1.4-1.9, 1.4-1.8, 1.4-1.7, 1.5-1.9, 1.5-1.8, 1.5-1.7, or 1.6-1.9. In some embodiments, the C-ave-day / C-ave-night ratio at steady state is 1.3, 1.35, 1.4, 1.45, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, or 1.9. In some embodiments, C-ave-day is the average amantadine plasma concentration measured between 5:00 AM, 6:00 AM, 7:00 AM, 8:00 AM, or 9:00 AM and 4:00 PM, 5:00 PM, 6:00 PM, 7:00 PM, or 8:00 PM, and C-ave-night is the average amantadine plasma concentration measured between 4:00 PM, 5:00 PM, 6:00 PM, 7:00 PM, 8:00 PM, 9:00 PM, 10:00 PM, or 11:00 PM and 4:00 AM, 5:00 AM, 6:00 AM, 7:00 AM, 8:00 AM, or 9:00 AM. In some embodiments, C-ave-day is the average amantadine plasma concentration measured within any 4-12 hours between 5:00 AM and 8:00 PM, and C-ave-night is the average amantadine plasma concentration measured within any 4-12 hours between 8:00 PM and 5:00 AM. In some embodiments, C-ave-day is the average amantadine plasma concentration measured within any 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours between 5:00 AM and 8:00 PM, and C-ave-night is the average amantadine plasma concentration measured within any 4, 5, 6, 7, 8, 9, 10, 11, or 12 hours between 8:00 PM and 4:00 AM.
[0121] In some embodiments described herein, the pharmaceutical composition of the present invention is administered to a subject 0-4 hours before bedtime. In some embodiments, the pharmaceutical composition of the present invention is administered to a subject 0-3, 0-2, or 0-1 hours before bedtime. In some embodiments, the pharmaceutical composition of the present invention is administered to a subject 0-240 minutes, 0-180 minutes (e.g., 0-120 minutes, 0-60 minutes, 0-45 minutes, 0-30 minutes, 0-15 minutes, or 0-10 minutes) before bedtime. In some embodiments, the pharmaceutical composition of the present invention is administered to a subject 60-240 minutes, 60-180 minutes, 60-120 minutes, or 60-90 minutes before bedtime.
[0122] Administration to a subject should be understood to include administration by a medical professional and self-administration by the subject.
[0123] Unless otherwise specified herein, the term "bedtime" refers to the time when a person goes to bed for the main sleep period during a 24-hour period.For the general public, bedtime is at night, but there are subjects whose bedtime is during the day, such as subjects who work at night.Therefore, in some embodiments, bedtime can be any time during the day or night.
[0124] As used herein, unless otherwise indicated, references to plasma concentration profiles or specific pharmacokinetic properties (e.g., Cmax, Cmin, AUC, Tmax, etc.) in human subjects refer to average values obtained in healthy adults determined in a typical Phase I clinical trial designed to measure the pharmacokinetic properties of a drug (see, e.g., Example 4 below), and unless otherwise indicated, fasting human pharmacokinetic studies with a single dose are dosed in the morning after an overnight fast. As used herein, Tmax and T 1 / 2 References to median and mean values, respectively, obtained after administration of a single dose in the fasting state, unless otherwise stated.
[0125] As described herein, the unit dose of amantadine or its pharmaceutically acceptable salt orally administered according to the method provided herein can generally be higher than the range that is usually prescribed for the immediate release composition containing amantadine or its pharmaceutically acceptable salt.For example, the recommended dose of amantadine for the treatment of Parkinson's disease is 100mg of immediate release amantadine or its equivalent amount of pharmaceutically acceptable salt, administered twice a day.In the limited cases of subjects who do not obtain sufficient benefit from the aforementioned dose and can tolerate higher doses, the daily dose can be increased to 300mg or 400mg or its equivalent amount of pharmaceutically acceptable salt, always administered in divided doses.The most commonly prescribed dose of amantadine is 200mg / day or its equivalent amount of pharmaceutically acceptable salt, always administered in divided doses.More than 200mg (e.g., 300mg) is always administered in divided doses. In contrast, the methods of the present invention may include administration of 260-420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt for the treatment of a subject having Parkinson's disease, and the methods and compositions of the present disclosure may include administration of a dose defined by any of these ranges, particularly a single nightly dose of 260 mg to 420 mg, most preferably 340 mg, of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof, once a day. In some such embodiments, such higher doses are administered at night, for example, after 4 p.m. and / or within 4 hours of bedtime. In additional embodiments, such higher doses may be administered at night in the form of 1, 2, or 3 capsules of size 0, 1, or 2, in regular or EL form.
[0126] In some embodiments of any of the aspects herein, amantadine is administered as a pharma- ceutically acceptable salt. In more specific embodiments, amantadine is administered as amantadine hydrochloride or amantadine sulfate.
[0127] In some embodiments of any of the aspects herein, a total daily amount of 260 mg to 420 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof is administered in a formulation after 4 p.m. and / or within 4 hours of bedtime. In some embodiments, the dose of amantadine or a pharma- ceutically acceptable salt thereof is greater than 300 mg / day. In various specific embodiments, the total amount of amantadine administered per day may be 260-275 mg, 270-285 mg, 280-295 mg, 290-305 mg, 300-315 mg, 310-325 mg, 320-335 mg, 330-345 mg, 340-355 mg, 350-365 mg, 360-375 mg, 370-385 mg, 380-395 mg, 390-405 mg, 400-415 mg, or 410-420 mg, or the dose may be an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the total amount of amantadine administered per day is 260 mg to 360 mg, 300-360 mg, 330-350 mg, or 340 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the dose of a pharma- ceutically acceptable salt of amantadine, e.g., amantadine hydrochloride, is 300-360 mg, 330-350 mg, or 340 mg. As described herein, the dose may be a once-daily dose, administered at night, e.g., after 4 p.m.
[0128] In some embodiments of any of the aspects herein, the total daily amount of amantadine administered is between about 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, or 300 mg, or an equivalent pharma- ceutically acceptable salt of amantadine, to about 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, or 420 mg, or an equivalent pharma- ceutically acceptable salt of amantadine.
[0129] Still other embodiments of any of the aspects herein, e.g., a method of increasing on-time without dyskinesia in a subject with Parkinson's disease, a method of reducing on-time with dyskinesia in a subject with Parkinson's disease, a method of reducing on-time with bothersome dyskinesia in a subject with Parkinson's disease, a method of reducing off-time in a subject with Parkinson's disease, a method of treating a hypokinetic disorder in a subject with multiple sclerosis, amantadine or a pharma- ceutically acceptable salt thereof. In a method for reducing gastrointestinal (GI) adverse events in a subject receiving treatment with amantadine or a pharma- ceutically acceptable salt thereof, the total daily dose of amantadine administered is about 68.5 mg, about 137 mg, about 205.5 mg, about 274 mg of amantadine, about 60 mg to about 80 mg, about 120 mg to about 155 mg, about 185 mg to about 230 mg, or about 245 mg to about 305 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the total daily dose administered is about 85 mg, about 170 mg, about 255 mg, about 340 mg, about 75 mg to about 95 mg, about 150 mg to about 190 mg, about 230 mg to about 285 mg, or about 305 mg to about 375 mg of amantadine hydrochloride. In some embodiments, the once-daily dose is administered in the evening. In certain embodiments, the once-daily dose is administered 0-4 hours before bedtime or 0-3 hours before bedtime. In certain embodiments, the once-daily dose is administered during the day. In some embodiments, the total daily amount is administered as 1, 2, or 3 separate dosage units, e.g., separate capsules. In certain embodiments, each dosage unit contains about 68.5 mg, about 137 mg, about 60 mg to about 155 mg, about 60 mg to about 80 mg, or about 120 mg to about 155 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, each dosage unit contains about 85 mg, about 170 mg, about 75 mg to about 190 mg, about 75 mg to about 95 mg, or about 150 mg to about 190 mg of amantadine hydrochloride.In certain embodiments, two or more dosage units containing different amounts of amantadine or a pharma- ceutically acceptable salt thereof are administered, e.g., one or more dosage units containing about 68.5 mg, or about 60 mg to about 155 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof, and one or more dosage units containing about 137 mg, or about 120 mg to about 155 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0130] In certain embodiments described herein, a subject's total daily dose of amantadine or a pharma- ceutically acceptable salt thereof is administered once less than about 4, 3, 2, or 1 hours before bedtime (e.g., after 4 p.m. or at any time the subject desires to sleep).
[0131] In some embodiments of any of the aspects herein, oral administration of the composition to a subject with Parkinson's disease results in a significant reduction in one or more Parkinson's disease symptoms or motor fluctuations. In some particular embodiments, administration of the composition of the present invention results in a reduction of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% in one or more Parkinson's disease symptoms or motor fluctuations. In further particular embodiments, the reduction in Parkinson's disease symptoms or motor fluctuations is measured on a numerical scale used or accepted by the FDA or other regulatory agencies to evaluate the effectiveness of and approve approved drugs for the treatment of Parkinson's disease symptoms or motor fluctuations. In further particular embodiments, the scale used to measure the reduction in Parkinson's disease symptoms or motor fluctuations can be the Unified Parkinson's Disease Rating Scale (UPDRS). Unified Parkinson's Disease Rating Scale (UPDRS, MDS-revised) - Part I: Aspects of non-motor symptoms experienced in daily life (13 items), - Part II: Aspects of motor symptoms experienced in daily life (13 items), - Part III: Examination of motor symptoms (33 items scored), Hoehn and Yahr severity classification (original or revised), or PD Home Diary: total on-time or total off-time.
[0132] In some embodiments of any of the aspects herein, oral administration of a composition of the invention to a subject with Parkinson's disease results in a significant reduction in levodopa-induced dyskinesia. In certain embodiments, administration of a composition of the invention results in about a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% reduction in levodopa-induced dyskinesia. In further embodiments, the reduction in levodopa-induced dyskinesia is measured on a numerical scale used or accepted by the FDA or other regulatory agencies to evaluate the efficacy of and approve approved drugs for the treatment of LID. In further specific embodiments, the scale used to measure the reduction in LID may be UDysRS, UPDRS part IV (subscores 32, 33), MDS-UPDRS part IV (total score and items 4.1 and 4.2), Dyskinesia Rating Scale (DRS), Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale, Parkinson's Disease Dyskinesia Scale (PDYS-26), Obeso Dyskinesia Rating Scale (CAPIT), Clinical Dyskinesia Rating Scale (CDRS), Lang-Fahn Activity of Daily Living Dyskinesia, or other scales developed for this purpose. In other specific embodiments, the reduction in LID is measured in a controlled clinical trial compared to a placebo. In other embodiments, the reduction in LID is measured in a controlled clinical trial compared to a baseline.
[0133] In some embodiments of any of the aspects herein, oral administration of the composition of the present invention to a subject with Parkinson's disease results in a significant reduction in Parkinson's fatigue. In certain embodiments, administration of the composition of the present invention results in about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% reduction in Parkinson's fatigue. In further specific embodiments, reduced fatigue is measured on a numerical scale used or accepted by the FDA or other regulatory agencies to evaluate the effectiveness of and approve approved drugs for the treatment of fatigue. In further specific embodiments, the scale used in measuring reduced fatigue can be the Fatigue Severity Scale (FSS), Fatigue Inventory, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT Fatigue), Multidimensional Fatigue Inventory (MFI-20), Parkinson's Fatigue Scale (PFS-16), and Fatigue Severity Inventory. In other specific embodiments, reduced fatigue is measured in a controlled clinical trial compared to placebo. In other embodiments, the reduction in fatigue is measured compared to baseline in a controlled clinical trial.
[0134] In some embodiments of any of the aspects herein, oral administration of the composition of the present invention to a subject results in a significant improvement in the Clinician Global Impression score. In some particular embodiments, administration of the composition of the present invention results in an improvement of about 0.5, 1.0, 1.5, 2.0, 2.5, or 3.0 points in the Clinician Global Impression score using a 7-point scale (or a proportional change using a different scale). In further particular embodiments, the improvement in the Clinician Global Impression score is measured on a numerical scale used or accepted by the FDA or other regulatory agencies to evaluate the efficacy of and approve approved drugs required for subjects with Parkinson's disease. In further particular embodiments, the scale used in measuring the improvement in the Clinician Global Impression score can be the Clinician Global Impression of Change (CGIC) scale. In other particular embodiments, the improvement in the Clinician Global Impression score is measured in a controlled clinical trial compared to a placebo. In other embodiments, the improvement in the Clinician Global Impression score is measured in a controlled clinical trial compared to a baseline.
[0135] II. Pharmaceutical Composition Formulations Provided herein is an oral pharmaceutical composition comprising amantadine or its pharmaceutically acceptable salt and pharmaceutically acceptable excipient as described herein.For example, the pharmaceutical composition of the present invention can be administered orally, be suitable for oral delivery, be formulated for oral delivery, or be intended for oral delivery, or be suitable for oral administration, be formulated for oral delivery, or be intended for oral delivery.In some embodiments, the pharmaceutical composition of the present invention is a sustained release formulation.
[0136] The sustained release oral pharmaceutical compositions suitable for use in the methods described herein can be made using various sustained release technologies, such as those described in the patent publications referenced in the Background section above, which are incorporated herein by reference in their entirety. In some embodiments, the pharmaceutical compositions of the present invention are in a pellet-in-capsule dosage form. In some embodiments, the pellets are a plurality of coated core seeds, where each coated core seed comprises a core seed, a drug coating surrounding the core seed, and a sustained release coating surrounding the drug coating. In some embodiments, one or more additional coatings are present. For example, in some embodiments, the core seed further comprises a sealing coating surrounding the drug coating, where the sealing coating is surrounded by a sustained release coating.
[0137] The drug coating may include amantadine or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients. In some embodiments, the one or more pharma- ceutically acceptable excipients include one or more binding agents or one or more anti-adherent agents, or any combination thereof.
[0138] The sustained release coating may include one or more release modifying excipients. In some embodiments, the sustained release coating further includes one or more plasticizers or one or more pore formers, or any combination thereof. In certain embodiments, the one or more release modifying excipients include ethylcellulose, and the one or more pore formers include povidone, HPMC, or Eudragit, or a combination thereof.
[0139] The seal coating may include one or more film-forming polymers. The seal coating may further include one or more anti-adherents, one or more binders, or any combination thereof. In some embodiments, the one or more film-forming polymers include HPMC, copovidone, or povidone, or a combination thereof.
[0140] In some embodiments, the coated core seed comprises two or more drug coatings, or two or more sustained release coatings, or a combination thereof. For example, the coated core seed may comprise a first drug coating surrounding the core seed, a sealing coating surrounding the first drug coating, an additional drug coating surrounding the sealing coating, and a sustained release coating surrounding the sealing coating. In other examples, the coated core seed comprises a drug coating surrounding the core seed, a first sustained release coating surrounding the drug coating, and an additional sustained release coating surrounding the first sustained release coating. The first and additional sustained release coatings may, for example, comprise different components, or different component ratios, or a combination thereof.
[0141] It should be understood that one or more of the coatings described herein, e.g., a drug coating, a sealing coating, or a sustained release coating, in some embodiments may completely surround the core seed, and in other embodiments may surround substantially all or a majority of the core seed, e.g., at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% of the surface area of the core seed is surrounded by the coating. One or more of the coatings may be of uniform thickness or may vary in thickness.
[0142] In some embodiments, the oral pharmaceutical composition comprises a plurality of coated core seeds. In some embodiments, the coated core seeds have an average diameter of, for example, 300-1700 microns or 500-1200 microns. The core seeds of the coated core seeds may comprise, for example, one or more inert compounds, for example, sugar (e.g., sucrose), microcrystalline cellulose, or starch. In some embodiments, the core seeds are generally spherical in shape. In some embodiments, the core seeds are spheres. In some embodiments, the core seeds are generally ovoid in shape. In some embodiments, the core seeds are ovoid. In certain embodiments, the core seeds comprise a sugar (e.g., sucrose), microcrystalline cellulose (MCC), or starch. In certain embodiments, the core seeds have an average diameter of 300-500 microns. In some embodiments, the coated core seeds may be prepared by a process such as, for example, granulation, extrusion, spheronization, or a combination thereof.
[0143] In some embodiments, the coated core seeds contain less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In certain embodiments, the organic solvent is an alcohol, such as isopropyl alcohol. Thus, in some embodiments, the coated core seeds contain less than 6000 ppm of organic solvent, such as alcohol, for example, isopropyl alcohol. As described herein, in some embodiments, the coated core seeds include one or more drug coatings, one or more sustained release coatings, and one or more sealing coatings. In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.). In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl)ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphoramide (e.g., hexamethylphosphoric triamide (HPMA), etc.). In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol)).In some embodiments, a mixture of two or more solvents may be used. In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents.
[0144] Some embodiments of the compositions described herein include less than a certain concentration of organic solvent (e.g., less than 6,000 ppm or less than 2,000 ppm), but it should be understood that in some embodiments, organic solvent may be used at one or more steps during the manufacture of the compositions of the present invention. In certain embodiments, the solvent concentration present during one or more of the manufacturing steps may be higher than the solvent concentration present in the final composition.
[0145] A. Drug Coating The coated core seeds include a core seed and a drug coating surrounding the core seed, wherein the drug coating comprises amantadine or a pharma- ceutically acceptable salt thereof. The drug coating may further include one or more pharma- ceutically acceptable excipients, such as one or more binders or one or more anti-adherents. In some embodiments, the drug coating includes one or more binders selected from the group consisting of hydroxypropylmethylcellulose, copovidone, povidone, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, and carboxymethylcellulose. In some embodiments, the drug coating includes one or more anti-adherents. For example, the drug coating may include one or more anti-adherents selected from the group consisting of magnesium stearate, calcium silicate, magnesium silicate, colloidal silicon dioxide, and talc. In some embodiments, the drug coating includes one or more anti-adherents selected from the group consisting of talc and magnesium stearate. In certain embodiments, the drug coating includes one or more additional excipients.
[0146] In some embodiments, the drug coating comprises amantadine or a pharma- ceutically acceptable salt thereof, one or more pharma- ceutically acceptable excipients, and one or more anti-adherents. In some embodiments, the drug coating comprises amantadine or a pharma- ceutically acceptable salt thereof, at least two pharma- ceutically acceptable excipients, and one or more anti-adherents. In some embodiments, the one or more or at least two pharma- ceutically acceptable excipients comprise one or more binders. In some embodiments, the one or more or at least two pharma- ceutically acceptable excipients are binders. In certain embodiments, the drug coating comprises amantadine or a pharma- ceutically acceptable salt thereof, one or more binders, and one or more anti-adherents. In some embodiments, the pharma- ceutically acceptable salt of amantadine is amantadine hydrochloride. In another embodiment, the pharma- ceutically acceptable salt of amantadine is amantadine sulfate.
[0147] In some embodiments, the drug coating comprises 60%-85%, 65%-80%, or 70%-75% by weight of a pharma- ceutically acceptable salt of amantadine, 15%-35%, or 20%-30% by weight of one or more binders, and 1%-5%, or 2%-4% by weight of one or more anti-adherents. In some embodiments, the pharma- ceutically acceptable salt of amantadine is amantadine hydrochloride, the one or more binders are hydroxypropyl methylcellulose and copovidone, and the one or more anti-adherents are talc. In some embodiments, the drug coating comprises amantadine or a pharma- ceutically acceptable salt thereof, hydroxypropyl methylcellulose, copovidone, and talc. In some embodiments, the drug coating comprises 60% to 85%, 65% to 80%, or 70% to 75% by weight of a pharma- ceutically acceptable salt of amantadine, 15% to 25% or 18% to 22% by weight of hydroxypropyl methylcellulose, 2% to 7% or 3% to 6% by weight of copovidone, and 1% to 5% or 2% to 4% by weight of talc.
[0148] In certain embodiments, the drug coating comprises less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In certain embodiments, the organic solvent is an alcohol (e.g., isopropyl alcohol). In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.). In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl)ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphoramide (e.g., hexamethylphosphoric acid triamide (HPMA), etc.). In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol)). In some embodiments, a mixture of two or more solvents may be used. In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents.
[0149] In some embodiments, the core seeds are coated with a drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof, and optionally one or more binders, anti-adherents, and / or solvents by conventional coating techniques such as fluidized bed coating, pan coating, etc. In some embodiments, the solvent does not comprise an organic solvent. In other embodiments, the solvent for the drug coating composition consists of water.
[0150] B. Time-release coating The coated core seed further comprises a sustained release coating, where the sustained release coating surrounds the drug coating. The sustained release coating can be formulated to delay the release of the drug from the coated core seed for a certain period of time after the dosage form is introduced into the environment of use. The sustained release coating comprises one or more release-modifying excipients. For example, the sustained release coating can comprise one or more pH-dependent or pH-independent release-modifying excipients or combinations thereof. Examples of pH-independent sustained release polymers include ethyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, copolymers of ethyl acrylate, and methyl methacrylate (e.g., Eudragit RS). Examples of pH-dependent release-modifying excipients include methacrylic acid copolymers, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, and cellulose acetate phthalate. The sustained release coating can further comprise one or more pore-forming agents. Examples of pore-forming agents include povidone; polyethylene glycol; hydroxypropylcellulose; hydroxypropylmethylcellulose; sugars such as sucrose, mannitol, and lactose; and salts such as sodium chloride and sodium citrate. The sustained release coating may further include one or more plasticizers, such as acetylated citrate esters, acetylated glycerides, castor oil, citrate esters, dibutyl sebacate, glyceryl monostearate, diethyl phthalate, glycerol, medium chain triglycerides, propylene glycol, or polyethylene glycol. The sustained release coating may also include one or more additional excipients, such as one or more lubricants, one or more anti-adherents. For example, in some embodiments, the sustained release coating includes one or more excipients selected from the group consisting of magnesium stearate, calcium silicate, magnesium silicate, colloidal silicon dioxide, and talc. In some embodiments, the sustained release coating includes one or more lubricants, such as magnesium stearate or talc.
[0151] A sustained release coating comprising one or more release-modifying excipients as described herein. Release-modifying excipients include, but are not limited to, insoluble plastics, hydrophilic polymers, and aliphatic compounds. Plastic matrices include, but are not limited to, methyl acrylate-methyl methacrylate, PVC, and polyethylene. Hydrophilic polymers include, but are not limited to, cellulose polymers such as methylcellulose and ethylcellulose, hydroxyalkyl celluloses such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and crosslinked acrylic acid polymers such as Carbopol® 934, polyethylene oxide, and mixtures thereof. Aliphatic compounds include, but are not limited to, various waxes such as carnauba wax and glyceryl tristearate, and wax-type substances including hydrogenated castor oil or hydrogenated vegetable oil, or mixtures thereof. In certain embodiments, the plastic material may be a pharma- ceutically acceptable acrylic polymer, including but not limited to acrylic and methacrylic acid copolymers, methyl methacrylate, methyl methacrylate copolymers, ethoxyethyl methacrylate, cyanoethyl methacrylate, aminoalkyl methacrylic acid copolymers, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamine copolymers poly(methyl methacrylate), poly(methacrylic acid)(anhydride), polymethacrylic acid, polyacrylamide, poly(methacrylic acid anhydride), and glycidyl methacrylate copolymers. In certain other embodiments, the acrylic polymer is composed of one or more ammonio methacrylic acid copolymers. Ammonio methacrylic acid copolymers are well known in the art and are described in NF XVII as fully polymerized copolymers of acrylic acid esters and methacrylic acid esters with a low content of quaternary ammonium groups. In yet another embodiment, the acrylic polymer is an acrylic resin lacquer (such as that available under the trade name Eudragit® from Rohm Pharma).In a further embodiment, the acrylic polymer comprises a mixture of two acrylic resin lacquers available from Rohm Pharma under the trade names Eudragit® RL30D and Eudragit® RS30D, respectively. Eudragit® RL30D and Eudragit® RS30D are copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups, with a molar ratio of ammonium groups to the remaining neutral (methacrylic) acrylic acid esters of 1:20 for Eudragit RL30D and 1:40 for Eudragit® RS30D. The average molecular weight is about 150,000. Eudragit® S-100 and Eudragit® L-100 are also suitable for use herein. The code names RL (high permeability) and RS (low permeability) refer to the permeability of these agents. Eudragit® RL / RS mixtures are insoluble in water and digestive fluids. However, multiparticulate systems formed to contain it are swellable and permeable in aqueous solutions and digestive fluids. The polymers (such as Eudragit® RL / RS) can be mixed in any desired ratio to ultimately obtain a sustained release formulation with a desired dissolution profile. Those skilled in the art will recognize that other acrylic polymers (such as Eudragit® L) can also be used.
[0152] As described herein, in some embodiments, the sustained release coating comprises one or more pore-forming agents (e.g., pore-forming substances). Pore-forming agents suitable for use in the sustained release coating can be organic or inorganic agents and include materials that can be dissolved, extracted, or leached from the coating in the environment of use. Pore-forming agents include, but are not limited to, organic compounds, such as monosaccharides, oligosaccharides, and polysaccharides, including sucrose, glucose, fructose, mannitol, mannose, galactose, lactose, sorbitol, pullulan, and dextran; polymers that are soluble in the environment of use, such as water-soluble hydrophilic polymers, such as povidone, crospovidone, polyethylene glycol, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyalkyl cellulose, carboxyalkyl cellulose, cellulose ether, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbowax, and Carbopol®, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols, or block polymers thereof, polyglycols, poly(α-Ω) alkylenediols; inorganic compounds, such as alkali metal salts, lithium carbonate, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium acetate, sodium citrate, suitable calcium salts, and the like. In certain embodiments, plasticizers can also be used as pore-forming agents. In some embodiments, the release modifying excipient is ethylcellulose. In certain embodiments, the pore former is povidone, HPMC, or Eudragit® or any combination thereof.
[0153] In some embodiments, the sustained release coating comprises one or more release modifying excipients, one or more pore formers, and one or more plasticizers. In some embodiments, the sustained release coating comprises 65% to 95%, or 70% to 90%, or 75% to 85% by weight of one or more release modifying excipients, 5% to 15% or 8% to 12% by weight of one or more pore formers, and 5% to 15% or 8% to 12% by weight of one or more plasticizers. In some embodiments, the one or more release modifying excipients are ethyl cellulose, the one or more pore formers are povidone, HPMC, or Eudragit®, or mixtures thereof, and the one or more plasticizers are medium chain triglycerides. Thus, in some embodiments, the sustained release coating comprises 65% to 95%, or 70% to 90%, or 75% to 85% by weight ethylcellulose, 5% to 15% or 8% to 12% by weight povidone, and 5% to 15% or 8% to 12% by weight medium chain triglyceride.
[0154] In certain embodiments, the sustained release coating comprises less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In certain embodiments, the organic solvent is an alcohol (e.g., isopropyl alcohol). In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.). In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl)ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphoramide (e.g., hexamethylphosphoric acid triamide (HPMA), etc.). In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol)). In some embodiments, a mixture of two or more solvents may be used. In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents.
[0155] The sustained release coating may be applied using conventional coating techniques, for example, fluidized bed coating, pan coating, etc. The drug-coated core seeds, optionally including a seal coat, may be coated with the sustained release coating by fluidized bed coating.
[0156] C. Additional Coatings In some embodiments, the coated core seed comprises one or more additional coatings (e.g., a sealing coat). In some embodiments, the sealing coat is formulated to prevent one or more components of the sustained release coating from interacting with one or more components of the core seed, or to prevent migration of one or more components of the core seed and / or drug coating from diffusing into the sustained release coating. The sealing coat may comprise one or more film-forming polymers, including, but not limited to, hydroxypropylmethylcellulose (HPMC), copovidone, povidone, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, or any combination thereof.
[0157] The sealing coating can further comprise one or more additional pharma- ceutically acceptable excipients.For example, the sealing coating can comprise one or more plasticizers, such as propylene glycol, triacetin, polyethylene glycol, or tributyl citrate, or any combination thereof; one or more anti-adherents, such as magnesium stearate, calcium silicate, magnesium silicate, colloidal silicon dioxide, or talc, or any combination thereof.In some embodiments, the film-forming polymer is HPMC, copovidone, povidone, or any combination thereof.In some embodiments, the film-forming polymer is HPMC.
[0158] The sealing coating may further include one or more buffers, colorants, opacifiers, surfactants, or bases, which are known to those skilled in the art.
[0159] In certain embodiments, the seal coating comprises one or more film-forming polymers and one or more anti-blocking agents. In some embodiments, the seal coating comprises 80%-100% or 85%-95% by weight of one or more film-forming polymers and 0%-20%, or 5%-15%, or 7%-13% by weight of one or more anti-blocking agents. In certain embodiments, the seal coating comprises hydroxypropyl methylcellulose and talc. In some embodiments, the seal coating comprises 80%-100% or 85%-95% by weight of hydroxypropyl methylcellulose and 0%-20%, or 5%-15%, or 7%-13% by weight of talc.
[0160] In certain embodiments, the sealing coating comprises less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In certain embodiments, the organic solvent is an alcohol (e.g., isopropyl alcohol). In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.). In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl)ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphoramide (e.g., hexamethylphosphoric acid triamide (HPMA), etc.). In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol)). In some embodiments, a mixture of two or more solvents may be used. In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents.
[0161] The seal coating can be applied to the core seed using conventional coating techniques, such as, for example, fluidized bed coating, pan coating, etc. In some embodiments, the drug-coated core seed is coated with a seal coat coating, optionally including one or more binders, anti-adherents, and / or solvents, by fluidized bed coating or pan coating. In certain embodiments, the solvent does not include an organic solvent. In some embodiments, the solvent for the seal coating composition consists of water.
[0162] D. Binder In some embodiments, the drug coating or additional coatings, if present, or any combination thereof, comprises one or more binders (e.g., film-forming polymers). For example, as described herein, the drug coating comprises one or more pharma- ceutically acceptable excipients, where the one or more pharma-ceutically acceptable excipients may comprise a binder. Suitable binders for use herein include alginic acid and its salts; cellulose derivatives, such as carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (e.g., Klucel®), ethylcellulose (e.g., Ethocel®), and microcrystalline cellulose (e.g., Avicel®); microcrystalline dextrose; amylose; magnesium aluminum silicate; polysaccharide acids; acid); bentonite; gelatin; polyvinylpyrrolidone / vinyl acetate copolymer; crospovidone; povidone; starch; pregelatinized starch; dextrin; sugars such as sucrose (e.g., Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (e.g., Xylitab®), and lactose; natural or synthetic gums such as acacia, tragacanth, ghatti gum, mucilage of isapol husk, polyvinylpyrrolidone (e.g., Polyvidone® CL, Kollidon® CL, Polyplasdone® XL-10), larch arabinogalactan, Veegum®, polyethylene glycol, waxes, sodium alginate, and the like.
[0163] E. Capsule In some embodiments, the oral pharmaceutical composition herein further comprises a capsule shell, where a plurality of coated core seeds are encapsulated in the capsule shell. The coated core seeds can be introduced into a suitable capsule shell using an encapsulation device equipped with a pellet injection chamber. The capsule size can be 00, 0, 0EL, 1, 1EL, 2, 2EL, 3, 4, or 5. In some embodiments, a unit dose of the oral pharmaceutical composition is encapsulated in one capsule shell. In other variations, a unit dose of the oral pharmaceutical composition described herein is encapsulated in a plurality of separate capsule shells (e.g., divided between two capsule shells).
[0164] In some embodiments, the composition providing the pharmacokinetic properties and plasma concentration profile is a pellet-in-capsule composition, wherein the pellets are a plurality of coated core seeds having a diameter of about 500 μm to 1.2 mm, preferably about 700 μm to 1000 μm, each coated core seed comprising: a core seed; a drug coating surrounding the core seed and comprising amantadine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient; and a sustained release coating surrounding the drug coating and comprising a release modifying excipient. In some embodiments, the sustained release coating extends the release of amantadine or a pharmaceutically acceptable salt thereof so as to provide the desired pharmacokinetic properties and amantadine plasma concentration profile described herein.
[0165] In some embodiments, the plurality of coated core seeds in the pellet-in-capsule formulation are capsules of size 0 or less, preferably size 1 or less. In some embodiments, the average diameter of the coated core seeds can be in the range of 500 μm to 1200 μm, e.g., 500 μm to 1100 μm, 500 μm to 1000 μm, 500 μm to 900 μm, 500 μm to 800 μm, 500 μm to 700 μm, 600 μm to 1100 μm, 600 μm to 1000 μm, 600 μm to 900 μm, 600 μm to 800 μm, 600 μm to 700 μm, 700 μm to 1100 μm, 700 μm to 1000 μm, 700 μm to 900 μm, or 700 μm to 800 μm. In some embodiments, the average particle diameter is ±10%, e.g., 500 μm, 550 μm, 600 μm, 650 μm, 700 μm, 750 μm, 800 μm, 850 μm, 900 μm, 950 μm, 1000 μm, 1050 μm, 1100 μm, 1150 μm, or 1200 μm.
[0166] In some embodiments, the composition of the present disclosure is an oral pharmaceutical composition comprising a plurality of coated core seeds encapsulated in a capsule shell, each coated core seed comprising: a core seed; a drug coating amantadine or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients, the one or more pharma- ceutically acceptable excipients being one or more binders, the drug coating surrounding the core seed; and a sustained release coating surrounding the drug coating, the sustained release coating comprising a release-modifying excipient (e.g., ethylcellulose), a pore-forming agent (e.g., hydroxypropylmethylcellulose or povidone), and a plasticizer.In some embodiments, the coated core seed can further comprise a sealing coating surrounding the drug coating, where the sustained release coating surrounds the sealing coating.The coated core seed can be prepared using methods known in the art, such as those described in Example 2.
[0167] In certain embodiments, amantadine or a pharma- ceutically acceptable salt thereof is present in an amount of 20-80%, 45-70%, 40-50%, 45-55%, 50-60%, 55-65%, 60-70%, 65-75%, 70-80%, or 40-60% by weight based on the combined weight of the plurality of coated core seeds, and one or more pharma- ceutically acceptable excipients (e.g., one or more binders, e.g., hydroxypropyl methylcellulose, copovidone, or mixtures thereof). ) is present in an amount of 1-25% by weight, core seeds, such as granulated sugar (nonpareils) or microcrystalline cellulose seeds (e.g., Celphere®) are present in an amount of 8-25% by weight, the sustained release coating comprises one or more release modifying excipients, one or more pore formers, and one or more plasticizers, where the release modifying excipients comprise ethylcellulose present in an amount of 10-20% by weight, the pore former, preferably povidone, is present in an amount of 1-4% by weight, and the plasticizer is present in an amount of 1-4% by weight. In another particular embodiment, based on the combined weight of the plurality of coated core seeds, the amantadine or a pharma- ceutically acceptable salt thereof is present in an amount of 50-70% by weight, the one or more pharma- ceutically acceptable excipients (e.g., one or more binders, e.g., hydroxypropyl methylcellulose, copovidone, or mixtures thereof) are present in an amount of 1-25% by weight, the core seeds, e.g., granulated sugar (nonpareils) or microcrystalline cellulose seeds (e.g., Celphere®), are present in an amount of 5-15% by weight, the one or more release modifying excipients in the sustained release coating are ethylcellulose and are present in an amount of 1-15% by weight, the sustained release coating comprises a pore former (e.g., povidone) present in an amount of 0.25-4% by weight, and the sustained release coating comprises a plasticizer present in an amount of 0.25-4% by weight.
[0168] In some embodiments, provided herein is an oral pharmaceutical composition comprising a plurality of coated core seeds and at least one capsule shell, wherein at least a portion of the core seeds are encapsulated within the capsule shell. In some embodiments, the plurality of coated core seeds are encapsulated within two separate capsule shells. In some embodiments, the plurality of coated core seeds comprises core seeds, wherein the core seeds comprise 5%-20%, or 10%-15%, or about 12.44% microcrystalline cellulose by weight of the composition. In some embodiments, the coated core seeds include a drug coating surrounding each core seed, the drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof at 20% to 60%, or 30% to 50%, or 40% to 50%, or about 43.54% by weight of the composition; a pharma- ceutically acceptable excipient at 5% to 18%, or 8% to 15%, or about 11.61% by weight of hydroxypropyl methylcellulose and copovidone at 1% to 5%, or 2% to 4%, or about 2.9% by weight of the composition; and an anti-adherent agent at 1% to 3%, or 1.5% to 2.5%, or about 2.17% by weight of the composition, which is talc. In certain embodiments, the amantadine or salt thereof is amantadine hydrochloride. In other embodiments, the coated core seeds include a sustained release coating surrounding the drug coating, the sustained release coating including a release modifying excipient that is ethylcellulose at 5% to 25%, or 10% to 20%, or about 15.91% by weight of the composition; a pore former that is povidone at 1% to 3%, or 1.5% to 2.5%, or about 2.15% by weight of the composition; and a plasticizer that is a medium chain triglyceride at 1% to 3%, or 1.5% to 2.5%, or about 2.15% by weight of the composition.In certain embodiments that may be combined with any of the preceding embodiments, the coated core seeds include a sealant coating surrounding the drug coating, where a sustained release coating surrounds the sealant coating, the sealant coating comprising a film-forming polymer, which is hydroxypropyl methylcellulose, between 3% and 10%, or between 5% and 8%, or about 6.6% by weight of the composition; and an anti-adherent agent, which is talc, between 0.25% and 1%, or between 0.5% and 0.75%, or about 0.66% by weight of the composition. In certain embodiments, the pharmaceutical composition further comprises magnesium stearate, between 0.01% and 0.2%, or between 0.08% and 0.12%, or about 0.1% by weight of the composition.
[0169] In some embodiments, the pharma- ceutically acceptable salt of amantadine is amantadine hydrochloride, hi another embodiment, the pharma- ceutically acceptable salt of amantadine is amantadine sulfate. In some embodiments, which may be combined with any other embodiment, the oral pharmaceutical composition contains amantadine in a unit dose of 40 mg to 500 mg, 45 mg to 400 mg, 50 mg to 350 mg, 55 mg to 300 mg, 60 mg to 290 mg, 68.5 mg to 274 mg, 50 mg to 80 mg, 55 mg to 75 mg, 60 mg to 70 mg, 120 mg to 150 mg, 135 mg to 145 mg, 130 mg to 140 mg, 250 mg to 300 mg, 260 mg to 290 mg, 270 mg to 280 mg, about 68.5 mg, about 137 mg, or about 274 mg, or an equivalent amount of a pharma- ceutically acceptable salt of amantadine. In some embodiments, the pharma- ceutically acceptable salt of amantadine is amantadine hydrochloride. In another embodiment, the pharma- ceutically acceptable salt of amantadine is amantadine sulfate. It will be clear to those skilled in the art how to calculate the "equivalent weight" of a compound salt, taking into account that the salt has an increased molecular weight. For example, in some embodiments, the composition contains about 68.5 mg of amantadine or the equivalent amount of amantadine hydrochloride. Thus, in some embodiments, the composition contains about 85 mg of amantadine hydrochloride. The unit dose may be in a single capsule or may be spread across multiple capsules.
[0170] As described herein, in some embodiments, the pharmaceutical composition has a lower concentration of organic solvent than other compositions. In some embodiments, the pharmaceutical composition comprises a plurality of coated core seeds, wherein the plurality of coated core seeds has a lower concentration of organic solvent than other compositions. For example, in some embodiments, the pharmaceutical composition provided herein, such as any of the embodiments disclosed herein, comprises a plurality of coated core seeds containing less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In some embodiments, the pharmaceutical compositions described herein contain less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In certain embodiments, the organic solvent is an alcohol. In some embodiments, the organic solvent is isopropyl alcohol. In other embodiments, the organic solvent comprises one or more compounds. For example, in some embodiments, the organic solvent comprises isopropyl alcohol and another alcohol. In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.). In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl) ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphorus amide (e.g., hexamethylphosphoric triamide (HPMA), etc.).In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol)). In some embodiments, a mixture of two or more solvents may be used. In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents.
[0171] Additional embodiments of the present disclosure are shown in the table below under the title "Various Amantadine ER Capsule Size 1 Formulations". Using the methods and compositions described herein, formulations can be made that achieve the desired solubility and target pharmacokinetic profile described herein. More specifically, a therapeutically effective amount of amantadine or a pharmaceutically acceptable salt thereof can be administered once nightly in up to two size 1 (or less, e.g., size 2 or 3) capsules using the manufacturing methods and compositions described herein to achieve these results. In particular, higher drug loading can be achieved using the compositions and manufacturing methods described herein. In some embodiments, higher drug loading can be achieved with the required dissolution profile but without changes in the sustained release coat using smaller sizes of coated core seeds and a concomitant increased drug coating thickness or multiple drug coatings on the smaller core seeds. In some embodiments, using alternative manufacturing approaches described herein (e.g., extrusion and spheronization), even higher drug loadings can be achieved to achieve the desired dissolution profile, thereby allowing for higher amantadine drug loadings with a suitable pharmacokinetic profile, resulting in compositions that are more therapeutically effective, at least as well tolerated, and can be filled into relatively small capsule sizes (e.g., sizes 1, 2, or 3) for ease of administration to patients. Table A: Various Amantadine ER Capsule Size 1 Formulations [Table A-1] [Table A-2]
[0172] Suitable plasticizers include medium chain triglycerides, diethyl phthalate, citrate esters, polyethylene glycol, glycerol, acetylated glycerides, castor oil, and the like. The coated core seeds are filled into capsules to provide the desired amantadine potency. An advantage of this composition is that it provides the desired release profile making the composition suitable for administration before bedtime. An additional advantage is that the sustained release coating is durable enough that the capsule can be opened and the pellets sprinkled on food for administration to patients who have difficulty swallowing pills without adversely affecting the release profile of the composition. When the composition is administered by sprinkling on food, it is preferred to use soft foods (such as applesauce or chocolate pudding) that are consumed within 30 minutes, preferably within 15 minutes. In some embodiments, yet another advantage of the compositions described herein is that they have very good batch-to-batch reproducibility and storage stability.
[0173] In some embodiments of the pellet-in-capsule compositions of the present disclosure, in addition to having any of the in vitro dissolution characteristics described herein and pharmacokinetic characteristics provided herein (e.g., in vivo release profile, Tmax, Cmax / Cmin ratio, etc.) that make the compositions suitable for administration during the hours prior to bedtime, the compositions have a Cmax of 1.3-2.4 ng / ml per mg of amantadine and an AUC of 42-75 ng*h / mL per mg of amantadine following oral administration of a single dose of the capsule to human subjects in the fasted state. 0-inf In some embodiments, the pellet-in-capsule composition provides a single nocturnal oral administration of the capsule to a human subject that provides a Cmax of 2.4-4.2 ng / ml per mg of amantadine, a Cmin of 1.1-2.6 ng / ml per mg of amantadine, and an AUC of 43-73 ng*h / mL per mg of amantadine. 0-24 The present invention is further characterized by a steady state plasma concentration that provides
[0174] The pellet-in-capsule compositions provided herein can be provided in strengths suitable for amantadine therapy. Typical strengths range from at least about 50 mg to about 250 mg. In certain embodiments, the capsule strength of amantadine is 70 mg, 80 mg, 85 mg, 90 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 160 mg, 170 mg, 180 mg, 190 mg, 210 mg, or 220 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof, with a single dose AUC per mg equivalent to a 100 mg tablet of an immediate release formulation of amantadine HCl (e.g., Symmetrel®, or other FDA Orange Book Reference listed drug). 0-inf In some embodiments, the capsule strength is 68.5 mg, 70 mg, 80 mg, 85 mg, 90 mg, 110 mg, 120 mg, 125 mg, 130 mg, 137 mg, 140 mg, 150 mg, 160 mg, 160 mg, 170 mg, 180 mg, 190 mg, 205.5 mg, 210 mg, or 220 mg of amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof, providing a single dose AUC per mg equivalent to a 100 mg tablet of an immediate release formulation of amantadine HCl (e.g., Symmetrel®, or other FDA Orange Book Reference listed drug). 0-inf For example, in some embodiments, the capsule strength includes 85 mg amantadine hydrochloride or 170 mg amantadine hydrochloride. One, two, or three such capsules may be administered to the subject in the hours before bedtime. In some embodiments, 220 mg to 650 mg amantadine hydrochloride is administered once at night using two capsules of a suitable ER formulation. In still other embodiments, the capsule strength is about 60 mg to about 155 mg, about 60 mg to about 80 mg, or about 120 mg to about 155 mg amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. In certain embodiments, the capsule strength is about 75 mg to about 190 mg, about 75 mg to about 95 mg, or about 150 mg to about 190 mg amantadine, or an equivalent amount of a pharma- ceutically acceptable salt thereof. One, two, or three such capsules may be administered to the subject in the hours before bedtime.
[0175] III. Preparation method Also provided herein is a method for preparing the pharmaceutical composition described herein.As described herein, in some embodiments, certain steps of the method of the present invention do not include organic solvent.By avoiding the use of organic solvent in certain steps of preparation, it can result in a pharmaceutical composition with lower residual organic solvent concentration and a lower incidence of one or more gastrointestinal effects when administered to a subject.In some embodiments, the gastrointestinal effects are selected from the group consisting of abdominal bloating, constipation, diarrhea, indigestion, gum pain, dry lips, lower abdominal pain, nausea, stomach discomfort, toothache, upper abdominal pain, and vomiting.
[0176] As described herein, in some embodiments, the pharmaceutical composition provided herein comprises a plurality of coated core seeds, including a core seed and one or more coatings surrounding the core seed, such as a drug coating, a sustained release coating, or a sealing coating, or a mixture thereof. These coatings can be applied, for example, by combining one or more of the coating components with a solvent to form a coating mixture, and applying the coating mixture to the core seed, for example, spraying the coating mixture onto the core seed. This can be done, for example, in a fluidized bed. The sprayed core seed can then be dried as desired, and additional coatings can be applied (for example, a drug coating followed by a sustained release coating). Process parameters for applying coatings to a plurality of core seeds, such as temperature air speed, inlet air temperature, spray rate, drying time, nozzle configuration, etc., will be understood by those skilled in the art.
[0177] In some embodiments, the coated core seeds include a drug coating surrounding the core seeds. The drug coating may be prepared by combining one or more drug coating components (e.g., amantadine or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients) with a solvent to produce a drug mixture, and coating a plurality of core seeds with the drug mixture. In some embodiments, using a solvent that is not an organic solvent or that contains, for example, less than 1% by weight of an organic solvent may result in a pharmaceutical composition having a lower concentration of residual organic solvent. Similarly, if present, a seal coating may be prepared by combining one or more seal coating components (e.g., a film coating polymer) with a solvent to produce a seal coat mixture, and coating a plurality of core seeds with the seal coat mixture. In some embodiments, using a solvent that is not an organic solvent or that contains, for example, less than 1% by weight of an organic solvent may result in a pharmaceutical composition having a lower concentration of residual organic solvent. As described herein, reducing the concentration of organic solvent in the pharmaceutical composition compared to a composition prepared with an organic solvent in the drug coating and / or seal coating step may result in reduced gastrointestinal effects in a subject. In certain embodiments, one or more of the components are suspensions when combined with the solvent. For example, in certain embodiments, the release modifying excipients are prepared as a suspension in water and then combined with other ingredients and solvents to produce the sustained release coating mixture.
[0178] Thus, in some aspects, there is provided a process for preparing an oral pharmaceutical composition comprising amantadine or a pharma- ceutically acceptable salt thereof, comprising: a) coating a plurality of core seeds with a drug mixture to form a plurality of drug-coated core seeds, the drug mixture comprising amantadine or a pharma- ceutically acceptable salt thereof, one or more pharma- ceutically acceptable excipients, and a solvent, the drug mixture comprising less than 1 wt% organic solvent; b) coating the plurality of drug coated core seeds with a sustained release mixture to form sustained release coated core seeds, the sustained release mixture comprising one or more release modifying excipients and a solvent; c) drying the plurality of sustained release coated core seeds; d) encapsulating the plurality of sustained release coated core seeds within a capsule shell to form an oral pharmaceutical composition, the oral pharmaceutical composition comprising: a core seed; a drug coating layer comprising amantadine or a pharma- ceutically acceptable salt thereof; and a sustained release coating layer; producing said plurality of sustained release coated core seeds comprising less than 6000 ppm of organic solvent.
[0179] In some embodiments, the process further comprises coating the plurality of drug-coated core seeds with a seal coat mixture prior to forming the sustained release coated core seeds, wherein the seal coat mixture comprises one or more film-forming polymers and a solvent, the seal coat mixture comprises less than 1% by weight of an organic solvent, and the oral pharmaceutical composition comprises a core seed, a drug coating layer comprising amantadine or a pharma- ceutically acceptable salt thereof, a seal coat layer, and a sustained release coating layer, and the plurality of sustained release coated core seeds comprises less than 6000 ppm of organic solvent. In some embodiments, the process comprises multiple drying steps (e.g., a drying step between each coating application). In some embodiments, the pharmaceutical composition of the present invention comprises less than 6000 ppm of organic solvent.
[0180] The coating step of the process (e.g., coating the core seed or drug-core seed) may include applying a mixture as described herein (e.g., drug mixture, sustained release mixture, or seal coat mixture) by any suitable means. Coating may include spraying or otherwise applying a mixture to the core seed or coated core seed such that at least a portion of the seed is surrounded by a portion of the mixture. In some embodiments, coating the core seed (or coated core seed) includes completely surrounding the core seed with a mixture as described herein. In other embodiments, coating the seed includes surrounding substantially all or a majority of the core seed, e.g., at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.9% of the surface area of the core seed is surrounded by the coating. The mixture may be applied in a uniform thickness or may vary in thickness.
[0181] In some embodiments, the organic solvent is a linear or cyclic ketone (e.g., acetone, methyl ethyl ketone, etc.). In some embodiments, the organic solvent is a sulfoxide (e.g., dimethyl sulfoxide, etc.). In some embodiments, the organic solvent is an amide (e.g., dimethylformamide, N-methylpyrrolidone, hexamethylphosphoric triamide (HMPT), etc.). In some embodiments, the organic solvent is a linear or cyclic ether (e.g., tetrahydrofuran, diethyl ether, bis(2-methoxyethyl)ether (diglyme), dimethoxyethane (glyme), 1,4-dioxane, etc.). In some embodiments, the organic solvent is a phosphoramide (e.g., hexamethylphosphoric triamide (HPMA), etc.). In some embodiments, the organic solvent is a chlorinated hydrocarbon (e.g., chloroform, dichloromethane, dichloroethane, carbon tetrachloride, etc.). In some embodiments, the organic solvent is a glycol (e.g., ethylene glycol, diethylene glycol, propylene glycol, etc.). In some embodiments, the organic solvent is a nitrogen-containing solvent (e.g., pyridine, acetonitrile, etc.). In some embodiments, the organic solvent is an alcohol such as isopropyl alcohol (e.g., a C1-C6 alcohol (e.g., ethanol, methanol, isopropanol, 1-butanol, 2-butanol, glycerol). In some embodiments, a mixture of two or more solvents may be used. In some embodiments, by reducing or avoiding the use of organic solvents in the drug coating mixture and optional seal coating mixture while still using organic solvents in the sustained release coating mixture, a pharmaceutical composition as described herein may be produced that includes a plurality of coated core seeds, e.g., sustained release coated core seeds containing less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent as described herein.In some embodiments of the concentrations of organic solvents described herein, the concentrations provided refer to the total amount of two or more organic solvents.
[0182] The components of each coating mixture can be any of the components described herein for coating a pharmaceutical composition. For example, in some embodiments, the one or more pharma- ceutically acceptable excipients include one or more binders and one or more anti-adherents, and the sustained release mixture further includes a plasticizer and a pore former. In other embodiments, the drug mixture includes hydroxypropyl methylcellulose, copovidone, talc, and a solvent, and the sustained release mixture includes ethylcellulose, povidone, medium chain triglycerides, and a solvent. In yet other embodiments, the seal coat mixture includes hydroxypropyl methylcellulose, talc, and a solvent. In some embodiments, the solvent in the seal coat mixture is water. In other embodiments, the solvent in the sustained release mixture includes alcohol and water. In yet other embodiments, the solvent in the drug mixture is water.
[0183] The process provided herein can produce an oral pharmaceutical composition comprising a plurality of coated core seeds, wherein the plurality of coated core seeds comprises less than 6000 ppm, less than 5500 ppm, less than 5000 ppm, less than 4500 ppm, less than 4000 ppm, less than 3500 ppm, less than 3000 ppm, less than 2500 ppm, less than 2000 ppm, less than 1500 ppm, or less than 1200 ppm of organic solvent. In some embodiments, the coated core seeds are sustained release coated core seeds.
[0184] The processes provided herein may produce pharmaceutical compositions containing any of the components as described herein in any weight, ratio, or weight percentage. For example, in some embodiments of the processes provided herein, the oral pharmaceutical composition comprises: 30% to 60% by weight of amantadine or a pharma- ceutically acceptable salt thereof; 1% to 25% by weight of hydroxypropyl methylcellulose; 1% to 4% by weight of copovidone; 10% to 20% by weight of ethyl cellulose; 0.25% to 4% by weight of intermediate triglycerides; 0.25% to 4% by weight of povidone, The multiple coated core seeds contain less than 2000 ppm alcohol.
[0185] In some embodiments, the pharmaceutical composition comprises less than 2000 ppm of an organic solvent, such as alcohol. In certain embodiments, the pharmaceutical composition comprises a plurality of coated core seeds, wherein the plurality of coated core seeds comprises less than 2000 ppm of an organic solvent, such as alcohol. In some embodiments of the processes provided herein, the oral pharmaceutical composition comprises core seeds comprising microcrystalline cellulose, 5% to 20%, or 10% to 15%, or about 12.44% by weight of the composition; a drug coating surrounding each core seed, the drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof, 20% to 60%, or 30% to 50%, or 40% to 50%, or about 43.54% by weight of the composition; a pharma- ceutically acceptable excipient, 5% to 18%, or 8% to 15%, or about 11.61% by weight of hydroxypropyl methylcellulose and 1% to 5%, or 2% to 4%, or about 2.9% by weight of the composition of copovidone; and an anti-adherent agent, 1% to 3%, or 1.5% to 2.5%, or about 2.17% by weight of the composition of talc, surrounding the drug coating. A sustained release coating comprising: a release modifying excipient that is ethylcellulose, between 5% and 25%, or between 10% and 20%, or about 15.91% by weight of the composition; a pore former that is povidone, between 1% and 3%, or between 1.5% and 2.5%, or about 2.15% by weight of the composition; and a plasticizer that is a medium chain triglyceride, between 1% and 3%, or between 1.5% and 2.5%, or about 2.15% by weight of the composition. and a sustained release coating surrounding the drug coating, the sealant coating comprising a film forming polymer that is hydroxypropyl methylcellulose at 3% to 10%, or 5% to 8%, or about 6.6% by weight of the composition; and an anti-adherent agent that is talc at 0.25% to 1%, or 0.5% to 0.75%, or about 0.66% by weight of the composition. In some embodiments, the amantadine or pharma- ceutically acceptable salt thereof is amantadine hydrochloride.In certain embodiments, the oral pharmaceutical composition further comprises magnesium stearate, between 0.01% and 0.2%, or between 0.08% and 0.12%, or about 0.1% by weight of the composition. In some embodiments, the pharma- ceutically acceptable salt of amantadine is amantadine hydrochloride. In another embodiment, the pharma- ceutically acceptable salt of amantadine is amantadine sulfate.
[0186] In some embodiments, the core seeds surrounded by the drug coating and optionally the sealing coating constitute 70%-90%, 75%-85%, or about 80.57% by weight of the final composition, and the sustained release coating is applied to increase the total weight by about 24%. In other embodiments, the core seeds surrounded by the drug coating and optionally the sealing coating constitute 70%-90%, 75%-85%, or about 79.92% by weight of the final composition, and the sustained release coating is applied to increase the total weight by about 25%. In certain embodiments, oral pharmaceutical compositions with an increased weight percentage of sustained release coating (e.g., increased by about 2%, about 1.5%, about 1%, or about 0.5%) result in a lower incidence of gastrointestinal effects compared to compositions having a lower weight percentage of sustained release coating.
[0187] Further provided herein are oral pharmaceutical compositions formed by any of the processes described herein. Also provided herein are oral pharmaceutical compositions that can be formed by any of the processes provided herein.
[0188] IV. Other sustained release dosage forms Those skilled in the art will understand that in addition to the capsule formulations described herein, other embodiments of sustained release oral compositions can be envisioned. Such other embodiments include sustained release solid dosage forms, such as tablets, capsules, gel capsules, powders, pellets, beadlets, etc. Such sustained release compositions include those that have the release characteristics and in vivo pharmacokinetic profiles used in the methods of the present disclosure. In some embodiments, those skilled in the art can use the sustained release technology described in U.S. Patent No. 5,358,721 to Guittard et al. or U.S. Patent No. 6,217,905 to Edgren et al. (each of which discloses an oral osmotic dosage form of amantadine, each of which is incorporated herein by reference in its entirety) with appropriate adjustment of design characteristics to achieve the required pharmacokinetic profile described herein. In other embodiments, one of skill in the art may use techniques described in U.S. Pat. No. 6,194,000 to Smith et al. or U.S. Patent Application Publication Nos. US2006 / 0252788, US2006 / 0189694, US2006 / 0142398, US2008 / 0227743, US2011 / 0189273, and US20150087721, all to Went et al., each of which discloses administration of an NMDA receptor antagonist, e.g., amantadine, optionally in a controlled release form, each of which is incorporated herein by reference in its entirety, with appropriate adjustment of design features.
[0189] Some embodiments herein provide a method of orally administering amantadine (or a pharma- ceutically acceptable salt thereof, e.g., amantadine hydrochloride) to a subject in need thereof once at night, comprising orally administering an extended release (ER) composition comprising amantadine or a pharma- ceutically acceptable salt thereof less than 4 hours prior to bedtime (and / or after 4 p.m.). In some embodiments, administration occurs less than 4 hours prior to bedtime. In some such methods, the method increases on-time without dyskinesia experienced by a subject with Parkinson's disease. In some such methods, the method reduces on-time with dyskinesia experienced by a subject with Parkinson's disease. In some such methods, the method reduces bothersome on-time with dyskinesia experienced by a subject with Parkinson's disease. In some embodiments, the method reduces off-time experienced by a subject with Parkinson's disease. In some embodiments, the method increases on-time without bothersome dyskinesia but does not induce or increase sleep disturbance in a subject with Parkinson's disease. In some embodiments, the method improves clinician global impression but does not induce or increase sleep disturbance in subjects with Parkinson's disease. In some embodiments, the composition is added to food prior to administration. In some embodiments, amantadine plasma concentrations do not increase for at least 1 hour after administration. In some embodiments, amantadine plasma concentrations do not increase for at least 2 hours after administration. In some embodiments, amantadine has a single dose Tmax of 9-18 hours and / or a steady state Tmax of 7-13 hours. In some embodiments, amantadine has a single dose Tmax of 12-18 hours and / or a steady state Tmax of 8-12 hours after administration. In some embodiments, amantadine has a single dose Tmax of 12-16 hours and / or a steady state Tmax of 9-12 hours after administration. In some embodiments, a single nighttime oral administration of the composition to a human subject provides a steady state plasma concentration profile characterized by an increase in concentration of amantadine of less than 25% at 3 hours after administration.In some embodiments, the PK curve has a Cmax / Cmin ratio of 1.4-1.9. In some embodiments, the C-ave-day / C-ave-night ratio at steady state is 1.2-1.7. In some embodiments, the mean daytime amantadine plasma concentration at steady state (C-ave-day) is 500-2000 ng / ml. In some embodiments, the amantadine is amantadine hydrochloride or amantadine sulfate. In some embodiments, the composition comprises 260-420 mg of amantadine hydrochloride. In some embodiments, the composition is administered as 2 or 3 or 4 unit dosage forms, each comprising 85-175 mg of amantadine hydrochloride. In some embodiments, the composition is administered as 2 unit dosage forms, each comprising 130-210 mg of sustained release amantadine hydrochloride. In some embodiments, the composition is present in capsules of capsule size #1. In some embodiments, the composition comprises 260 mg to 340 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof. In some embodiments, the composition comprises 340 mg of a pharma- ceutically acceptable salt of amantadine, e.g., amantadine hydrochloride. In some embodiments, the composition comprises 170 mg of amantadine hydrochloride. In some embodiments, oral administration of a single dose of the composition to a fasted human subject results in a maximum plasma concentration (Cmax) of 1.1 to 2.1 ng / ml per mg of amantadine and an AUC of 42 to 72 ng*h / mL per mg of amantadine. 0-inf In some embodiments, oral administration of a single dose of the composition to a human subject once at night provides: (a) a Cmax of 2.0 to 3.1 ng / ml per mg of amantadine; (b) a Cmin of 1.3 to 2.0 ng / ml per mg of amantadine, and (c) AUC of 42 to 68 ng*h / mL per mg of amantadine 0-24In some embodiments, the steady state plasma concentration profile is further characterized by (d) no increase in amantadine plasma concentration for at least 1 hour after administration, and (e) a Cmax / Cmin ratio of 1.4 to 1.9. In some embodiments, the steady state plasma concentration profile is further characterized by (f) no increase in amantadine plasma concentration for at least 2 hours after administration, and (g) a Cmax / Cmin ratio of 1.4 to 1.9.
[0190] In some embodiments, the composition has an AUC 0-inf The partial AUC from 0 to 4 hours is less than 0.25% of the AUC 0-inf The partial AUC from 0 to 8 hours was less than 3.5% of the AUC 0-inf The partial AUC from 0 to 12 hours, which is approximately 5 to 12% of the AUC 0-inf The partial AUC from 0 to 18 hours, which is approximately 25 to 60% of the AUC 0-inf In some embodiments, the composition has an AUC profile following administration of a single dose of the composition characterized by a partial AUC from 0 to 24 hours that is about 20-27% of the AUC 0-24 The partial AUC from 0 to 4 hours, which is approximately 2 to 25% of the AUC 0-24 The partial AUC from 0 to 8 hours, which is approximately 15 to 50% of the AUC 0-24 The partial AUC from 0 to 12 hours, which is approximately 30 to 70% of the AUC 0-24 The composition has an AUC profile following a single nightly administration at steady state conditions characterized by a partial AUC from 0-18 hours that is about 60-95% of the AUC from 0-18 hours. In some such embodiments, the method increases on-time without bothersome dyskinesias. In some such embodiments, the method reduces off-time experienced by a subject with Parkinson's disease.
[0191] Some embodiments provide herein a method of reducing sleep disturbance in a human subject undergoing treatment with amantadine, comprising administering a sustained release (ER) composition comprising amantadine or a pharma- ceutically acceptable salt thereof orally once at night less than 4 hours before bedtime (and / or after 4 p.m.). In some such methods, the method reduces on-times experienced by a Parkinson's disease subject with dyskinesia. In some such methods, the method reduces on-times experienced by a Parkinson's disease subject with bothersome dyskinesia. In some embodiments, the method reduces off-times experienced by a Parkinson's disease subject. In some embodiments, the method increases on-times without bothersome dyskinesia but does not induce or increase sleep disturbances or gastrointestinal adverse events in a Parkinson's disease subject. In some embodiments, the composition is added to food prior to administration. In some embodiments, amantadine plasma concentration is not increased for at least 1 hour after administration. In some embodiments, the composition is added to food prior to administration. In some embodiments, the amantadine plasma concentration does not increase for at least 1 hour after administration.In some embodiments, the amantadine plasma concentration does not increase for at least 2 hours after administration.
[0192] In some embodiments of the methods described herein, e.g., methods of administration or methods of reducing one or more side effects or methods of treating another condition, the unit dose of amantadine is 40 mg to 500 mg, 45 mg to 400 mg, 50 mg to 350 mg, 55 mg to 300 mg, 60 mg to 290 mg, 68.5 mg to 274 mg, 50 mg to 80 mg, 55 mg to 75 mg, 60 mg to 70 mg, 120 mg to 150 mg, 135 mg to 145 mg, 130 mg to 140 mg, 250 mg to 300 mg, 260 mg to 290 mg, 270 mg to 280 mg, about 68.5 mg, about 137 mg, or about 274 mg, or an equivalent amount of a pharma- ceutically acceptable salt of amantadine. In some embodiments, the pharma- ceutically acceptable salt of amantadine is amantadine hydrochloride. In another embodiment, the pharma- ceutically acceptable salt of amantadine is amantadine sulfate. It will be clear to one skilled in the art how to calculate the "equivalent" of a salt of a compound, taking into account that the salt has an increased molecular weight. For example, in some embodiments, the method comprises administering about 68.5 mg of amantadine or an equivalent amount of amantadine hydrochloride. Thus, in some embodiments, the method comprises administering about 85 mg of amantadine hydrochloride. The unit dose may be in a single capsule or may be spread across multiple capsules.
[0193] Pharmacokinetic parameters detailed herein on a "per mg of drug" basis may be calculated using mg of the form of amantadine in the composition. Thus, for example, if the composition contains amantadine, the calculation may use the weight of amantadine present. If the composition contains a pharmaceutically acceptable salt of amantadine, the calculation may use the weight of the pharmaceutically acceptable salt. Furthermore, one of skill in the art will know how to convert the value of a pharmacokinetic parameter calculated using the weight of one form (e.g., amantadine or a pharmaceutically acceptable salt of amantadine) to a value corresponding to the use of another form. Thus, for example, a parameter that quotes or is based on the weight of amantadine may be converted to a parameter that quotes or is based on the weight of a pharmaceutically acceptable salt of amantadine, e.g., amantadine hydrochloride. Examples of such parameters include AUC, which has units of ng*hr / ml per mg. inf pAUC with units of ng*hr / ml per mg 0-6 pAUC with units of ng*hr / ml per mg 0-8 mean Cmax in ng / ml per mg; mean Cmin in ng / ml per mg; or mean AUC in ng*h / mL per mg 0-24 may be included.
[0194] Numbered embodiments Embodiment I-1 An oral pharmaceutical composition comprising: 137 mg to 500 mg of amantadine or a pharma- ceutically acceptable salt thereof; and at least one excipient that modulates the release of the drug; The oral pharmaceutical composition, when administered to healthy subjects in a single-dose fasted human pharmacokinetic study, has (i) a Tmax of amantadine of 11 to 19 hours, (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf and (iii) pAUC of amantadine between 1.0 and 2.0 ng*hr / ml per mg of the drug. 0-8 1. An oral pharmaceutical composition comprising:
[0195] Embodiment I-2 An oral pharmaceutical composition comprising: 137 mg to 500 mg of amantadine or a pharma- ceutically acceptable salt thereof; and at least one excipient that modulates the release of the amantadine or pharma- ceutically acceptable salt thereof; The oral pharmaceutical composition, when administered to healthy subjects in a single-dose fasted human pharmacokinetic study, has (i) a Tmax of amantadine of 11 to 19 hours, (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf and (iii) a pAUC of amantadine between 0.3 and 0.9 ng*hr / ml per mg of the drug. 0-6 1. An oral pharmaceutical composition comprising:
[0196] Embodiment I-3 The oral pharmaceutical composition, when administered to healthy subjects in a single-dose fasting human pharmacokinetic study, has a pAUC of amantadine of 0.3 to 0.9 ng*hr / ml per mg of the drug. 0-6 The oral pharmaceutical composition according to embodiment I-1, having the following structure:
[0197] Embodiment I-4 An oral pharmaceutical composition comprising: 137 mg to 500 mg of amantadine or a pharma- ceutically acceptable salt thereof; and at least one excipient that modulates the release of the amantadine or pharma- ceutically acceptable salt thereof; the oral pharmaceutical composition has a dissolution profile of amantadine exhibiting at least three of the following: (i) 0% to 10% within 2 hours, (ii) 3% to 14% within 4 hours, (iii) 23% to 40% within 6 hours, (iv) 50% to 70% within 8 hours, and (v) 80% or greater within 12 hours, as determined in a USP Type 2 apparatus (paddle) at 37.0±0.5° C. and 50 rpm using 500 ml of water as the dissolution medium; When the oral pharmaceutical composition is administered to healthy subjects in a fasting human pharmacokinetic study at a single dose, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours, and (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf 1. An oral pharmaceutical composition comprising:
[0198] Embodiment I-5. The oral pharmaceutical composition of embodiment I-4, wherein the dissolution profile is: (i) 0%-9% within 2 hours, (ii) 3%-14% within 4 hours, (iii) 24%-40% within 6 hours, (iv) 45%-70% within 8 hours, and (v) 82% or more within 12 hours.
[0199] Embodiment I-6 A method of administering an oral pharmaceutical composition to a subject in need thereof, comprising: orally administering the oral pharmaceutical composition to the patient once daily 0 to 4 hours before bedtime; The oral pharmaceutical composition comprises 137 mg to 500 mg of amantadine or a pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of the amantadine or a pharma- ceutically acceptable salt thereof; When the oral pharmaceutical composition is administered to healthy subjects in a fasting human pharmacokinetic study at a single dose, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours, (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf and (iii) pAUC of amantadine between 1.0 and 2.0 ng*hr / ml per mg of the drug. 0-8 1. An oral pharmaceutical composition comprising:
[0200] Embodiment I-7 A method of administering an oral pharmaceutical composition to a subject in need thereof, comprising: The method includes orally administering the pharmaceutical composition to a subject once daily, 0 to 4 hours before bedtime; The oral pharmaceutical composition comprises 137 mg to 500 mg of amantadine or a pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of the amantadine or pharma- ceutically acceptable salt thereof; When the oral pharmaceutical composition is administered to healthy subjects in a fasting human pharmacokinetic study at a single dose, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours, (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf and (iii) a pAUC of amantadine between 0.3 and 0.9 ng*hr / ml per mg of the drug. 0-6 1. An oral pharmaceutical composition comprising:
[0201] Embodiment I-8 The oral pharmaceutical composition, when administered to healthy subjects in a single-dose fasting human pharmacokinetic study, has a pAUC of amantadine of 0.3 to 0.9 ng*hr / ml per mg of the drug. 0-6 The method of embodiment I-6, comprising the steps of:
[0202] Embodiment I-9 A method of administering an oral pharmaceutical composition to a subject in need thereof, comprising: The method includes orally administering the oral pharmaceutical composition to a subject once a day, 0 to 4 hours before bedtime; The oral pharmaceutical composition comprises 137 mg to 500 mg of amantadine or a pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of the amantadine or pharma- ceutically acceptable salt thereof; the oral pharmaceutical composition has a dissolution profile of amantadine exhibiting at least three of the following: (i) 0% to 10% within 2 hours, (ii) 3% to 14% within 4 hours, (iii) 23% to 40% within 6 hours, (iv) 50% to 70% within 8 hours, and (v) 80% or greater within 12 hours, as determined in a USP Type 2 apparatus (paddle) at 37.0±0.5° C. and 50 rpm using 500 ml of water as the dissolution medium; When the oral pharmaceutical composition is administered to healthy subjects in a fasting human pharmacokinetic study at a single dose, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours and (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf The method comprising:
[0203] The method of embodiment I-9, wherein the dissolution profile is: (i) 0%-9% within 2 hours, (ii) 3%-14% within 4 hours, (iii) 24%-40% within 6 hours, (iv) 45%-70% within 8 hours, and (v) 82% or more within 12 hours.
[0204] Embodiment I-11 A method of reducing adverse gastrointestinal events in a subject to which a pharmaceutical composition comprising amantadine or a pharma- ceutical acceptable salt thereof is orally administered, comprising: 137 mg to 500 mg of amantadine or a pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of the amantadine or pharma- ceutically acceptable salt thereof; When the oral pharmaceutical composition is administered to healthy subjects in a fasting human pharmacokinetic study at a single dose, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours, (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf and (iii) pAUC of amantadine between 1.0 and 2.0 ng*hr / ml per mg of the drug. 0-8 The method comprising:
[0205] Embodiment I-12 A method of reducing adverse gastrointestinal events in a subject to which a pharmaceutical composition comprising amantadine or a pharma- ceutical acceptable salt thereof is orally administered, comprising: 137 mg to 500 mg of amantadine or a pharma- ceutically acceptable salt thereof; and at least one excipient that modulates the release of the amantadine or pharma- ceutically acceptable salt thereof; When the oral pharmaceutical composition is administered to healthy subjects in a fasting human pharmacokinetic study at a single dose, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours, (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf and (iii) a pAUC of amantadine between 0.3 and 0.9 ng*hr / ml per mg of the drug. 0-6 The method comprising:
[0206] Embodiment I-13 The oral pharmaceutical composition, when administered to healthy subjects in a single-dose fasting human pharmacokinetic study, has a pAUC of amantadine of 0.3 to 0.9 ng*hr / ml per mg of the drug. 0-6 The method of embodiment I-11, comprising the steps of:
[0207] Embodiment I-14 A method of reducing adverse gastrointestinal events in a subject to which a pharmaceutical composition comprising amantadine or a pharma- ceutical acceptable salt thereof is orally administered, comprising: 137 mg to 500 mg of amantadine or a pharma- ceutically acceptable salt thereof; and at least one excipient that modulates the release of the amantadine or pharma- ceutically acceptable salt thereof; the oral pharmaceutical composition has a dissolution profile of amantadine exhibiting at least three of the following: (i) 0% to 10% within 2 hours, (ii) 3% to 14% within 4 hours, (iii) 23% to 40% within 6 hours, (iv) 50% to 70% within 8 hours, and (v) 80% or greater within 12 hours, as determined in a USP Type 2 apparatus (paddle) at 37.0±0.5° C. and 50 rpm using 500 ml of water as the dissolution medium; When the pharmaceutical composition is administered to healthy subjects in a fasting human pharmacokinetic study at a single dose, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours, and (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf The method comprising:
[0208] Embodiment I-15. The method of embodiment I-14, wherein the dissolution profile is: (i) 0%-9% within 2 hours, (ii) 3%-14% within 4 hours, (iii) 24%-40% within 6 hours, (iv) 45%-70% within 8 hours, and (v) 82% or more within 12 hours.
[0209] Embodiment I-16 A process for preparing an oral pharmaceutical composition comprising amantadine or a pharma- ceutically acceptable salt thereof, comprising: a) coating a plurality of core seeds with a drug mixture to form drug-coated core seeds; the drug mixture comprises amantadine or a pharma- ceutically acceptable salt thereof, one or more pharma- ceutically acceptable excipients, and a solvent; forming the drug mixture containing less than 1% by weight of an organic solvent; b) coating the plurality of drug-coated core seeds with a sustained release mixture to form sustained release coated core seeds; forming a sustained release mixture comprising one or more release modifying excipients and a solvent; c) drying the plurality of sustained release coated core seeds; d) encapsulating the plurality of sustained release coated core seeds within a capsule shell to form an oral pharmaceutical composition; The oral pharmaceutical composition comprises a core seed, a drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof, and a sustained release coating; producing said plurality of sustained release coated core seeds comprising less than 6000 ppm of organic solvent.
[0210] Embodiment I-17 Before forming the sustained release coated core seed coating a plurality of drug-coated core seeds with a seal coat mixture, the seal coat mixture comprising one or more film-forming polymers and a solvent; the seal coat mixture comprising less than 1% by weight of an organic solvent; coating the oral pharmaceutical composition, the coating comprising a core seed, a drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof, a sealing coating, and a sustained release coating; The process of embodiment I-16, further comprising producing said plurality of sustained release coated core seeds comprising less than 6000 ppm of organic solvent.
[0211] Embodiment I-18. The process of embodiment I-16 or I-17, wherein the organic solvent is an alcohol.
[0212] Embodiment I-19. The process of any one of embodiments I-16 to I-18, wherein the organic solvent is isopropyl alcohol.
[0213] Embodiment I-20 The process of any one of embodiments I-16 to I-19, wherein the one or more pharma- ceutically acceptable excipients comprise one or more binders and one or more anti-adherents, and the sustained release mixture further comprises a plasticizer and a pore former.
[0214] Embodiment I-21 The process of any one of embodiments I-16 to I-20, wherein the drug mixture comprises hydroxypropyl methylcellulose, copovidone, talc, and a solvent, and the sustained release mixture comprises ethylcellulose, povidone, a medium chain triglyceride, and a solvent.
[0215] Embodiment I-22 The process of any one of Embodiments I-17 through I-21, wherein the seal coat mixture comprises hydroxypropyl methylcellulose, talc, and a solvent.
[0216] Embodiment I-23. The process of any one of embodiments I-16 through I-22, wherein the plurality of sustained release coated core seeds comprises less than 2000 ppm of organic solvent.
[0217] Embodiment I-24 The oral pharmaceutical composition comprises: 30% to 60% by weight of amantadine or a pharma- ceutically acceptable salt thereof; 1% to 25% by weight of hydroxypropyl methylcellulose; 1% to 4% by weight of copovidone; 10% to 20% by weight of ethyl cellulose; 0.25% to 4% by weight of intermediate triglycerides; 0.25% to 4% by weight of povidone, The process of any one of embodiments I-16 to I-23, wherein the plurality of sustained release coated core seeds comprises less than 2000 ppm alcohol.
[0218] Embodiment I-25. The process of any one of embodiments I-16 to I-24, wherein the solvent in the drug mixture comprises water.
[0219] Embodiment I-26. The process of embodiment I-25, wherein the solvent in the drug mixture comprises greater than 99% water by weight.
[0220] Embodiment I-27 The process of embodiment I-25 or I-26, wherein the solvent in the drug mixture is water.
[0221] Embodiment I-28. The process of any one of Embodiments I-17 through I-27, wherein the solvent in the seal coat mixture comprises water.
[0222] Embodiment I-29. The process of embodiment I-28, wherein the solvent in the sealing mixture comprises greater than 99% water by weight.
[0223] Embodiment I-30. The process of embodiment I-28 or I-29, wherein the solvent in the sealing mixture is water.
[0224] Embodiment I-31. The process of any one of embodiments I-16 to I-30, wherein the solvent in the sustained release mixture comprises water.
[0225] Embodiment I-32. The process of any one of embodiments I-16 to I-30, wherein the solvent in the sustained release mixture comprises an organic solvent.
[0226] Embodiment I-33 The process of any one of embodiments I-16 to I-32, wherein the solvent in the sustained release mixture comprises water and an organic solvent.
[0227] Embodiment I-34. The process of embodiment I-33, wherein the solvent in the sustained release mixture comprises water and up to 50% by weight of an organic solvent.
[0228] Embodiment I-35. An oral pharmaceutical composition formed by the process of any one of Embodiments I-16 to I-34.
[0229] Embodiment I-36. An oral pharmaceutical composition that can be formed by the process of any one of embodiments I-16 to I-35.
[0230] Embodiment I-37 An oral pharmaceutical composition comprising amantadine or a pharma- ceutically acceptable salt thereof, A plurality of coated core seeds, each coated core seed comprising: Core Seed, a plurality of coated core seeds comprising a drug coating surrounding said core seeds, said drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients, and a sustained release coating surrounding said drug coating, said sustained release coating comprising one or more release modifying excipients; and a capsule shell, the plurality of coated core seeds being encapsulated within the capsule shell; The oral pharmaceutical composition, wherein the plurality of coated core seeds comprises less than 6000 ppm of organic solvent.
[0231] Embodiment I-38 The oral pharmaceutical composition of embodiment I-37, wherein the organic solvent is an alcohol.
[0232] Embodiment I-39 The oral pharmaceutical composition of embodiment I-37 or I-38, wherein the organic solvent is isopropyl alcohol.
[0233] Embodiment I-40. The oral pharmaceutical composition of any one of embodiments I-37 to I-39, further comprising a sealant coating surrounding the drug coating, the sealant coating comprising one or more film-forming polymers, and surrounded by the sustained release coating.
[0234] Embodiment I-41 An oral pharmaceutical composition according to any one of embodiments I-37 to I-40, wherein the one or more pharma- ceutically acceptable excipients comprise one or more binders and one or more anti-adherents, and the sustained release coating further comprises a plasticizer and a pore former.
[0235] Embodiment I-42 The one or more pharma- ceutically acceptable excipients are one or more binders and one or more anti-adherents, wherein the one or more binders comprise hydroxypropyl methylcellulose and copovidone, and the one or more anti-adherents comprise talc; the sustained release coating comprises a release modifying excipient, a plasticizer, and a pore former; The oral pharmaceutical composition of any one of embodiments I-37 to I-41, wherein the release modifying excipient comprises ethylcellulose, the pore former comprises povidone, and the plasticizer comprises a medium chain triglyceride.
[0236] Embodiment I-43. The oral pharmaceutical composition of any one of Embodiments I-40 to I-42, wherein the film forming polymer comprises hydroxypropylmethylcellulose and the seal coating further comprises talc.
[0237] Embodiment I-44. The oral pharmaceutical composition of any one of embodiments I-37 to I-43, wherein the plurality of coated core seeds comprises less than 2000 ppm of organic solvent.
[0238] Embodiment I-45 The pharmaceutical composition comprises: 30% to 60% by weight of amantadine or a pharma- ceutically acceptable salt thereof; 1% to 25% by weight of hydroxypropyl methylcellulose; 1% to 4% by weight of copovidone; 10% to 20% by weight of ethyl cellulose; 0.25% to 4% by weight of intermediate triglycerides; 0.25% to 4% by weight of povidone, The oral pharmaceutical composition of any one of embodiments I-37 to I-44, wherein the plurality of coated core seeds comprises less than 2000 ppm alcohol.
[0239] Embodiment I-46 The drug coating 40% to 50% by weight of amantadine or a pharma- ceutically acceptable salt thereof; 10% to 15% by weight of hydroxypropyl methylcellulose; 2% to 3.5% by weight of copovidone; 1.8% to 2.5% by weight of talc; The sustained release coating comprises: 10% to 20% by weight of ethyl cellulose; 1.5% to 2.5% by weight of povidone; 1.5% to 2.5% by weight of medium chain triglycerides.
[0240] Embodiment I-47. An oral pharmaceutical composition according to any one of embodiments I-37 to I-46, wherein the sealing coating comprises 5% to 10% by weight of hydroxypropyl methylcellulose and 0.25% to 1% by weight of talc.
[0241] Embodiment I-48 An oral pharmaceutical composition according to any one of embodiments I-37 to I-47, wherein the unit dose of amantadine is from 40 mg to 500 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0242] Embodiment I-49 An oral pharmaceutical composition according to any one of embodiments I-37 to I-48, wherein the unit dose of amantadine is from 60 mg to 300 mg, or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0243] Embodiment I-50 The oral pharmaceutical composition of any one of embodiments I-37 to I-49, wherein the oral pharmaceutical composition is formulated for once-daily administration.
[0244] Embodiment II-1 An oral pharmaceutical composition comprising: a drug which is amantadine or a pharma- ceutical acceptable salt thereof, the oral pharmaceutical composition comprising 50 mg to 500 mg of the amantadine or an equivalent amount of the pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of at least a portion of the drug; The oral pharmaceutical composition comprises: (i) 0% to 10% within 2 hours, (ii) 3% to 14% within 4 hours; (iii) 23% to 40% within 6 hours; (iv) 50% to 70% within 8 hours, and (v) having a dissolution profile for the drug that exhibits at least four of 80% or greater within 12 hours; The dissolution profile was determined using a USP Type 2 apparatus (paddle) at 37.0±0.5° C., 50 rpm with 500 ml of water as the dissolution medium; When the oral pharmaceutical composition is administered to healthy subjects in a single-dose human pharmacokinetic study, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours and (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf wherein the subject is dosed in the morning after an overnight fast.
[0245] Embodiment II-2. The oral pharmaceutical composition of embodiment II-1, wherein the dissolution profile is: (i) 0%-9% within 2 hours, (ii) 3%-14% within 4 hours, (iii) 24%-40% within 6 hours, (iv) 45%-70% within 8 hours, and (v) 82% or more within 12 hours.
[0246] Embodiment II-3 An oral pharmaceutical composition comprising: a drug which is amantadine or a pharma- ceutical acceptable salt thereof, the oral pharmaceutical composition comprising 50 mg to 500 mg of the amantadine or an equivalent amount of the pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of at least a portion of the drug; The oral pharmaceutical composition comprises: (i) less than 10% dissolution in 2 hours; (ii) 5% to 13% dissolution in 4 hours; (iii) 20% to 43% dissolution in 6 hours; (iv) 50% to 70% dissolution in 8 hours, and (v) having a dissolution profile for the drug that exhibits at least four of the following: at least 80% dissolution at 12 hours; The dissolution profile was determined using a USP Type 2 apparatus (paddle) at 37.0±0.5° C., 50 rpm with 500 ml of water as the dissolution medium; When the oral pharmaceutical composition is administered to healthy subjects in a single-dose human pharmacokinetic study, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours and (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf wherein the subject is dosed in the morning after an overnight fast.
[0247] Embodiment II-4 An oral pharmaceutical composition comprising: a drug which is amantadine or a pharma- ceutical acceptable salt thereof, the oral pharmaceutical composition comprising 50 mg to 500 mg of the amantadine or an equivalent amount of the pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of at least a portion of the drug; The oral pharmaceutical composition was dissolved in 500 ml of water at 37.0±0.5° C. using USP Apparatus II (paddle) at 50 rpm. (i) less than 9% dissolution in 2 hours; (ii) 3% to 14% dissolution in 4 hours; (iii) 20% to 43% dissolution in 6 hours; (iv) 45% to 70% dissolution in 8 hours, and (v) at least 82% dissolution at 12 hours; The dissolution profile was determined using a USP Type 2 apparatus (paddle) at 37.0±0.5° C., 50 rpm with 500 ml of water as the dissolution medium; When the oral pharmaceutical composition is administered to healthy subjects in a single-dose human pharmacokinetic study, the oral pharmaceutical composition has (i) a Tmax of amantadine of 11 to 19 hours and (ii) an AUC of amantadine of 44 to 72 ng*hr / ml per mg of the drug. 0-inf wherein the subject is dosed in the morning after an overnight fast.
[0248] Embodiment II-5: An oral pharmaceutical composition according to any one of embodiments II-1 to II-4, wherein the Tmax of amantadine is 12 to 18 hours.
[0249] Embodiment II-6: The oral pharmaceutical composition according to any one of embodiments II-1 to II-5, wherein the oral pharmaceutical composition exhibits each of (i) to (v).
[0250] Embodiment II-7 The oral pharmaceutical composition according to any one of embodiments II-1 to II-6, wherein said oral pharmaceutical composition has a dissolution of 9% in 4 hours.
[0251] Embodiment II-8 The oral pharmaceutical composition according to any one of embodiments II-1 to II-7, wherein said oral pharmaceutical composition has a dissolution of 31% in 6 hours.
[0252] Embodiment II-9 The oral pharmaceutical composition according to any one of embodiments II-1 to II-8, wherein said oral pharmaceutical composition has a dissolution of 61% in 8 hours.
[0253] Embodiment II-10. The oral pharmaceutical composition according to any one of embodiments II-1 to II-9, wherein said oral pharmaceutical composition has a dissolution of 94% in 12 hours.
[0254] Embodiment II-11 An oral pharmaceutical composition comprising: a drug which is amantadine or a pharma- ceutical acceptable salt thereof, the oral pharmaceutical composition comprising 50 mg to 500 mg of the amantadine or an equivalent amount of the pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of at least a portion of the drug; When administered to healthy subjects in a single-dose human pharmacokinetic study, the oral pharmaceutical composition exhibits the following properties when administered in the morning after an overnight fast: Amantadine Tmax, 11 to 19 hours; AUC of amantadine from 44 to 72 ng*hr / ml per mg of drug 0-inf , and pAUC of amantadine between 1.0 and 2.0 ng*hr / ml per mg of drug 0-8 An oral pharmaceutical composition comprising:
[0255] Embodiment II-12 When administered to healthy subjects in a single-dose human pharmacokinetic study, the oral pharmaceutical composition has a pAUC of amantadine of 0.3-0.9 ng*hr / ml per mg of drug when the subjects are dosed in the morning after an overnight fast. 0-6 The oral pharmaceutical composition according to embodiment II-11,
[0256] Embodiment II-13 An oral pharmaceutical composition comprising: a drug which is amantadine or a pharma- ceutical acceptable salt thereof, the oral pharmaceutical composition comprising 50 mg to 500 mg of the amantadine or an equivalent amount of the pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of at least a portion of the drug; When administered to healthy subjects in a single-dose human pharmacokinetic study, the oral pharmaceutical composition exhibits the following properties when administered in the morning after an overnight fast: (i) AUC 0-inf The partial AUC from 0 to 4 hours is less than 1% of the (ii) AUC 0-inf a partial AUC from 0 to 8 hours that is 4.5% or less of the (iii) AUC 0-inf The partial AUC from 0 to 12 hours is approximately 5% to 15% of the (iv) AUC 0-inf The partial AUC from 0 to 18 hours is approximately 20% to 35% of the (v) and AUC 0-inf The oral pharmaceutical composition provides a partial AUC from 0 to 24 hours that is about 34% to 48% of the oral pharmaceutical composition.
[0257] In embodiment II-14, the partial AUC of 0 to 4 is AUC 0-inf The oral pharmaceutical composition according to embodiment II-13, wherein the amount of EDTA is less than 0.2%.
[0258] In embodiment II-15, the partial AUC from 0 to 8 hours is AUC 0-inf The oral pharmaceutical composition according to embodiment II-13 or II-14, wherein the amount of the active ingredient is 1.0% to 4.0%.
[0259] In embodiment II-16, the partial AUC from 0 to 8 hours is AUC 0-inf The oral pharmaceutical composition according to any one of embodiments II-13 to II-15, wherein the oral pharmaceutical composition is 1.5% to 3.75% of the total amount.
[0260] In embodiment II-17, the partial AUC from 0 to 8 hours is AUC 0-infThe oral pharmaceutical composition according to any one of embodiments II-13 to II-16, wherein the amount of the active ingredient is 1.75% to 3.5%.
[0261] Embodiment II-18 AUC 0-inf The partial AUC from 0 to 12 hours is about 7.0% to 12.0% of the oral pharmaceutical composition according to any one of embodiments II-13 to II-17.
[0262] In embodiment II-19, the partial AUC from 0 to 18 hours is AUC 0-inf The oral pharmaceutical composition according to any one of embodiments II-13 to II-18, wherein the amount of the active ingredient is about 22.5% to 27.5% of the active ingredient.
[0263] Embodiment II-20 An oral pharmaceutical composition comprising: a drug which is amantadine or a pharma- ceutical acceptable salt thereof, the oral pharmaceutical composition comprising 50 mg to 500 mg of the amantadine or an equivalent amount of the pharma- ceutical acceptable salt thereof; and at least one excipient that modulates the release of at least a portion of the drug; When administered to healthy subjects in a single-dose human pharmacokinetic study, the oral pharmaceutical composition exhibits the following properties when administered in the morning after an overnight fast: AUC 0-inf A partial AUC from 0 to 4 hours that is less than 0.25% of AUC 0-inf A partial AUC from 0 to 8 hours that is less than 3.5% of the AUC 0-inf a partial AUC from 0 to 12 hours that is approximately 5 to 12% of AUC 0-inf The oral pharmaceutical composition provides a partial AUC from 0 to 18 hours that is about 25 to 60% of the oral dose.
[0264] EMBODIMENT II-21 An oral pharmaceutical composition according to any one of embodiments II-1 to II-20, comprising 100 mg to 450 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0265] An oral pharmaceutical composition according to any one of embodiments II-1 to II-21, comprising 120 mg to 150 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0266] Embodiment II-23 An oral pharmaceutical composition according to any one of embodiments II-1 to II-22, comprising 137 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0267] Embodiment II-24 An oral pharmaceutical composition according to any one of embodiments II-1 to II-21, comprising 260 mg to 305 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0268] An oral pharmaceutical composition according to any one of embodiments II-1 to II-21 or II-24, comprising 274 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0269] Embodiment II-26 An oral pharmaceutical composition according to any one of embodiments II-1 to II-25, comprising 1, 2, 3, or 4 unit dosage forms.
[0270] An oral pharmaceutical composition according to any one of embodiments II-1 to II-26, comprising embodiment II-271 or a two-unit dosage form.
[0271] Embodiment II-28 The oral pharmaceutical composition of any one of embodiments II-1 to II-27, wherein the drug is a pharma- ceutically acceptable salt of amantadine.
[0272] Embodiment II-29 The oral pharmaceutical composition according to any one of embodiments II-1 to II-28, wherein the drug is amantadine hydrochloride.
[0273] Embodiment II-30 An oral pharmaceutical composition according to any one of embodiments II-1 to II-29, comprising less than 6000 ppm of organic solvent.
[0274] Embodiment II-31 An oral pharmaceutical composition according to any one of embodiments II-1 to II-30, comprising less than 2000 ppm of organic solvent.
[0275] Embodiment II-32 A plurality of coated core seeds, Each coated core seed is Core Seed, a drug coating surrounding said core seed, said drug coating comprising amantadine or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients; a plurality of coated core seeds comprising a sustained release coating surrounding the drug coating, the sustained release coating comprising one or more release modifying excipients; and The oral pharmaceutical composition according to any one of embodiments II-1 to II-31, comprising a capsule shell, wherein the plurality of coated core seeds are encapsulated within the capsule shell.
[0276] EMBODIMENT II-33. The oral pharmaceutical composition of embodiment II-32, wherein the plurality of coated core seeds comprises less than 6000 ppm of organic solvent.
[0277] EMBODIMENT II-34. The oral pharmaceutical composition of embodiment II-32, wherein the plurality of coated core seeds comprises less than 2000 ppm of organic solvent.
[0278] Embodiment II-35 A method for reducing levodopa-induced dyskinesia (LID) in a subject having Parkinson's disease in need thereof, comprising orally administering to the subject once daily an oral pharmaceutical composition according to any one of embodiments II-1 to II-34, wherein LID is reduced in the subject.
[0279] The method of embodiment II-35, wherein reducing LID comprises reducing the severity of dyskinesia.
[0280] The method of embodiment II-35 or II-36, wherein the reduction in LID is assessed by the Unified Dyskinesia Rating Scale (UDysRS).
[0281] EMBODIMENT II-38 A method of increasing on-time without bothersome dyskinesias in a subject having Parkinson's disease in need of increasing on-time without bothersome dyskinesias, the subject having levodopa-induced dyskinesias (LID), the method comprising orally administering to the subject once daily an oral pharmaceutical composition according to any one of embodiments II-1 to II-34.
[0282] The method of embodiment II-38, wherein the increase in on-time without bothersome dyskinesias is determined in a placebo-controlled, double-blind clinical trial.
[0283] Embodiment II-40 A method for reducing off-time in a subject having Parkinson's disease in need of reducing off-time, the subject having levodopa-induced dyskinesia (LID), the method comprising orally administering to the subject once daily an oral pharmaceutical composition according to any one of embodiments II-1 to II-34, the oral pharmaceutical composition reducing off-time in the subject.
[0284] The method of embodiment II-40, wherein the increase in off-time is determined in a placebo-controlled, double-blind clinical trial.
[0285] EMBODIMENT II-42 A method of treating a hypokinetic disorder in a subject with multiple sclerosis in need thereof, comprising orally administering to the subject once daily an oral pharmaceutical composition according to any one of embodiments II-1 to II-34.
[0286] Embodiment II-43 The method of embodiment II-42, wherein said hypokinetic disorder is a gait disorder.
[0287] Embodiment II-44. The method of any one of embodiments II-35 to II-43, wherein the oral pharmaceutical composition is administered to the subject once at night.
[0288] Embodiment II-45. The method of any one of embodiments II-35 to II-44, wherein the oral pharmaceutical composition is administered to the subject 0 to 4 hours before bedtime.
[0289] Embodiment II-46 The method of any one of embodiments II-35 to II-45, wherein the daily amount administered to the subject is between 100 mg and 450 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0290] Embodiment II-47 The method of any one of embodiments II-35 to II-46, wherein the once daily dose administered to the subject is 120 mg to 150 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0291] Embodiment II-48 The method of any one of embodiments II-35 to II-47, wherein the once-daily dose administered to the subject is 137 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0292] Embodiment II-49 The method of any one of embodiments II-35 to II-46, wherein the once-daily dose administered to the subject is 260 mg to 305 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0293] Embodiment II-50 The method of any one of embodiments II-35 to II-46 or II-49, wherein the once daily dose administered to the subject is 274 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0294] Embodiment II-51 The method according to any one of embodiments II-35 to II-50, wherein the oral pharmaceutical composition is administered in 1, 2, 3, or 4 unit dosage forms.
[0295] Embodiment II-52 The method according to any one of embodiments II-35 to II-51, wherein the oral pharmaceutical composition is administered in one or two unit dosage forms.
[0296] Embodiment II-53 The method of any one of embodiments II-35 to II-52, wherein the oral pharmaceutical composition is administered in two or three unit dosage forms, each containing 68.5 to 175 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0297] Embodiment II-54 The method of any one of embodiments II-35 to II-52, wherein the drug is a pharma- ceutically acceptable salt of amantadine.
[0298] Embodiment II-55 The method of any one of embodiments II-35 to II-53, wherein the drug is amantadine hydrochloride.
[0299] EMBODIMENT II-56 An oral pharmaceutical composition according to any one of Embodiments II-1 to II-34 for use in a method for reducing levodopa-induced dyskinesia (LID) in a subject having Parkinson's disease in need thereof, the method comprising orally administering the oral pharmaceutical composition to the subject once daily.
[0300] Embodiment II-57. The oral pharmaceutical composition for use according to embodiment II-56, wherein reducing LID comprises reducing the severity of dyskinesia.
[0301] The oral pharmaceutical composition for use according to embodiment II-56 or II-57, wherein the reduction in LID is assessed by the Unified Dyskinesia Rating Scale (UDysRS).
[0302] EMBODIMENT II-59 An oral pharmaceutical composition according to any one of embodiments II-1 to II-34 for use in a method for increasing on-time without bothersome dyskinesias in a subject having Parkinson's disease in need of increasing on-time without bothersome dyskinesias, wherein the subject has levodopa-induced dyskinesias (LID), the method comprising orally administering the oral pharmaceutical composition to the subject once daily.
[0303] EMBODIMENT II-60. An oral pharmaceutical composition for use according to embodiment II-59, wherein the increase in on-time without bothersome dyskinesias is determined in a placebo-controlled, double-blind clinical trial.
[0304] Embodiment II-61 An oral pharmaceutical composition according to any one of embodiments II-1 to II-34 for use in a method for reducing off-time in a subject with Parkinson's disease in need thereof, the subject having levodopa-induced dyskinesia (LID), the method comprising orally administering the oral pharmaceutical composition to the subject once daily.
[0305] EMBODIMENT II-62. The oral pharmaceutical composition for use according to embodiment II-61, wherein the increase in off-time is determined in a placebo-controlled, double-blind clinical trial.
[0306] EMBODIMENT II-63 An oral pharmaceutical composition according to any one of Embodiments II-1 to II-34 for use in a method of treating a hypokinetic disorder in a subject with multiple sclerosis in need of such treatment, the method comprising orally administering the oral pharmaceutical composition to the subject once daily.
[0307] EMBODIMENT II-64. An oral pharmaceutical composition for use according to embodiment II-63, wherein said hypokinetic disorder is a gait disorder.
[0308] Embodiment II-65. The oral pharmaceutical composition for use according to any one of embodiments II-56 to II-64, wherein the oral pharmaceutical composition is administered to the subject once at night.
[0309] Embodiment II-66. The oral pharmaceutical composition for use according to any one of embodiments II-56 to II-65, wherein said oral pharmaceutical composition is administered to said subject 0 to 4 hours before bedtime.
[0310] Embodiment II-67. An oral pharmaceutical composition for use according to any one of embodiments II-56 to II-66, wherein the daily amount administered to the subject is between 100 mg and 450 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0311] Embodiment II-68. An oral pharmaceutical composition for use according to any one of embodiments II-56 to II-67, wherein the once-daily dose administered to the subject is 120 mg to 150 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0312] Embodiment II-69. An oral pharmaceutical composition for use according to any one of embodiments II-56 to II-68, wherein the once-daily dose administered to the subject is 137 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0313] Embodiment II-70. An oral pharmaceutical composition for use according to any one of embodiments II-56 to II-67, wherein the once-daily dose administered to the subject is between 260 mg and 305 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0314] Embodiment II-71 An oral pharmaceutical composition for use according to any one of embodiments II-56 to II-67 or II-70, wherein the once-daily dose administered to the subject is 274 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0315] Embodiment II-72 The oral pharmaceutical composition for use according to any one of embodiments II-56 to II-71, wherein said oral pharmaceutical composition is administered in 1, 2, 3, or 4 unit dosage forms.
[0316] Embodiment II-73 The oral pharmaceutical composition for use according to any one of embodiments II-56 to II-72, wherein said oral pharmaceutical composition is administered in one or two unit dosage forms.
[0317] Embodiment II-74 An oral pharmaceutical composition for use according to any one of embodiments II-56 to II-73, wherein the oral pharmaceutical composition is administered in two or three unit dosage forms, each containing 68.5 to 175 mg of amantadine or an equivalent amount of a pharma- ceutically acceptable salt thereof.
[0318] Embodiment II-75. An oral pharmaceutical composition for use according to any one of claims 56-74, wherein the drug is a pharma- ceutically acceptable salt of amantadine.
[0319] Embodiment II-76. The oral pharmaceutical composition for use according to any one of embodiments II-56 to II-75, wherein the drug is amantadine hydrochloride. EXAMPLES
[0320] The present disclosure may be better understood with reference to the following examples, which are illustrative and are not intended to limit the scope of the disclosure in any way.
[0321] Example 1: Type C Amantadine sustained release coated pellet formulation An amantadine HCl sustained release coated pellet composition designed for oral administration was prepared using the ingredients and relative amounts shown in Table 1 below.
[0322] The drug coating dispersion was prepared by adding HPMC (5 cps) and copovidone to isopropyl alcohol with stirring. Purified water was added to the dispersion and stirring was continued until a clear solution was formed. Then, the drug (amantadine HCl) was added to the clear solution and stirring was continued until the drug was completely dissolved. Finally, talc was added and dispersed uniformly by stirring.
[0323] Seed pellets, Celphere beads (sieve size #35-#50 (i.e., 300-500 microns)) were loaded into a Wurster coating unit. The drug coating dispersion was sprayed onto the seed pellets until the desired coating weight was increased, thereby forming a drug coating of amantadine and excipients on the seed pellets, followed by drying for a period of time to remove residual organic solvent and water in the drug-coated pellets. The resulting drug-coated pellets were sieved to retain the sieve #18-#24 fraction (approximately 700 μm to 1 mm diameter).
[0324] The seal coating dispersion was prepared by adding HPMC (5 cps) to isopropyl alcohol with stirring. Purified water was added to the dispersion and stirring was continued until a clear solution was formed. Talc was added and uniformly dispersed by stirring. The sieved drug-coated pellets were loaded into a Wurster coating unit. The seal coating dispersion was sprayed onto the drug-coated pellets followed by drying for a period of time to remove the residual organic solvent and water in the pellets. The resulting seal coated pellets were sieved to retain the fraction of sieves #18 to #24.
[0325] The ER coating solution was prepared by dissolving ethylcellulose (viscosity 7 cps) in isopropyl alcohol and purified water and stirring until a clear solution was formed. Povidone K-90 was then dissolved in this clear solution followed by the addition of plasticizer Miglyol 812N with stirring to form a clear solution. The sieved seal coated pellets were loaded into the Wurster coating unit. The ER coating solution was sprayed onto the seal coated pellets followed by drying for a period of time to affect the ER coat and remove the residual solvent and water in the pellets. After drying, magnesium stearate was applied to the top layer of the coated pellets in the annular region followed by recirculating the pellets in the Wurster unit to blend the magnesium stearate with the coated pellets. The resulting ER coated pellets were sieved to retain the fraction of sieves #18 to #24.
[0326] The ER coated pellets containing unit doses of amantadine hydrochloride were filled into empty hard gelatin capsule shells using a capsule machine equipped with a pellet injection chamber. Size 1 capsule shells were used for 48.4 mg amantadine (60 mg amantadine HCl) and 112.8 mg amantadine (140 mg amantadine HCl). The 48.4 mg capsules had a moisture content of 2.0% by Karl Fischer and a residual isopropyl alcohol concentration of 6464 ppm, and the 112.8 mg capsules had a moisture content of 1.8% by Karl Fischer and a residual isopropyl alcohol concentration of 6709 ppm. Table 1: Composition of Type C Amantadine HCl ER Capsules [Table 1-1] [Table 1-2]
[0327] Example 2: Type D Amantadine sustained release coated pellet formulation An amantadine HCl sustained release coated pellet composition designed for oral administration was prepared using the ingredients and relative amounts shown in Table 2 below.
[0328] The drug coating dispersion was prepared by incorporating the coating dispersion ingredients in Table 2 in purified water without the use of organic solvents.
[0329] Seed pellets, Celphere beads (sieve size #35-#50 (i.e., 300-500 microns)) were loaded into a Wurster coating unit. The drug coating dispersion was sprayed onto the seed pellets until the desired coating weight was increased, thereby forming a drug coating of amantadine and excipients on the seed pellets, followed by drying for a period of time to remove residual water. The resulting drug-coated pellets were sieved to retain the sieve #18-#24 fraction (approximately 700 μm to 1 mm diameter).
[0330] The seal coating dispersion was prepared by incorporating the components of the seal coating dispersion in Table 2 in purified water without organic solvent. The sieved drug coated pellets were loaded into a Wurster coating unit. The seal coating dispersion was sprayed onto the drug coated pellets followed by drying for a period of time to remove the residual water in the pellets. The resulting seal coated pellets were sieved to retain the fraction of sieves #18 to #24.
[0331] The ER coating solution was prepared by dissolving ethylcellulose (viscosity 7 cps) in isopropyl alcohol and purified water and stirring until a clear solution was formed. Povidone K-90 was then dissolved in this clear solution followed by the addition of plasticizer Miglyol 812N with stirring to form a clear solution. The sieved seal coated pellets were loaded into the Wurster coating unit. The ER coating solution was sprayed onto the seal coated pellets followed by drying for a period of time to affect the ER coat and remove the residual solvent and water in the pellets. After drying, magnesium stearate was applied to the top layer of the coated pellets in the annular region followed by recirculating the pellets in the Wurster unit to blend the magnesium stearate with the coated pellets. The resulting ER coated pellets were sieved to retain the fraction of sieves #18 to #24.
[0332] The ER coated pellets containing unit doses of amantadine hydrochloride were filled into empty hard gelatin capsule shells using a capsule machine equipped with a pellet injection chamber. For 68.5 mg of amantadine (85 mg of amantadine HCl), a size 2 capsule shell was used. For 137 mg of amantadine (170 mg of amantadine HCl), a size 0 capsule shell was used. The capsules had a moisture content of 2% by Karl Fischer and a residual isopropyl alcohol concentration of 1051 ppm. Table 2: Composition of Type D Amantadine HCl ER Capsules [Table 2-1] [Table 2-2]
[0333] Example 3: Dissolution of Amantadine sustained release coated pellet formulations Dissolution of the capsules of Examples 1 and 2 was carried out using USP Apparatus II (paddle) at 50 rpm with 500 ml of water at 37.0±0.5° C. as the dissolution medium. The average results are shown in Table 3 below and in FIG.
[0334] In vitro dissolution shows a decrease in amantadine release from the composition over the first 4, 6 and 8 hours. Table 3: Dissolution profile [Table 3]
[0335] Example 4: Pharmacokinetic study of two amantadine ER coated pellet formulations OBJECTIVES: The primary objective of this study was to evaluate the pharmacokinetic profile of the two formulations of ER amantadine HCl of Examples 1 and 2. The secondary objective was to evaluate the safety and tolerability of a single 340 mg dose of the two formulations of ER amantadine HCl of Examples 1 and 2.
[0336] Study Design: This was a phase 1, randomized, single-dose, open-label, two-drug, two-period crossover, fasted pharmacokinetic study comparing the amantadine ER capsule formulations of Example 1 (Type C) and Example 2 (Type D), a single 340 mg dose of the investigational drug, with each other. The study included 42 healthy subjects who were randomly assigned in a 1:1 ratio to one of two treatment sequences (Type C->Type D or Type D->Type C). For Type C, the 340 mg amantadine hydrochloride consisted of two 140 mg capsules and one 60 mg capsule. For Type D, the 340 mg amantadine hydrochloride consisted of two 170 mg capsules.
[0337] Methods: Subjects were screened for inclusion and exclusion criteria within 21 days of study screening. On the day before the first dosing period, subjects were admitted to the hospital and remained there until 48 hours after blood samples were taken. In each study period, subjects were dosed the day after admission and discharged after blood samples were taken 48 hours after dosing. Subjects returned for subsequent blood draws (72 and 96 hours). There was a 7-14 day washout period between the first and second doses. Safety monitoring was performed during and after each study drug dose.
[0338] For each study period, study drug was administered to subjects in a sitting position with 240 mL of water after an overnight fast. Subjects were required to maintain a sitting position for at least 2 hours after dosing. No food was permitted until 4 hours after administration of study drug. Blood samples were collected at 0 (pre-dose), 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 15, 16, 18, 20, 24, 30, 36, 48, 72, and 96 hours after each dose. Plasma samples were assayed for amantadine by a validated liquid chromatography / tandem mass spectrometry (LC / MS / MS) method. Pharmacokinetic parameters were calculated using noncompartmental analysis with WinNonlin software (version 6.2.1; Pharsight Corporation).
[0339] Adverse events were monitored throughout the study. Vital signs (pulse rate, blood pressure, and temperature), clinical laboratory measures (biochemistry, hematology, and urinalysis), and ECGs were collected at various time points during the study.
[0340] Results: A total of 42 subjects, including healthy male and female adults, were screened and randomly assigned to the above treatment groups, and 39 subjects completed the study. All 42 subjects were included in the safety analysis population, and 39 subjects were included in the primary analysis population.
[0341] The pharmacokinetic results of this study, shown in Table 4 below and Figure 2, demonstrate that these formulations have similar Cmax, Tmax, AUC 0-inf , AUC0-24 and t 1 / 2 This indicates that the Table 4: Pharmacokinetic data from single dose PK studies (mean ± SD unless noted). [Table 4]
[0342] According to the partial AUC values over the first 4, 6, 8, 10, 12, 14 and 16 hours for the two formulations, the exposure early after administration of the Type D composition is less than that of the Type C composition (see Table 5 below), which is also shown in Figure 3. Table 5: pAUC values (ng*hr / ml per mg of amantadine HCl) from single dose PK studies [Table 5-1] [Table 5-2]
[0343] Safety Analysis Results: Adverse events were recorded and coded using MedDRA version 17.0 among the 42 subjects randomized to the study. The number and percentage of subjects reporting at least one adverse event within each organ system class are shown in Table 6 below. The frequency of gastrointestinal disorders for Type C and Type D compositions was compared with a logistic model fit using generalized estimating equations (GEE, exchangeable correlation structure). The analysis yielded an odds ratio of 3.407 and a p-value of 0.0685, indicating that the odds of gastrointestinal adverse events were 3.4 times higher for Type C formulations than Type D formulations. Table 6: Adverse events observed [Table 6-1] [Table 6-2]
[0344] Example 5: Statistical analysis of GI adverse events across studies Objective: To compare the incidence of gastrointestinal adverse events from single-dose fasting human pharmacokinetic studies of type C and type D formulations.
[0345] This post-hoc analysis aggregated GI adverse events (based on MedDRA coding) across the five single-dose fasted human pharmacokinetic studies to determine whether the differences in GI adverse events observed in Example 4 were statistically significant. For studies with treatments other than type C or type D formulations, only type C and type D groups were included. Furthermore, only fasted single-dose groups were included. Aggregating the results resulted in a large number of subjects and adverse events. The included studies are listed in Table 7 below. Statistical analysis of the data was performed using a logistic model fit using generalized estimating equations (GEE, exchangeable correlation structure). Table 7: Number of subjects in the study for analysis and number of GI adverse events [Table 7-1] [Table 7-2]
[0346] The study included 147 different subjects, and the statistical results for gastrointestinal adverse effects of pooled data showed an odds ratio of 16.247 for type C vs type D and a p-value of <0.0001. The smaller p-value compared to the previous example can be partially explained by the increase in sample size and partially explained by the increase in effect size (2 of 58 for type C vs 9 of 128 for type D).
[0347] Example 6: A randomized, double-blind, placebo-controlled study of the efficacy and safety of amantadine sustained-release oral capsules for the treatment of levodopa-induced dyskinesia in Parkinson's disease This study was conducted using a type C amantadine hydrochloride formulation prepared according to the process of Example 1 above. Study Objective: This study was designed to evaluate the efficacy of three dose strengths of amantadine extended release (ER) oral capsules administered once nightly for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). In addition, this study was designed to demonstrate the safety and tolerability of amantadine ER oral capsules administered once nightly for the treatment of LID in subjects with PD. Study Design: This was a multicenter, randomized, double-blind, placebo-controlled, parallel four-arm study of amantadine ER in subjects with PD and LID. Consenting subjects who met the eligibility criteria were assigned 1:1:1:1 to receive one of the following four treatments (administered once nightly and overnight, respectively): Treatment A: placebo, Treatment B: 260 mg amantadine ER (ADS-5102) (prepared according to the process for Type C in Example 1); Treatment C: 340 mg amantadine ER (ADS-5102) (prepared according to the process for Type C in Example 1) Treatment D: 420 mg amantadine ER (ADS-5102) (prepared according to the process for Type C in Example 1)
[0348] Subjects assigned to Treatment C received, in a double-blind fashion, 260 mg amantadine ER once nightly during week 1, increased to 340 mg once nightly at the beginning of week 2. Subjects assigned to Treatment D received, in a double-blind fashion, 260 mg amantadine ER once nightly during week 1, increased to 340 mg amantadine ER once nightly during week 2, and further increased to 420 mg once nightly at the beginning of week 3. Nominal dosing continued for all groups through week 8.
[0349] After completing the baseline visit and randomization, subjects returned to the clinic after 1, 2, 4, 6, and 8 weeks of treatment, and for a follow-up visit 14 days after the last dose of study drug. Study visits and assessments were scheduled between 10:00 AM and 4:00 PM. Two series of 24-hour diaries were completed during the 48 hours prior to randomization and the 48 hours prior to selected study visits. The diaries were used to score the following five different states at 30-minute intervals: asleep, off, on with no dyskinesias, on with non-troublesome dyskinesias, and on with bothersome dyskinesias.
[0350] At selected study visits, blood samples were collected for determination of amantadine plasma concentrations and evaluation of steady-state population pharmacokinetics. Subject participation during the study was for a maximum of 12 weeks, including a 2-week (maximum) screening period, an 8-week (maximum) treatment period, and a 2-week follow-up period. Subjects unable to tolerate the assigned study drug were permanently discontinued from study drug and continued to be followed for safety for 2 weeks after the last dose of study drug.
[0351] Patient Eligibility Criteria: Subjects were eligible to participate in the study if they met the inclusion criteria and did not meet the exclusion criteria. Key criteria selected were:
[0352] Inclusion Criteria: An adult male or female ● Between 30 and 85 years old (inclusive), Ability to walk or use an assistive device (e.g., walker or cane) during ON to enable subjects to complete study testing Where appropriate, have a knowledgeable and reliable caregiver / study partner to accompany the subject to study visits and, where necessary and permitted, assist with completing study assessments. Have signed a current IRB / IEC approved informed consent form After diary training, subjects are cooperative and able to understand and complete a 24-hour PD home diary (may be assisted by a caregiver / study partner) Have been diagnosed with concomitant Parkinson's disease according to the UKPDS Brain Bank Diagnostic Criteria for Parkinson's Disease - Patients must have been receiving a stable antiparkinsonian medication regimen (including levodopa) for at least 30 days prior to screening, with optional levodopa administered at least three times daily, and be willing to continue this regimen during study participation. Have a score of at least 2 on the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, item 4.2 (functional impact of dyskinesia) at screening and Day 1 (baseline) Using a 48-hour PD home diary completed immediately prior to Day 1 (baseline), at least two 30-minute periods between 10:00 am and 4:00 pm during each 24-hour period were recorded as "ON with bothersome dyskinesias"
[0353] Important exclusion criteria: History of deep brain simulation therapy; exclusively biphasic, off-state, myoclonic dyskinesia without peak-dose dyskinesia or history of dyskinesia with akathisia History of other neurological diseases affecting cognition or motor function as determined by the investigator, including, but not limited to, Alzheimer's disease, Huntington's disease, dementia with Lewy bodies, frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy, motor or sensory disorders secondary to stroke or head trauma, or multi-lacunar infarct dementia. • The presence of cognitive impairment as evidenced by a Mini-Mental State Examination (MMSE) score of less than 24 during screening. The presence of an acute or chronic major psychiatric disorder (e.g., major depressive disorder) or symptoms (e.g., hallucinations, agitation, paranoia) that, in the opinion of the investigator, would affect the ability to complete the study History of sensory impairment (e.g., hearing, vision) that, in the investigator's judgment, would affect the ability to complete the study History of alcohol or drug dependence or abuse within 2 years prior to screening - History of seizures within 2 years prior to screening History of stroke or TIA within 2 years prior to screening History of myocardial infarction or NYHA class III or IV heart failure within 2 years prior to screening History of cancer within 5 years prior to screening (with the following exceptions: adequately treated nonmelanoma skin cancer, localized bladder cancer, nonmetastatic prostate cancer, or epithelial cervical cancer) Any of the following laboratory test results at screening: hemoglobin less than 10 g / dL, WBC count 3.0 x 10 9 / L, neutrophil count 1.5 × 10 9 / L, lymphocyte count 0.5 × 10 9 / L, platelet count less than 100 × 10 9 / L, hemoglobin A1C >9%, or aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) >2x the upper limit of normal ● According to the Modified Renal Diet (MDRD) formula, GFR is 50mL / min / 1.73m 2 Being rated as less than Any clinically significant ECG abnormality (including any evidence of isolated PVC or abnormal ventricular conduction of rhythm other than first-degree AV block) Inability to swallow oral capsules or history of gastrointestinal malabsorption that precludes the use of oral medications
[0354] Study Endpoints: The primary efficacy endpoint was the change from baseline to week 8 in the Unified Dyskinesia Rating Scale (UDysRS) total score. Key secondary endpoints included: ●UDysRS objective total score (III, IV) On-time without bothersome dyskinesias based on PD home diary (on-time without dyskinesias + on-time with non-bothersome dyskinesias) On-time symptoms of bothersome dyskinesias based on a standardized PD home diary Total on-time with dyskinesia (non-bothersome dyskinesia and bothersome dyskinesia) ●Total off time Unified Parkinson's Disease Rating Scale (MDS-UPDRS), total score (parts I, II, and III) - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV, item 4.1 (time spent with dyskinesia) and item 4.2 (functional impact of dyskinesia) Individual part scores (I, II, III, and IV) of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Clinician Global Impression of Change in Overall PD Symptoms as Determined by Questions Answered by the Investigator Health-related quality of life as measured by the PDQ-39, a PD-specific HRQoL instrument Fatigue measured by the Fatigue Severity Scale (FSS), which includes nine questions answered by the patient using a rating scale from 1 (not at all) to 7 (very much). Safety (including adverse events, discontinuation of investigational drug related to safety, vital signs, and laboratory tests).
[0355] The following combination of traditional and novel measures was selected for this study: The Unified Dyskinesia Rating Scale (UDysRS) was used for the primary outcome measure. This scale has four parts with a possible total score of 104: I: Historical disability as a result of on-dyskinesia (patients' perceptions) II: Historical disability as a result of on-dystonia (patients' perceptions) III: Objective impairment (dyskinesia severity, anatomical distribution, and type based on the four observed activities) IV: Objective disability based on Part III activities -On-time without bothersome dyskinesias based on a standardized Parkinson's disease home diary. • Part IV of the Unified Parkinson's Disease Rating Scale (UPDRS), items 4.1 (duration of dyskinesias: 0=none, 4=76–100% of waking hours) and 4.2 (disability impairment due to dyskinesias: 0=no impairment, 4=complete impairment) were secondary outcome items.
[0356] statistical methods Efficacy Analysis: The efficacy analysis population included all randomized, dosed subjects who provided at least one post-baseline efficacy assessment and met the pre-determined inclusion criteria. Unless otherwise stated, all efficacy endpoints were analyzed using analysis of covariance (ANCOVA) models with the change from baseline to week 8 as the dependent variable, treatment group as the factor, and the baseline value of the corresponding endpoint as the covariate. These models are used for both pairwise comparisons between each amantadine ER dose group versus placebo and to examine linear dose-response relationships. Dose-response studies are performed using scores 0, 260, 340, and 420, additively with equally spaced treatment group scores. For the efficacy endpoint of UDysRS score, the primary analysis compared the 340 mg amantadine ER group to the placebo group using a two-sided test at the 5% significance level.
[0357] Secondary endpoints were analyzed using the same type of ANCOVA model as described for the primary endpoint, except for CGIC, which was a CMH analysis. All secondary comparisons between treatment groups were performed using two-sided tests at the 5% significance level. A last observation carried forward (LOCF) approach was used for missing data. The primary efficacy analysis was repeated for the per protocol population (the subpopulation of the efficacy analysis population that provided an efficacy assessment at week 8). CGI was a CMH analysis. ●Results: The results of the selected studies are shown in the table below. Table 8 [Table 8-1] [Table 8-2] [Table 8-3]
[0358] Dyskinesia-free on-time increased from baseline to week 8 in all groups, but the increase in dyskinesia-free on-time in treatment groups, including the 340 mg treatment group, was greater than the increase in placebo group.
[0359] Clinician Global Impression of Change in Overall PD Symptoms is summarized in the table below. Results for the MITT population show statistically significant improvements in the 340 mg treatment group but not in the other groups. Table 9 [Table 9-1] [Table 9-2]
[0360] The CGI-C results showed that 75% of patients in the 340 mg dose group had a moderate to marked improvement in their clinical status (related to overall PD, including but not limited to LID) at week 8, compared with 32% of placebo patients. A further summary of the analysis is provided in the figures. Further discussion of this data can be found in US20150087721.
[0361] Although certain embodiments of the present disclosure are shown and described herein, such embodiments are provided for illustrative purposes only.Those skilled in the art will readily recognize numerous variations, modifications, and substitutions without departing from the present disclosure.It should be understood that various alternatives to the embodiments of the present disclosure described herein can be used in carrying out the methods described herein or preparing the compositions described herein.All references cited herein are incorporated herein in their entirety by reference.
[0362] Example 7: A randomized, double-blind, placebo-controlled study of the efficacy and safety of two formulations of amantadine sustained-release oral capsules for the treatment of levodopa-induced dyskinesia in Parkinson's disease Study Objectives: This study is designed to evaluate the efficacy of two formulations of amantadine extended-release (ER) oral capsules administered once nightly for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). In addition, this study is designed to demonstrate the safety and tolerability of two formulations of amantadine ER oral capsules administered once nightly for the treatment of LID in subjects with PD. Study Design: This is a multicenter, randomized, double-blind, placebo-controlled, parallel three-arm study of amantadine ER formulations in subjects with PD and LID. Consenting subjects who meet the eligibility criteria will be assigned 1:1:1 to receive one of the following three treatments (administered once nightly and overnight, respectively): Treatment A: placebo, Treatment B: 340 mg of amantadine hydrochloride ER (type C), ●Treatment C: 340 mg of amantadine hydrochloride ER (type D)
[0363] Subjects randomized to treatment B or C will receive, in a double-blind fashion, 170 mg amantadine ER hydrochloride type C or type D, respectively, once nightly during week 1, increasing to 340 mg amantadine ER hydrochloride type C or type D, respectively, once nightly at the beginning of week 2. Nominal dosing will continue through week 8 for all groups.
[0364] After completing the baseline visit and randomization, subjects return to the clinic after 1, 2, 4, 6, and 8 weeks of treatment, and a follow-up visit 14 days after the last dose of study drug. Study visits and assessments are scheduled between 10:00 AM and 4:00 PM. Two series of 24-hour diaries are completed during the 48 hours prior to randomization and the 48 hours prior to the selected study visit. The diaries are used to score the following five different states at 30-minute intervals: asleep, off, on with no dyskinesias, on with non-troublesome dyskinesias, and on with bothersome dyskinesias.
[0365] At selected study visits, blood samples will be collected for determination of amantadine plasma concentrations and assessment of steady-state population pharmacokinetics. Subject participation during the study will be for up to 12 weeks, including a 2-week (maximum) screening period, an 8-week (maximum) treatment period, and a 2-week follow-up period. Subjects who are unable to tolerate the assigned study drug will be permanently discontinued from study drug and followed for safety for 2 weeks after the last dose of study drug.
[0366] Patient Eligibility Criteria: Subjects are eligible to participate in the study if they meet the inclusion criteria and do not meet the exclusion criteria. Key criteria selected are:
[0367] Inclusion Criteria: An adult male or female ● Between 30 and 85 years old (inclusive) Ability to walk or use an assistive device (e.g., walker or cane) during ON to enable subjects to complete study testing Where appropriate, have a knowledgeable and reliable caregiver / study partner to accompany the subject to study visits and, where necessary and permitted, assist with completing study assessments. Have signed a current IRB / IEC approved informed consent form After diary training, subjects are cooperative and able to understand and complete a 24-hour PD home diary (may be assisted by a caregiver / study partner) Have been diagnosed with concomitant Parkinson's disease according to the UKPDS Brain Bank Diagnostic Criteria for Parkinson's Disease - Patients must have been receiving a stable antiparkinsonian medication regimen (including levodopa) for at least 30 days prior to screening, with optional levodopa administered at least three times daily, and be willing to continue this regimen during study participation. Have a score of at least 2 on the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, item 4.2 (functional impact of dyskinesia) at screening and Day 1 (baseline) Using a 48-hour PD home diary completed immediately prior to Day 1 (baseline), at least two 30-minute periods between 10:00 am and 4:00 pm during each 24-hour period were recorded as "ON with bothersome dyskinesias"
[0368] Important exclusion criteria: History of deep brain simulation therapy; exclusively biphasic, off-state, myoclonic dyskinesia without peak-dose dyskinesia or history of dyskinesia with akathisia History of other neurological diseases affecting cognition or motor function as determined by the investigator, including, but not limited to, Alzheimer's disease, Huntington's disease, dementia with Lewy bodies, frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy, motor or sensory disorders secondary to stroke or head trauma, or multi-lacunar infarct dementia. • The presence of cognitive impairment as evidenced by a Mini-Mental State Examination (MMSE) score of less than 24 during screening. The presence of an acute or chronic major psychiatric disorder (e.g., major depressive disorder) or symptoms (e.g., hallucinations, agitation, paranoia) that, in the opinion of the investigator, would affect the ability to complete the study History of sensory impairment (e.g., hearing, vision) that, in the investigator's judgment, would affect the ability to complete the study History of alcohol or drug dependence or abuse within 2 years prior to screening - History of seizures within 2 years prior to screening History of stroke or TIA within 2 years prior to screening History of myocardial infarction or NYHA class III or IV heart failure within 2 years prior to screening History of cancer within 5 years prior to screening (with the following exceptions: adequately treated nonmelanoma skin cancer, localized bladder cancer, nonmetastatic prostate cancer, or epithelial cervical cancer) Any of the following laboratory test results at screening: hemoglobin less than 10 g / dL, WBC count 3.0 x 10 9 / L, neutrophil count 1.5 × 10 9 / L, lymphocyte count 0.5 × 10 9 / L, platelet count less than 100 × 10 9 / L, hemoglobin A1C >9%, or aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) >2x the upper limit of normal ● According to the Modified Renal Diet (MDRD) formula, GFR is 50mL / min / 1.73m 2 Being rated as less than Any clinically significant ECG abnormality (including any evidence of isolated PVC or abnormal ventricular conduction of rhythm other than first-degree AV block) Inability to swallow oral capsules or history of gastrointestinal malabsorption that precludes the use of oral medications
[0369] Study Endpoints: The primary efficacy endpoint was the change from baseline to week 8 in the Unified Dyskinesia Rating Scale (UDysRS) total score. Key secondary endpoints included: ●UDysRS objective total score (III, IV) On-time...
Claims
[Claim 1] The invention as depicted in the drawings.
Citation Information
Patent Citations
Method and composition for adminstering an NMDA receptor antagonist to a subject
US20060142398A1
Composition and method for treating neurological disease
US20060189694A1
Methods and compositions for the treatment of CNS-related conditions
US20060252788A1
Compositions and Kits for Treating Influenza
US20080227743A1
Antiviral therapy
US5358721A
